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Summary 
Enzymes are critical to the vital functioning of any living system and play an 
important role in regulation of cellular processes. There are around 18-29% of 
eukaryotic genomes which encode enzymes. However, little is still understood about 
the physiological role, substrate specificity and downstream targets of enzymes. There 
is a pressing need to develop platforms for high-throughput identification and 
characterization of enzyme activities. This research is now referred to as “Catalomics” 
which defines an emerging ‘-omics’ field where high-throughput studies of enzymes 
are carried out by using advanced chemical proteomics approaches. One key 
challenge in “Catalomics” is to develop robust tools for substrate fingerprinting of 
enzymes in high throughput. This thesis examines and addresses these challenges by 
integration of various emerging interdisciplinary and enabling platforms. Chapter 2 
describes a novel FRET assay for activity-based fingerprinting of proteases from 
different classes. Chapter 3 presents a novel phosphorylated peptide array for 
substrate specificity studies of phosphotases. With this platform, new phosphatase 
biology was discovered. Chapter 4 presents a combinatorial peptide microarray for 
large-scale studies of substrate specificity of 14-3-3 proteins. Chapter 5 presents an 
affinity based microarray approach for mapping the substrate specificity of PTPs. 
Chapter 6 demonstrates a site-specific protein labeling approach via SrtA mediation 
which could be potentially applied into bioimaging field to study the enzyme activity 
in vivo. These approaches should provide comprehensive insights into the catalytic 
mechanism of different clusters of enzymes. The substrate fingerprints obtained 
would not only provide the invaluable information for identification of physiological 
substrates but also aid in the design of selective and potent inhibitors. 
 ix 
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Enzymes are critical to the vital functioning of any living system and play 
fundamental roles in cellular processes and metabolic transformations.1 It is well known 
that many human diseases are caused by the aberrant regulation of enzymes inside cells.2 
Consequently, enzymes account for >20% of all drug targets.3 There is a pressing need to 
develop the robust platforms which allows unraveling the role of enzymes with normal 
and diseased cellular processes. 
Recent advances in proteomics have provided impetus towards the development 
of robust technologies for high-throughput studies of enzymes. At the 11th Asian 
Chemical Congress in Seoul, we introduced the term “Catalomics” to define an emerging 
field in ‘-omics’ in which high-throughput studies of enzymes are carried out using 
chemical proteomics approaches (Figure 1.1).4 One key challenge in Catalomics is to 
develop robust tools capable of not only functional annotation, but more importantly 
substrate fingerprinting, of enzymes in high throughput. This is because the substrate 
fingerprint of an enzyme reveals the type of chemical entities accepted by the enzyme as 
its potential substrates, its catalytic mechanism and properties, thereby aiding in the 
design of potent and selective inhibitors. In a biological context, it is the ability of closely 
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related enzymes to discriminate among potential substrates that makes them an essential 
component in maintaining the fidelity of cellular processes. Alternatively, the pattern 
generated by an unknown enzyme using a set of substrates may possibly be used to 
obtain its identity. Recently, the field has witnessed climactic developments due to the 
growing importance of its role in drug discovery and enzyme engineering. Of the various 
available methods to accelerate the functional annotation of enzymes, microarrays have 
emerged as a powerful and versatile platform as it is compatible with many of the 
traditional solution-based enzyme bioassays. In addition, the salient features of the 
microarray technology, i.e. miniaturization, parallelization and automation, make it very 
convenient to undertake thousands of enzyme assays simultaneously. For a more 
comprehensive coverage of microarray field, please refer to several recent reports.5 
1.2 Conventional Enzyme Assays 
Enzyme assays which render enzyme-catalysed chemical transformations visible 
are available in various formats for the different enzyme classes.6 Many different 
enzymes can be screened in parallel in 96-, 384- or even 1,536-well microtiter plates by 
using labelled substrates including fluorogenic or chromogenic substrates, FRET 
substrates or sensors for product information, for instance, pH indicators for ester 
hydrolyses.7 Such assays are also highly sensitive since they allow intrinsic signal 
amplification owing to multiple turnovers by the enzyme. Fluorescence-based detection 
methods, in particular, are well suited for microarray-based applications as a result of 
their sensitivity, reliability and operational simplicity.8 Fluorogenic molecules of 
umbelliferone and coumarinbased enzyme substrates have been extensively used to detect 
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glycosidases, lipases, esterases and proteases but the relative instability and susceptibility 
to cleavage by other factors made these substrates problematic to work with.8 In 1998, 
Reymond and coworkers developed a new type of fluorogenic substrate to alleviate some 
of these problems.9 In their substrates, an alcohol group was first transformed into a 
ketone which underwent subsequent β-elimination to release the fluorescent 
umbelliferone reporter group. By avoiding a direct ester linkage between umbelliferone 
and the enzyme-recognition head, the chemical stability of the fluorogenic substrate was 
substantially increased. Thus far, similar strategies have been employed by the same 
group and others to generate diverse substrates for assaying a variety of enzymes in an 
enantioselective and stereoselective manner including epoxide hydrolases,10 
transaldolases,11 lipases and esterases,10,12,13 phosphatases,10,14 acylases,10 
proteases,15transketolases,16 Baeyer–Villigerases17and β-lactamase.18 Fluorescence 
resonance energy transfer (FRET) is another method widely used in fluorescence-based 
enzyme assays. The assay involves monitoring of enzyme activity by measuring an 
increase in fluorescence or shift in wavelength following cleavage of the enzyme-labile 
bond between fluorophore–quencher or fluorophore–fluorophore pairs. A FRET-based 
screening assay was used to facilitate identification of novel inhibitors of HIV-1 
protease.19 FRET-based enzyme assays are also compatible for screening the activity of 
other bond-cleaving enzymes including helicases,20 phosphatases21 and lipases.22 The 
availability of new support materials offering better enzyme accessibility has also 
allowed for direct on-bead FRET assays as reported by Hailing et al.23 St. Hilaire and 
coworkers used two combinatorial FRET substrate libraries synthesized on PEGA beads 
to probe substrate specificity of papain.23 In a highly innovative application of FRET-
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based techniques to study enzymes, Blum et al. reported the use of quenched 
activitybased probes (qABPs) to image the activity of cathepsin B and L in real-time 
inside live cells.23 Through a combination of cell-permeability and covalent binding to 
the active site cleft, the qABPs render the enzymes visible. The low background and the 
high selectivity of qABPs make this an attractive approach for future studies in imaging 
of diseased states. 
1.3 Microarray Technology 
     Microarray-based technologies were originally introduced by Fodor et al.24 in 1991 in 
the form of peptide microarray and later adopted by Affymetrix and the Brown group 25 
to create the now highly popular DNA microarray. Small-molecule and protein 
microarrays were subsequently developed by MacBeath et al.;26 for the first time the 
array-based detection of kinase activity using peptide substrates was also demonstrated. 
In essence, these pioneering studies set the precedent for development of various types of 
microarray-based enzyme assays capable of sensitive detection of different enzyme 
classes.5 At present, four key microarray-based platforms, namely protein-, peptide-, 
small-molecule- and cell-based arrays, have been successfully developed for catalomics 
or the high-throughput study of enzymes. Irrespective of the platform type, one of the 
prerequisites and key steps to establish reliable and reproducible on-chip enzyme assays 
is ligand immobilization (protein/peptides/small molecules). Various immobilization 
strategies available in the literature are discussed below.  
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Figure 1.1. Overview of Catalomics-highthroughput studies of enzymes using the 
chemical proteomics approaches, and its platform technologies and applications. 
1.3.1 Immobilization Strategies in Microarray Applications 
1.3.1.1 Immobilization of Proteins 
     Unlike DNA, proteins and especially enzymes are much more fragile. Loss of enzyme 
activity often accompanies the immobilization of the enzyme onto the solid surface. 
Consequently, one of the critical steps for the development of an enzyme array is the 
immobilization of proteins with minimal loss in their enzymatic activity. Non-specific 
protein immobilization uses hydrophobic surfaces such as nitrocellulose, PVDF and 
polystyrene which adsorb proteins.27 Such random orientation may result in steric 
blockage of either the enzyme active site (for proteins) or the structural element 
recognized by the enzyme (for small molecules and peptides).28 In the first ever report of 
site specific tethering of proteins, Zhu et al. immobilized 5,800 yeast proteins, expressed 
with glutathione-S-transferase– polyhistidine (GST-His6) tag at the N-terminus, onto a 
nickel–nitrilotriacetic acid (Ni-NTA)-coated slide to generate the “yeast proteome 
array”.29 However this method offered limited use as the non-covalent interaction 
between Ni-NTA and the His6 tag is relatively weak and can be easily disrupted by 
commonly used chemicals and salts in biological assays. In addition, no microaray-based 
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enzyme assay was available to fully explore the potential of this platform as discussed by 
Chattopadhaya and Yao.5 Several groups, including our own, have developed alternative 
strategies that allow stable, site-specific immobilization of proteins on glass slides and 
other solid surfaces.30-38 Mrksich and coworkers immobilized cutinase-fused proteins 
onto phosphonate-modified selfassembled monolayers (SAMs).31 Johnsson et al. 
developed a site-specific method to immobilize hAGT fusion proteins to a chemically 
modified glass slide,32 whereas Walsh et al. exploited the Sfp phosphopantetheinyl 
transferase to mediate immobilization of target proteins fused to peptide-carrier protein 
(PCP).33 Our input into this area has been through the development of inteinmediated 
approaches to express recombinant proteins which are site-specifically biotinylated at the 
C-termini, either in vitro or in vivo in bacterial and mammalian cells and subsequently 
used for fabrication of protein microarray by immobilization onto avidin-functionalized 
slides (Figure 1.2a).30 Site-specific protein biotinylation at the C terminus has also been 
achieved in a cell-free protein translation system using puromycin–biotin.34 In yet another 
complementary approach, we have chemoselectively immobilized N-terminal cysteine-
containing proteins, generated via intein-cleavage, to a thioester functionalized slide.35 
Other recent advances in sitespecific protein immobilization include the utilization of 
heterodimeric leucine zipper pairs,36 Staudinger ligation reaction between azide-modified 
proteins and phosphane-modified slides 37 and use of the split intein- mediated protein 
trans-splicing reaction.38 
 
1.3.1.2 Immobilization of Peptides 
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     Peptides are natural substrates of many enzymes. Correspondingly, peptide arrays 
have proved to be powerful tools for high-throughput enzyme screening and to generate 
substrate fingerprints of enzymes.39 Advances in peptide synthesis and combinatorial 
chemistry have made it possible to rapidly generate diverse libraries for such endeavours. 
There are two main methodologies for fabrication of peptide arrays: in situ synthesis 
directly on the array surface or immobilization of pre-synthesized peptide derivatives. In 
situ generation of peptide arrays can be done by either light-directed parallel synthesis 
using photolithography 24 or SPOT synthesis.40 For high-density peptide arrays, robotic 
spotting of pre-synthesized peptides is more economical than in situ synthesis. 
Chemoselective immobilization of peptides is preferred in enzyme assays as it allows 
precise control over peptide orientation, density and may include an “inherent” 
purification step. Chemically “inert” truncated sequences can be washed away following 
covalent surface immobilization of target peptides. Site-specific immobilization of N-
terminal cysteine containing peptides to the glyoxylic acid derivatized slide was first 
reported by Falsey et al.41 Mrksich and colleagues used the classic Diels–Alder reaction 
to couple N-terminal cyclopentadiene-containing peptides onto quinine groups on the 
SAM surface.42 SAM was generated by modification of a gold surface using 
poly(ethylene glycol) (PEG) and alkanethiol. The inert SAM surface provided a uniform 
platform for quantitative assays and prevented non-specific protein adsorption thus 
minimizing background signals during subsequent enzyme assays. In an alternative 
approach, the same group later immobilized N-terminal cysteine-peptides onto 
maleimide-derivatized SAM surfaces.42 Our group developed two novel approaches for 
peptide immobilization. In the first strategy, N-terminal cysteine-containing peptides 
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were spotted onto the thioester-functionalized slide (Figure 1.2b).43 The strategy is 
advantageous as it allows facile synthesis of peptides, and the native peptide bond formed 
between the peptide and surface is highly stable. The second strategy relies on 
immobilization of peptides biotinylated at the N terminus onto avidin-functionalized 
slides. Avidin and biotin interaction is robust and the reaction takes place instantaneously 
which reduces the incubation time greatly. Moreover, the avidin serves as a protective 
molecular layer thereby minimizing the non-specific binding to the slide. The utility of 
these arrays have been subsequently demonstrated in kinase assays.44 
1.3.1.3 Immobilization of Small Molecules  
     Though small molecules have critical roles at all levels of biological complexity, 
identification of small-molecule modulators does not require a priori knowledge of the 
target protein or pathway.5, 45 Consequently, small molecule microarrays (SMMs) have 
emerged as a versatile platform for the high-throughput screening and analysis of 
enzymes. The first small-molecule microarray (SMM) was generated in 1999 by 
MacBeath and Schreiber 26 who showed that thousands of binding assays could be 
performed in parallel from molecules synthesized on individual beads. In addition, it was 
also shown that the SMM can be used to study the weak binding pairs, such as FKBP12 
and its ligand (Kd values in the µM range). Kuruvilla et al. also identified the small 
molecule uretupamine, which can selectively modulate the yeast transcriptional repressor 
Ure2p, from a library of 3,780.46 Similarly, Uttamchandani et al. from our group 
identified four novel ligands for human IgG from a library of 2,688 triazine compounds.46 
The best hits showed the Kd values of 2.02 µM. Immobilization strategies for SMM 
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necessitate that the diverse molecular species and scaffolds are uniformly presented so as 
to maximize protein/ enzyme–ligand interactions. Considerable effort has been expended 
to develop mild and selective methods for anchoring small molecules via unique 
“handles” introduced during the synthesis step. Immobilization chemistries have involved 
the Michael reaction as reported by MacBeath et al. in 1999,26 reaction between a 
primary alcohol and silyl chloride, and that between a phenolic derivative and 
diazobenzylidene as reported by the Schreiber group in 2000 and 2003, respectively.46  
 
Figure 1.2 Selected examples of immobilization strategies in microarrays: a. Site-specific 
protein immobilization by native chemical ligation, b. Site-specific peptide 
immobilization of N-terminal Cysteine-containing peptides onto a thioester-modified 
glass surface, c. Small-molecule immobilization using the Staudinger reaction. 
 
Waldmann et al. and Raines et al. have independently developed methods based on the 



















of water and oxygen (Figure 1.2c). For a more exhaustive discussion on SMM 
immobilization strategies, please refer to other recent literature.5, 48 
1.3.2 Microarray-based Screening Assays 
     Traditionally, enzyme assays have been carried out in microtiter plate format in which 
individual wells serve as self-contained compartments preventing cross contamination 
from neighbouring wells. In a microarray, potentially thousands of different enzyme 
assays have to be carried out on the same flat surface with no physical barrier present 
between assays to prevent free diffusion of reagents from one assay to the next. As such, 
most microtiter plate enzyme assays have to be modified before they may be adapted for 
microarray-based screenings. In the following sections, we shall examine the various 
microarray-based approaches in terms of three different aspects of highthroughput study 
of enzymes, namely functional annotation, substrate fingerprinting and inhibitor 
fingerprinting (Figure 1.3). 
 
1.3.2.1 Functional Annotation  
     In microtiter plate-based assays, functional annotation of enzymes is readily 
conducted in individual wells using substrates that report the progress of an enzymatic 
conversion into some form of measurable read-out (e.g. fluorescence, UV and 
luminescence). Similarly, a microarray platform requires screening assays that can 
translate the enzymatic activity of each individual protein spot into quantifiable readouts 
while minimizing interference from neighbouring proteins. In theory, by using a protein 
microarray, many thousands of proteins may be simultaneously examined, and unknown 
enzymes can be identified in high throughput. Activity-based profiling (ABP), originally 
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developed by Cravatt et al. in 1999 to study serine hydrolases,49 is mainly used for the 
identification and characterization of enzymes present in a mixture of unrelated proteins. 
The method uses small-molecule probes capable of covalently reacting with a (or a class 
of) target enzyme(s) on the basis of the enzyme’s catalytic activity, and is normally 
carried out in a gel-based format. Over the years, a number of research groups, including 
our own, have expanded this strategy further and developed a variety of other types of 
activity-based probes, affinity-based probes (AfBPs) and even substrate-based probes that 
cover a wide range of different enzymes, including all 4 major classes of proteases (i.e. 
serine, cysteine, aspartic and metallo proteases), phosphatases, kinases and 
glycosidases.50-54 In 2003, we reported the first example of functional annotation of 
enzymes in a protein microarray by utilizing activity-based probes and their ability to 
detect enzymes on the basis of their catalytic activity (Figure 1.3a).55 In our study, a 
protein microarray with enzymes immobilized on it was treated with different ABPs, 
leading to selective covalent reactions between the immobilized enzymes and the probe. 
Because the probes were pre-labelled with a fluorescent dye, the formation of covalent 
enzyme–probe adducts rendered the enzymes detectable. Since different mechanism-
based inhibitors, either highly specific or general in terms of their reactivity, are known, 
the strategy would allow for the identification of a variety of different enzymes. 
Furthermore, we have established that the probes react in a time- and concentration-
dependent fashion on the array, thus allowing for quantitative kinetic data to be obtained 
for the complete characterization of enzyme activity. Our strategy was successfully 
carried out with a protein microarray immobilized with different classes of enzymes, 
including phosphatases, cysteine proteases and serine hydrolases, using a panel of 
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different mechanismbased probes. Two different approaches were employed on the 
enzyme array. First, direct labelling of the enzymes was effected by the application of the 
probes to the array, which allowed for high-throughput identification and assignment of 
protein function by virtue of their enzymatic activities. Second, inhibition studies were 
carried out using potential enzyme inhibitors, either general or specific, to simultaneously 
probe and intercompare the efficacy of such inhibitors towards different enzymes. Rapid 
profiling of enzymes provided by this approach empowers researchers to uncover either 
broad- or narrow-range inhibitors that regulate a variety of enzyme activities. Based on 
this strategy, Eppinger et al. and Funeriu et al. have developed a robust strategy which 
allows the measurement the kinetic constants of inhibitors on the chips according to the 
fluorescence readout.56 The enzymes immobilized on the chip were incubated with 
fluorescently tagged affinity label (FAL) under a variety of conditions and the 
fluorescence data obtained was normalized to analyze the kinetic constant and inhibitor 
constant of the enzyme. More recently, we have successfully extended the strategy to the 
functional annotation of enzymes by their substrate recognition preference, rather than 
their enzyme mechanism.56 This was made possible by screening an enzyme microarray 
with our newly developed substrate-based small-molecule probes.54 
 
1.3.2.2 Substrate Fingerprinting 
      In the post-genomic era, emphasis is shifting from mere protein identification to 
protein functional analysis. While distinguishing the different enzyme classes is easily 
achieved since they exhibit orthogonal reactivities across different reaction types, 
differentiating closely related enzymes is more difficult as they display identical 
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reactivity patterns. In a biological context, it is the ability of closely related enzymes to 
discriminate among potential substrates that makes them an essential component in 
maintaining the fidelity of cellular processes. Insights into the substrate fingerprint(s) of 
an enzyme would not only provide invaluable information for identification of 
physiological substrates and help in the dissection of complex biological pathways, but 
also aid in the design of potent, selective inhibitors. The microplate format has been 
traditionally used for fingerprinting experiments and different enzyme classes of have 
been studied in this fashion, including cytochrome P450, protein kinases and hydrolytic 
enzymes.57 Microarray-based substrate fingerprinting has so far been successfully 
developed using peptide and the small-molecule (including carbohydrate) arrays. The 
bulk of these studies have focussed mainly on kinases and proteases—two of the most 
prevalent and important enzyme classes—and to a lesser extent on carbohydrate-
modifying enzymes. Phosphorylation events mediated by kinases are involved in the 
intricate control of cellular signal transduction pathways and form an essential facet of 
the regulatory mechanism in the cell. Consequently, kinases are believed to be highly 
“drugable” proteins. The earliest functional kinase assay in a microarray format was in 
the example of Kemptide phosphorylation catalysed by cAMP-dependent protein kinase 
A (PKA) reported by MacBeath and Schreiber in 2000.26 In a more extensive study, Zhu 
et al. tested 119 of the 122 putative yeast kinases against a panel of 17 different proteins 
immobilized in a nanowell format.58 The group was able to identify as many as 27 
proteins possessing novel tyrosine kinase activities. However, the rate-limiting step in the 
use of proteins as substrates for such studies remains in the production of a large number 
of pure and biologically active proteins. The use of peptides as kinase substrates was first 
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demonstrated by Falsey et al.41 who showed the incorporation of 33P into an immobilized 
peptide by p60c-src tyrosine kinase. Alternatively, in 2002 Houseman et al.42 reported the 
construction of a peptide array on a self-assembled monolayer (SAM) to quantitatively 
evaluate kinase activities. A recent addition to the identification of peptide kinase 
substrates has been the use of “phospho-site” collection arrays.59 These high-density 
arrays contain libraries of peptides derived from annotated phosphorylation sites in 
human proteins. Following synthesis by SPOT technology, the peptides were 
immobilized chemoselectively via an N-terminus aminooxyacetyl moiety. Fluorescently 
tagged antibodies or autoradiography-based detection was used to profile different 
kinases including PKA, CK2, Abl-tyrosine kinase and NEK-6. Schutkowski et al. applied 
this method to the study of key events in kinase recognition and regulation.59 Panse et al. 
also applied this method to investigate the phosphorylation of cytoplasmic domains of 
human membrane proteins by CK2 and the selectivity, subsite specificity and cross 
reactivity of generic anti-phosphoamino antibodies.59 Although these strategies detailed 
analysis of the kinase activity, the radioactivity-based detection methods possess health 
concerns. In order to obviate these drawbacks, we developed an alternative detection 
strategy by utilizing the fluorescently labelled anti-phosphoamino antibodies which can 
specifically recognize the phosphorylated amino acids (Figure 1.3b).43-44 The utility of 
this approach was demonstrated with the peptides ALRASLG and YIYGSFK which are 
substrates for PKA and p60c-src kinase, respectively. The peptides were immobilized site-
specifically onto avidin and/or thioester slides, treated with the cognate kinase and 
probed with the antibody. The antibody detected not only the phosphorylated amino acids 
with high fidelity but also permitted the concentration-dependent study of 
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phosphorylation events, thereby demonstrating that antibody-based detection can 
potentially be extended to the screening of inhibitors/agonists of any kinase, in high 
throughput, in a microarray format. In another study by Uttamchandani et al., starting 
with the putative substrates YIYGSFK, three different classes of combinatorial peptide 
libraries, namely alanine scanning, deletion and positional scanning, were synthesized 
and site-specifically immobilized via an N-terminal CGG linker onto PEGylated thioester 
slides.44 Following kinase treatment and detection with the fluorescently labelled anti-
phosphotyrosine antibody, a unique fingerprint was generated that showed the 
requirement of a backbone comprising a minimum of six amino acids with isoleucine and 
phenylalanine at −1 and +3 positions, respectively, as being critical for the 
phosphorylation event. An alternative, fluorescence-based method for the detection of 
phosphorylated peptides/proteins has also become commercially available that makes use 
of the dye ProQ Diamond.60 This dye is capable of quantification and sensitive 
identification of the phosphorylated substrates: as low as 315–635 fg of substrate could 
be detected on the microarray.  
     Proteases comprise approximately 2% of the encoded genes in organisms whose 
genomes have been decoded. These enzymes regulate diverse physiological processes 
ranging from digestion to cell migration and apoptosis and are therefore naturally linked 
to disease states like cancer, AIDS and neurodegenerative disorders like Alzheimer’s 
disease. As such, proteases must be highly discriminating for substrate cleavage 
sequences. A number of microarraybased protease profiling methods have recently been 
developed. Ellman et al. recently developed an elegant approach for potential high-
throughput profiling of proteases in a microarray format.61 They made use of 
 16 
combinatorial libraries of peptidyl coumarin derivatives immobilized site-specifically in a 
microarray. In this method, cleavage of the peptides was monitored as a function of 
increase in fluorescence due to the release of coumarin by hydrolysis of the peptide 
anilide bond. With this method it was possible to generate the complete specificity profile 
of a given protease, in this case thrombin, and obtain kcat/Km values which concur well 
with those from solution-phase results. This strategy has been applied to profile 
specificity of serine and cysteine protease.62 We independently developed an analogous 
approach to detect hydrolytic enzymes including esterase, phosphatases, proteases and 
epoxide hydrolases.63 A fluorogenic coumarin derivative was suitably modified to 
generate a series of substrates that were immobilized on a glass slide to yield a small-
molecule array. The coumarin derivative served as a bi-functional handle to immobilize 
the substrates via a carboxyl group and also had an electron-donating hydroxyl/amino 
group for attaching the enzyme recognition head that, in turn, was tailored to target a 
particular enzyme class or differentiate between enzymes with altered substrate 
specificities within a given class. By using a solid support for peptide immobilization, 
Kiyonaka et al. studied protease activities using fluorogenic peptides trapped in a 3D 
supramolecular hydrogel.64 Cleavage of a pentapeptide-5-dimethylaminonaphthalene-1-
(N-2-aminoethyl) sulfonamide (DANSen) conjugate by lysyl endopeptidase (LEP) was 
monitored as a function of the increase in fluorescence intensity of DANsen. The method 
was extended to profile other proteases such as V8 and chymotrypsin, as well as to screen 
for LEP inhibitors like Nα-tosyl-lysine chloromethylketone (TLCK). Gosalia and 
Diamond recently described the use of a “liquid-phase” microarray that utilizes nanolitre 
sample volumes for protease screenings.65 For the purpose of array fabrication, glycerol 
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droplets were spotted on glass slides to form individualized reaction centres. 
Homogeneous enzyme assays were then assembled onto the array by simple aerosol 
deposition of reagents, thus doing away with the need for elaborate surface modifications 
which are common in other chip-based enzyme assays. Such fluidphase reactions are 
advantageous as it is possible to tailor optimized reaction conditions at each individual 
position on the array. By using fluorogenic peptide substrates, the authors were able to 
detect multiple enzymes on a single array and demonstrated that the approach is 
amenable to enzymatic profiling and inhibition studies in a highthroughput manner.  
      Sugars and their conjugates, for example glycoproteins, mediate important cellular 
events including cell–cell communication, cell adhesion, signal transduction and the 
attachment of microbes to cells during infection. As such, carbohydrate microarrays have 
been investigated in a series of reports.66-68 The usefulness of these arrays for functional 
enzymatic studies has also been demonstrated. Houseman and Mrksich reported a 
carbohydrate microarray in which the Diels–Alder reaction was used for carbohydrate 
immobilization.68 They subsequently used the “carbochip” to profile the binding 
specificities between rhodamine-labelled lectins and different monosaccharides, as well 
as to characterize the substrate specificity of β-1, 4- galactosyltransferase and also 
quantitatively estimate the inhibitory concentration of methyl α-mannoside for 
concanavalin A in competitive binding studies. In a related study reported in 2003, the 
same group profiled the binding specificity of lectins against an array of 
monosaccharide– thiol conjugates immobilized onto a self-assembled monolayer (SAM) 
derivatized with maleimide groups.42 Park et al. reported the fabrication of carbohydrate 
arrays by immobilization of maleimide-terminated carbohydrates on thiol-coated glass 
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slides.69 Using these arrays, the group demonstrated both qualitative and quantitative 
bindings of lectins to α-, β- and N-linked carbohydrates. They were also able to track the 
glycosylation reactions mediated by β-1,4-galactosyltransferase and α-1,3-
fucosyltransferase, thereby showing that, besides aiding in the identification and 
characterization of novel carbohydrate-binding proteins, the carbohydrate array may be 
equally amenable for assaying and profiling carbohydrate-modifying enzymes en masse.  
 
1.3.2.3 Inhibitor Fingerprinting 
     Small-molecule microarrays (SMMs) are emerging as an important tool for high-
throughput drug discovery, primarily owing to their ability for rapid screening of large 
chemical libraries in parallel. The critical limitation of SMM, however, lies not so much 
in hit identification as in hit validation. This is because most SMM screening methods 
rely on non-covalent ligand–protein interactions, which invariably introduce false 
positives as a result of inconsequential affinity between the ligand and nontargeted 
regions of the protein. Without time-consuming validation, it remains unconfirmed 
whether any of the initial “hits” detected are relevant to the desired biological context. 
When applying the microarray technology for high-throughput screening of inhibitors of 
enzymes, ideally one would like an SMM technology which allows for direct 
identification of potential inhibitors on the basis of their ability to inhibit the catalytic 
activity of an enzyme, thus doing away with tedious hit validation processes. With such 
technology, a true “inhibitor fingerprinting” experiment of enzymes in a microarray-
based format may be achieved. Diamond and Gosalia were the first to develop a novel 
nanolitre-scale screening assay by utilizing nanolitre droplets as microreactors for testing 
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small-molecule inhibitors against three different human caspases.70 Three hundred and 
fifty two small-molecule inhibitors were printed as individual spots of glycerol on a glass 
slide. Subsequently an aerosol mixture of caspase and a fluorogenic substrate were 
applied to assembly multicomponent reactions at each reaction centre. The strength of 
fluorescence signal generated reciprocally correlates with inhibitor potency. This strategy 
revealed a caspase inhibitor that showed high potency against all three of the caspase 
isoforms screened. However use of the viscous mediums such as glycerol and DMSO 
limits the overall applicability of this strategy in scenarios requiring predominantly 
aqueous environments. We have developed an alternative “nanodroplet” method for 
screening of inhibitors.71,72 In our earlier work,71 37 enzymes belonging to different 
classes were spotted in spatially addressable, segregated droplets on a glass slide coated 
with suitable fluorogenic substrates (either small-moleculeor protein-based). Upon 
incubation, nanodroplets containing active enzymes showed up on the microarray as 
discrete fluorescent spots whose intensities directly correlated with the relative activity of 
the spotted enzymes. The feasibility of our strategy for high-throughput identification of 
enzyme inhibitors was demonstrated by screening a 400 member peptide-based small-
molecule library against thermolysin (Figure 1.3c).72 Each member of the library had a 
hydroxamic acid “warhead” and an invariant isobutyl moiety at the P1’ position while 
diversity was generated by substituting P2′ and P3′ positions with combinations of all the 
20 natural amino acids. By printing pre-incubated nanodroplets of enzyme–inhibitor 
mixtures onto a protease-sensitive glass surface, we obtained the inhibitor fingerprint 
profiles for thermolysin in the terms of fluorescence intensity of the spots. Overall this 
strategy offers not only a rapid method for inhibitor profiling and discovery, but also a 
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viable method for the chemical screening of huge combinatorial libraries against virtually 
any enzyme class. 
 
Figure 1.3. Selected microarray-based enzyme screening assays: a functional annotation 
of enzymes in a protein microarray with activity-based probes,55 b substrate 
fingerprinting of kinases with a peptide microarray,43,44 c inhibitor fingerprinting of 
metalloproteases using a small-molecule microarray.72 
 
1.3.3 Other Recent Developments 
     Muralidhar and Kodadek have made use of peptoid arrays to obtain “molecular 
fingerprints” against three fluorescently labelled proteins, namely GST, maltose-binding 
protein and ubiquitin.73 A total of 7,680 octameric peptoids with C-terminal cysteines 
were synthesized and arrayed on a maleimide-functionalized glass slide. Upon screening 
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with the target proteins, a unique and reproducible fingerprint against each protein was 
generated across the whole peptoid array. Moreover, it was also demonstrated that the 
unique fingerprint of GST can be discerned when it arrayed in the presence of a large of 
excess of other bacterial proteins. This report presents a valuable approach for 
identification of protein through unique small-molecule fingerprinting and may have 
diagnostic use to identify cancer or other disease states. Schultz and colleagues reported 
the development of a peptide nucleic acid (PNA)-tagged, small-molecule array that in 
conjunction with the standard DNA microarray technology can be used to monitor the 
levels and activities of enzymes on a proteomic scale.74 Using the split-pool 
combinatorial method, a small-molecule library based on mechanism-based inhibitors of 
cysteine proteases was synthesized, with each member of the library having a PNA tag. 
The PNA tags did not alter the activity/selectivity of these small molecules and, at the 
same time served as molecular “barcodes” which could be used to decode the library by 
hybridization to a suitable DNA microarray. In proof-of-concept experiments reported in 
2001, an equimolar mixture of six cysteine protease inhibitors, having an acrylamide 
moiety as the mechanism-based “warhead” which is highly specific towards cysteine 
proteases, was incubated against individual cathepsins.74 The resulting enzyme–inhibitor 
adducts were fractionated by size-exclusion filtration to remove any free, unreacted 
small-molecule probes. The protein fractions, with PNA-tagged small molecules still 
covalently attached to them, were then hybridized to a GenFlex oligonucleotide 
microarray. Fluorescence signals generated on the array, as a result of hybridization, 
enabled the identification of small molecules which are highly specific, and thus most 
reactive, towards the target cathepsin. Alternatively, in 2002 the Schultz group reported 
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the utility of the method to monitor enzymatic activity on a proteomic scale was 
demonstrated by the detection and characterization of caspase-3 activity in crude extracts 
of cells undergoing apoptosis triggered by Granzyme B.74 Since the enzyme activity 
governs its  binding to the small molecule, the approach may potentially be used to guide 
the design of drugs against diseased phenotypes. The PNA approach has also been 
applied to measure protease activity in crude cell lysates, clinical blood samples and even 
in dust mite extracts.75 From screening with dust mite extracts, an inhibitor for Der p1 
was subsequently identified. Our own inputs into the area of genome-wide identification 
of enzyme activities using the DNA microarray technology have been through the 
development of the socalled expression display technique which combines the advantages 
of three different methods, namely ribosome display, DNA microarray and activity-based 
enzyme profiling.76 In this approach, a mixture of proteins was expressed, in a single 
vessel, from its cDNA library by ribosome display which ensured that each protein 
member was linked and, thus encoded by its own mRNA sequence, via the formation of a 
stable mRNA–ribosome–protein ternary complex. Subsequent functional selections using 
an activity-based small-molecule probe enriched only complexes that contain proteins 
having the desired enzymatic activity. The identity of these enzymes was then decoded in 
a high-throughput manner, following hybridization of their tethered mRNA to a DNA 
microarray. So far we have demonstrated that this approach can be used to isolate and 
identify, in a single experiment, representative yeast tyrosine phosphatases from a large 
pool of unrelated proteins. We envision that, in future, this work can be extended to the 
high-throughput screening of other enzyme classes. Although the arrays described above 
are powerful tools for the study of catalomics, there remain many unresolved questions: 
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hits identified through in vitro HTS may not be effective in vivo. Furthermore toxicity 
and clinical safety evaluation of the small-molecule inhibitors remain to be addressed. 
Sabatini et al. have developed cell arrays to resolve some of these issues.77 The 
usefulness of cell arrays for toxicity screens of small molecules have been evaluated by 
using an array of small molecules embedded in biodegradable poly(D,L-lactide/glycolide) 
copolymer.78 Concurrent efforts from Clark et al. have yielded a metabolizing enzyme 
toxicology assay chip (MetaChip) that combines high-throughput P450 catalysis with 
cellbased screening on a micro-scale platform.79 The utility of the MetaChip concept as 
an alternative method for toxicity screens has been demonstrated by assessing the ability 
of sol-gel encapsulated P450s to activate the prodrug cyclophosphamide. 
1.4 Bioimaging Technology 
 While most of enzyme assays described previously mainly focus on the purified 
enzymes or the crude cell lysates, it will be more meaningful if one could assess the 
enzyme activity in the native cellular environment. By closely monitoring the enzyme 
activity in the live cells, it could allow one to understand how, when and where the 
enzymes function inside the cell and trigger the downstream signaling.  The fluorescent 
protein can be tagged to certain genes or proteins which opens up the possibilities to track 
down the dynamic movement and interactions of proteins/enzymes inside the living cells. 
However, the inherent property of fluorescent proteins has hindered the development of 
this approach due to its bulky size and other factors, especially considering the enzymes 
are very sensitive with the macromolecule fusion. More recently, the small molecule 
based probes for site specific labeling of the proteins have been developed to address 
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these problems and proven useful in protein chemistry. The field has witnessed a 
tremendous development over these years. There are numerous novel examples for 
specific labeling of proteins via small molecule approach reported. Tsien group 
developed a novel approach by exploiting the interactions between organoarsenicals and 
a pair of thios.80 Proteins genetically engineered with CCXXCC motif could be 
recognized and labeled with cell permeable FIAsH ligand specifically.  Keppel et al. 
reported another strategy by utilizing the enzymatic reaction of hAGT.81 hAGT is known 
to transfer the alkyl group from O6 alkylguanine DNA to its cysteine residue.  hAGT 
protein is able to recognize the O6 benzylguanine (BG) or BG derivatives. By fusion the 
target protein with the hAGT, the target protein could be labeled with BGBT and BGAF, 
which contain the biotin and fluoresceine at the 4- position of the benzyl ring.   Our group 
reported the intein-mediated small molecule labeling strategy for specific labeling N-
terminal cysteine-containing proteins.82 Vogel et al. reported the labeling of the 
membrane proteins containing the polyhistdine sequence with a NTA probe in the live 
cells.83 Cornish et al. exploited the strong interaction between DHFR and Mtx and 




The aim of this thesis is to develop enzyme assays which could provide the 
complete fingerprints in terms of their substrate specificities and kinetic measurements of 
a given enzyme. Such fingerprint analysis could be used to solve the issue of functional 
convergence of enzymes on a broad scale and offer unqiue insight into enzyme catalytic 
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mechanism. It is also hoped that the substrate fingerprints of an enzyme would not only 
provide invaluable information for identification of physiological substrates and help in 
the dissection of complex biological pathways, but also aid in the design of potent, 
selective inhibitors. As new roles of enzymes emerge, 85 many more novel applications of 


























Activity Based Fingerprinting of Proteases Using 






           We have successfully developed a protease assay using fluorescence resonance 
energy transfer based peptide libraries, which allows not only general detection of 
enzymatic activities, but more importantly substrate fingerprinting of proteases from 
different classes. The method allows the generation of substrate fingerprints of a protease 
from both the nonprime and prime sites. Therefore, it is well suited for profiling of major 
metalloproteases such as thermolysin and MMPs. We envisage that this method will 




     Enzymes are arguably the most important class of proteins in our cells. Of the many 
classes of enzymes, proteases comprise one of the biggest (in their number) and most 
ubiquitous (in their participation in various biological processes). Many of them are 
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implicated in major human diseases such as cancer, AIDS, infectious and 
neurodegenerative diseases.86 Knowledge of the substrate specificity in these enzymes is 
crucial for revealing the mechanism of their biochemical and cellular processes, as well 
as designing potential protease inhibitors. This calls for the development of high-
throughput protease assays capable of not only detecting the catalytic activity but more 
importantly profiling the substrate fingerprint of proteases.87 
     Microplate-based assays have traditionally been used for enzyme identification and 
fingerprinting experiments.8 So far, a number of different enzyme classes have been 
studied in this fashion, including cytochrome P450, protein kinases, proteases, and other 
hydrolytic enzymes. For proteases alone, a number of well-established approaches, such 
as the use of fluorescence resonance energy transfer (FRET) peptides, Bodipy Casein 
Assay, courmarin-containing fluorogenic peptide libraries, are readily available. More 
recently, some of these assays have been successfully adopted in microarray formats, thus 
making them amenable for high-throughput protease fingerprinting experiments.88 
Microarray-based technologies, pioneered by Fodor, Brown, Schreiber, and others, are 
now increasingly becoming a routine method in chemistry and biology for 
highthroughput screening.5 Ellman et al. first reported the use of peptide microarray for 
protease fingerprinting.61 They made use of combinatorial libraries of peptidyl coumarin 
derivatives immobilized in a microarray. In this method, cleavage of the peptides was 
monitored as a function of increase in fluorescence because of the release of coumarin as 
a result of peptide hydrolysis. We independently developed an analogous approach to 
detect hydrolytic enzymes including esterases, phosphatases, proteases, and epoxide 
hydrolases, also using coumarin fluorogenic conjugates.63 More recently, Gosalia and 
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Diamond have extended this strategy for protease screening in a ‘‘liquid-phase’’ 
microarray that utilizes nanoliter sample volumes of coumarin-conjugated peptides. 70 
The authors were able to detect multiple enzymes on a single array and demonstrated that 
the approach is amenable to enzymatic profiling and inhibition studies in a high 
throughput manner. One of the biggest drawbacks of all coumarin-based protease assays, 
however, is that they can only be used to fingerprint the P-site residues within a protease 
substrate (e.g. the substrate-binding sites N-terminal to the scissile bond). Therefore, they 
cannot be used to profile proteases that prefer P’-site recognition, i.e. most 
metalloproteases including thermolysin and matrix metalloproteases (MMPs).72,86 To 
address this issue, Craik et al. recently developed a fluorogenic assay utilizing ligand-
enhanced lanthanide ion fluorescence, which showed some promise in the profiling of the 
prime sites of proteases.89 The fsa group released from the peptide conjugated with 5-
fluorosalicyclic acid (fsa) and coordinated with a lanthanide ion terbium (III) to produce 
a fluorescent signal upon enzyme cleavage. This may serve as a complementary approach 
to coumarinbased protease assays. However, the generality of this strategy has not yet 
been proven, nor is it suitable for microarray applications. In a different approach, 
Kiyonaka et al. studied protease activities using FRET peptides trapped in a 3D supra-
molecular hydrogel.64 Cleavage of a pentapeptide-5- dimethylaminonaphthalene-1-(N-2-
aminoethyl) sulphona- mide (DANSen) conjugate by lysyl endopeptidase (LEP) was 
monitored as a function of the increase in fluorescence intensity of DANsen. By 
successfully extending this approach to profile other proteases such as V8 and 
chymotrypsin, as well as to screen for LEP inhibitors like Na-tosyl-lysine 
chloromethylketone (TLCK), the authors showed that FRET-based protease assays are 
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also suitable in a microarray format, and therefore may be used for potential high-
throughput characterization and fingerprinting of protease activities. In this work, we 
were interested to know whether FRET-based assays could be used to resolve the long-
standing problem faced with assays using coumarin fluorogenic substrates (that is, their 
inability to fingerprint the prime sites of protease substrates). We investigated and 
compared three most commonly used protease assays (Scheme 2.1) using a variety of 
proteases: (1) Bodipy Casein Assay (commercially available under the trade name of 
EnzChekTM Protease Assay Kit),90 (2) coumarin-based fluorogenic peptides, and (3) 
FRET-based peptides. By doing so, we aimed to determine the suitability and potential of 
FRET-based assays in high-throughput identification and fingerprinting experiments, as 
well as the delineation of protease substrate specificity. Ultimately, we sought to develop 
a universal and facile platform in ‘‘Catalomics’’ that allows the general detection of 
protease activity with high sensitivity, as well as provides substrate specificity profiles of 





SCHEME 2.1 The three approaches used to study protease activity and substrate 
fingerprint: (a) Bodipy Cascein Assay; (b) coumarin-based fluorogenic peptide libraries; 
(c) FRET peptide libraries. 
 
2.3 Results and Discussion 
 
2.3.1 Protease Assays 
 
     Of the three most commonly used protease assays (Scheme 2.1), the Bodipy Casein 
Assay is the most general in the activity based detection of most proteases, regardless of 
their substrate specificities. If a protease is enzymatically active, it will likely give out a 
fluorescence signal upon treatment with Bopipy casein provided by the kit. The assay 
works by utilizing a Bodipy labeled casein as a fluorogenic protease substrate. Casein is a 
protein cleaved by many endogenous proteases, and hence a natural substrate for most 
proteases. In this case, it is heavily labeled by Bodipy (a fluorophore) such that the 
fluorescence of the labeled protein is internally quenched, rendering it virtually 
nonfluorescent (Scheme 2.1a). Upon cleavage by a protease, the protein is degraded into 
multiple peptide fragments and thus releases a strong fluorescence signal. The assay is 
useful in detecting the catalytic activity of many proteases from different subclasses (i.e. 
serine, cysteine, aspartic, and metallo-proteases). However, it does not provide any 
information about the enzyme substrate specificity, and thus cannot be used for substrate 
fingerprinting experiments. In our studies, we use this assay as a benchmark for general 
detection of protease activities against all proteins tested.  
To assess whether FRET-based peptide libraries could be used for substrate 
fingerprinting experiments against proteases that prefer both prime and nonprime sites, 
we synthesized a total of 20 mixture-based peptide libraries, ACCXXPXXX- K(Dabcyl), 
in which a donor molecule (ACC) and quencher molecule (Dabcyl) were flanked by a          
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hexapeptide. The peptide libraries were synthesized using standard solid phase Fmoc 
chemistry as shown in Scheme 2.2. ‘‘X’’ in the hexapeptide stands for an isokinetic 
mixture of 19 amino acids (except cysteine). ‘‘P’’ represents a specific amino acid from 
the 20 natural amino acids. As such, each library has 5 randomized residues and 1 fixed 
Figure 2.1 The chemical synthesis of Fmoc-Lys(Dabcyl) and Fmoc-Lys(Biotin). a) N-
hydroxysuccinimide, DCC, 12h, 85%; b) Fmoc-Lys-OH, DIEA, 12h, 60%; c) N-





























































SCHEME 2.2 Synthesis of 20 FRET peptide libraries. 
 
position, thus giving >2 million (i.e. 195) different sequences based on theoretical 
calculation. The fixed position was located in the center of the peptide in order to 
maximize binding by a potential protease. Before enzyme cleavage, the fluorescence 
from the donor fluorophor (ACC) in the FRET peptide was quenched by the nearby 
quencher (Dabcyl) and thus very little fluorescence was observed at this stage. Upon 
proteolysis, the quencher was cleaved off and thus the probe was switched on, releasing a 
strong fluorescent signal, which directly correlates with the amount of the cleaved 
peptide. The fluorescence signal can be generated from any cleavage site between the 
donor and quencher in the FRET peptide, thus the assay is compatible with proteases that 
recognize both prime and/or nonprime substrate binding sites. Unfortunately for the same 
reason, it does not tell unambiguously the exact site of cleavage, as well as the preferred 
residues and their locations flanking the scissile bond. It is our hope, however, that by 
making positional scanning (PS) libraries of FRET peptides, in which each position is 
systematically ‘‘scanned’’ with every amino acid, and screening the libraries against a 
target protease to generate a fingerprint, one might be able to extract useful information 
concerning the substrate specificity of the protease, from which the scissile bond, the 
prime and nonprime site residues may be deduced.  
          
2.3.2 FRET-Based Assay 
     Seventeen different proteins were used to test against our 20 FRET-based peptide 
libraries; they include serine proteases (trypsin, α -chymotrypsin, β -chymotrypsin, 
subtilisin, and proteinase K), cysteine proteases (bromelain, papain, chymopapain, ficin, 
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SrtA A and TEV), metalloproteases (thermolysin and actinase E), aspartic proteases 
(rennin and pepsin), achromopeptidase, as well as BSA, which is not a protease (as a 
negative control). We found that, upon enzyme treatment, the fluorescence signal 
obtained for libraries containing the preferred amino acid residues (at the fixed position) 
were at least 10 folds higher than the background fluorescence reading (e.g. before 
enzyme cleavage), which provided a very good signal-to-noise ratio when compared with 
results from Bodipy Casein Assay tested against the same enzyme. We also tested the 
libraries against BSA, a protein that does not possess any protease activity; no increase in 
fluorescence signal was observed from any of the 20 libraries after 1 h incubation. As 
expected, BSA did not show any protease activity either when tested with Bodipy Casein 
Assay. This confirms that our FRET libraries are useful in detecting the general 
enzymatic activity of most proteases and not limited to any particular protease class. TEV 
and SrtA are two well-known proteases that recognize only highly specific substrate 
sequences spanning at least 5 amino acids long.91 They were screened against both the 
FRET peptide libraries and Bodipy Casein Assay. Not surprisingly, both enzymes failed 
to generate much fluorescence read-outs from either assay, indicating the potential 
limitation of our approach in screening highly specific proteases. 
 
2.3.3 Detection Limit 
     Subsequently, we carried out the study of detection limits of our FRET-based 
approach by using one of the FRET libraries, ACC-XXKXXX-Lys(Dabcyl), in which 
lysine residue was represented at the ‘‘P’’ position, against the enzyme trypsin. Trypsin is 
well known to cleave peptide sequences having basic residues such as Lys and Arg at the 
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P1 position. By choosing this sublibrary, we expect that trypsin will cleave the library at 
the carboxyl end of K in the peptide sequence, generating a detectable fluorescence signal. 
Different amounts of the enzyme were used in the assay ranging from 10 pg to 0.1 µg (in 
100 µl assay volume). After 1 h incubation, the fluorescence reading was recorded using 
a SpectraMAXTM Gemini XS fluorescence plate reader at ex = 355 nm and em = 460 
nm. The relative fluorescence intensity was plotted against the enzyme concentration to 
determine the detection limit and the linear range of the assay (Figure 2.1); as little as 10 
ng/ml of the enzyme could be detected from this assay, indicating the high sensitivity of 
this assay. The fluorescence signal increased with the increase of the enzyme 
concentration, until saturation point was reached, indicating complete cleavage of the 
peptide. At lower enzyme concentrations, the relative fluorescence signal was directly 
proportional to the enzyme concentration, providing a good linear relationship for 
potential determination of relative enzyme activities using this assay. 
 
FIGURE 2.2 Hydrolysis of ACC-XXKXXX-Lys(Dabcyl) by trypsin. The two different 




2.3.4 Substrate Fingerprinting 
     Having successfully validated the FRET-based strategy in sensitive detection of 
different classes of proteases, we screened the 20 FRET peptide libraries against all 14 
different proteases (excluding TEV and SrtA) in a quantitative matter. Upon 
normalization, the collected data was plotted in the form of a heatmap to generate the 
‘‘substrate fingerprint’’ of the enzymes (Figure 2.2), in which each enzyme was 
represented with a unique substrate specificity ‘‘molecular barcode". The 14 proteases 
were hierarchically clustered based on the similarity of their fingerprint profiles, which is 
shown as the tree structure. The degree of similarity of proteases is indicated as a 
function of the height of lines connecting profiles. As shown in Figure 2.2, in most cases 
the fingerprint profile of each protease correlated reasonably with the enzyme’s known 
substrate preference.91 For example, trypsin and bromelain are known to prefer basic 
residues such as Lys and Arg at the P1 position. Correspondingly, they both showed high 
(and almost exclusive) fluorescence signals toward the two FRET libraries having ‘‘Lys’’ 
and ‘‘Arg’’ residues (at the fixed position; same denotation below), i.e. Acc-
XXKXXXK(Dabcyl) and Acc-XXRXXX-K(Dabcyl), respectively. Achromopeptidase 
also showed good fluorescence signals toward a number of different amino acids, but it 
clearly had the highest activity toward ‘‘Lys,’’ which is also in good agreement with its 
known substrate preferences. Actinase E, which is known to have similar substrate 
specificities as thermolysin, expectedly gave a similar fingerprint profile, and was 
clustered together as well. Both enzymes were shown to prefer ‘‘Leu,’’ ‘‘Ile,’’ ‘‘Met,’’ 
‘‘Val,’’ and ‘‘Phe,’’ most of which are hydrophobic in nature, which is once again in 
good agreement with their known substrate specificities. Renin and pepsin, both acid 
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proteases, gave similar fingerprint profiles and were clustered together. a-chymotrypsin 
and β-chymotrypsin, two isoforms of the same enzyme, were clustered together. They 
also showed preferences toward FRET libraries having ‘‘Leu,’’ ‘‘Phe,’’ and ‘‘Tyr,’’ most 
of which are known to be the preferred P1 residues of the two proteases. Three proteases 
known to possess broad-spectrum substrate preferences, papain, subtilisin, and proteinase 
K, showed good activities towards most FRET libraries and gave ‘‘less-than-unique’’ 
fingerprints. Consequently, they were clustered together. We reckon this may underline 
the limited utilities of our approach toward other proteases having similar broad substrate 
specificities. 
 
Figure 2.3 Substrate fingerprint of the 20 FRET peptide libraries against 14 different 
proteases. The heatmap was generated using the programs ‘‘Tree View’’ and  ‘‘Cluster’’ 
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developed by Eisen group, 92 which converts the numerical values into the color formats. 
Color in each grid stands for the relative signal generated by each probe, which was 
obtained by the microplate experiments. The 14 proteases were arrayed along the x axis 
and the 20 FRET substrates were arrayed along the y axis. As the purity and activity of 
commercial enzymes differ from each other, the signal generated was internally 
normalized, by defining ‘‘maximum signal", which comes from the most preferred 




     In summary, we have successfully developed a protease assay using FRET-based 
peptide libraries, which allows not only general detection of enzymatic activities, but 
more importantly substrate fingerprinting of proteases from different classes. When 
compared with other existing protease-fingerprinting approaches, i.e. coumarin-based PS 
libraries and other FRET-based combinatorial libraries,93 the biggest advantage of this 
method lies in its ability to generate substrate fingerprints of a protease from both the 
nonprime and prime sites. Therefore, it is suitable for future studies of major 
metalloproteases such as thermolysin and MMPs. One major disadvantage of the FRET 
method is that it does not unambiguously define the exact site of the scissile bond, as well 
as the location/identity of preferred amino acids flanking the site. Based on our results, 
however, we showed this problem may be partially addressed by our 20-member FRET 
library which has so far only scanned one position. In future, a complete PS library that 
‘‘scan’’ every position within a putative protease substrate sequence may be used which 
might give rise to a more comprehensive fingerprinting profile of the protease. We 

















           This chapter describes the first peptide microarray for studying the Ser/Thr 
phosphatases. Phosphatases didn’t get as much as attention as kinase due to its substrate 
promiscuity as well as the difficulty to synthesize the phosphopeptides.Until recently, 
there are much of the reports about the function and crystal structure of phosphatases, 
there are seldom reports dealing with the substrate specificity of Ser/Thr phosphatases. 
Herein, we presented the first peptide microarray for studing the Ser/Thr phosphatases by 
1) a knowledge based library derived from the proteins which potentially undergoes the 
dephosphorylation in vivo, 2) the ultrasensitive ProQ Diamond Dye and 3) simultaneous 
and quantitative measuremnets of enzyme  dephosphorylation on the glass surface, we 





Reversible phosphorylation of proteins (a critical posttranslational event catalyzed 
by kinases and phosphatases) occurs in >20% of human proteins.94 Although kinases 
have been studied extensively,95 knowledge about the biological characterization of 
phosphatases, for example, their cellular partners and substrate specificities, is limited. 96 
The reason is, in part, the lack of strict substrate specificity in many phosphatases, as well 
as a shortage of techniques that enable quick and accurate determination of potential 
phosphatase substrates. There are two main classes of protein phosphatases, namely 
tyrosine phosphatases (PTPs) and Ser/Thr phosphatases. Most approaches developed thus 
far have focused on mapping the substrate specificity of PTPs.97-99 Early studies involved 
kinetic assays of individually synthesized phosphopeptides.97 More recently, 
combinatorial peptide libraries and SPOT synthesis were introduced.98 In the latest 
example, Waldmann and co-workers introduced a peptide-microarray strategy for 
mapping the substrate specificity of PTPs. 99 by immobilizing phosphopeptides on glass 
slides and detecting their dephosphorylation with a fluorescently labeled anti-pTyr 
antibody; the strategy is a major improvement over previous membrane-based 
methods.100 The main drawback, however, is that it can only study PTPs due to the lack 
of reliable anti-pSer/Thr antibodies. Herein, we report the first peptide microarray for 
high-throughput studies of Ser/Thr phosphatases.  
A peptide microarray is a miniaturized screening platform that enables thousands 
of individually addressable peptides to be simultaneously interrogated on a glass slide.101 
Over the last few years, the peptide microarray has become a viable choice for high-
throughput determination of enzyme substrate specificities. 41,42,44,61 In our current work, 
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we show that glass slides that have multiple peptide substrates of Ser/Thr phosphatases 
immobilized on them can be used to simultaneously determine the preference of the 
enzymes for the different substrates; with this information, new biology may be 
discovered. In contrast to the approach of Waldmann and co-workers, our method is 
amenable to both Ser/Thr phosphatases and PTPs. Compared to other approaches, it 
offers unique advantages in terms of throughput and sensitivity.102  
To detect peptide dephosphorylation on the glass slide, we used a signal-decrease 
assay with the commercially available Pro-Q Diamond dye, which is capable of 
fluorescence-based measurement of pSer/Thr/Tyr residues present in peptides and 
proteins (Scheme 3.1a).60 Compared to other microarraybased methods that report 
phosphorylation/dephosphorylation, 41, 44, 99 the Pro-Q method is advantageous in terms of 
its safety, ease of handling, and sensitivity. 60 On each peptide microarray, 6 identical 
subarrays were fabricated, with each containing all 87 putative Pin1 peptides individually 
spotted in duplicate (Scheme 3.1b). Each subarray comprises approximately 200 different 
spots, thereby allowing up to 1200 different enzymatic assays to be simultaneously 
performed on the same slide. By closely monitoring the dephosphorylation event of every 
peptide in the whole collection (Scheme 3.1 b), one can 1) carry out kinetic 
measurements and obtain the relative rates of dephosphorylation (kobs) for many peptides 
against a phosphatase, 2) generate unique and comparative substrate “fingerprints” of 
different phosphatases, and 3) discover potential phosphatase/substrate pairs regulated by 
Pin1. In our studies, the peptide microarray was designed for Ser/Thr phosphatases, but 
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                                     (b) 
 
Scheme 3.1 Overall flow of strategy. (a) Scheme of the p(Ser/Thr)-Pro peptide 
microarray used to target Ser/Thr phosphatases. (b) The subarray format and three types 
of applications introduced in the current study.  
 
3.3 Results and Discussion 
 
3.3.1 Peptide Libraray Design 
 
We designed and synthesized 87 putative peptide substrates of Ser/Thr 
phosphatases, each containing 11 amino acid residues with a centrally located p(Ser/Thr)-
Pro moiety franked by 5 and 4 amino acids on each side (Scheme 3.1a see Table 10.1 for 
complete sequences). Protein phosphrylation/desphorylation on (Ser/Thr)-Pro moieties is 
highly prevalent amongst known kinase/phosphatase substrates and a key signaling 
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mechanism for the control of numerous cellular processes.103 These peptide sequences 
were extracted from putative protein substrates of the peptidyl prolyl cis/trans isomerase 
(PPIase), or Pin1, by data mining through published literature and available public 
databases. Pin1, together with its regulatory kinases/phosphatases, has recently been 
identified as a key cellular regulating molecule, and shown to play a role in cancer and 
Alzheimer’s disease.103 By working synergetically with its regulatory 
kinases/phosphatases, Pin1 serves as a conformational switch to control the 
interconversion of the (Ser/Thr)-Pro moiety, either nonphosphorylated or phosphorylated, 
in the substrate protein. Many substrate proteins of Pin1 are involved in cell cycle 
regulation, transcription and response to DNA damage. Much less is known, however, 
about the enzymes that control their phosphorylation/desphosphorylation status. In fact, 
PP2A is the only Pin1-regulated phosphatase identified to date.104 Our aims in this work 
were therefore to develop a peptide microarray that allows quantitative determination of 
candidate Ser/Thr phosphatases and their activities against putative Pin1 peptide 
substrates, and to identify unknown physiological phosphatase/substrate pairs whose 
activity is regulated by Pin1 cis/trans isomerization. The peptides were individually 
synthesized by standard solid-phase peptide chemistry and characterized by LC-MS. An 
extra hydrophilic linker and biotin were introduced to the N-terminus of each peptide, 
which was then subsequently immobilized onto an avidin-coated glass slide to generate 































































Scheme 3.2 Scheme of the peptide synthesis and the final peptide structure. Both 


























































                           


























































































   
 
Figure 3.1 Representative LC-MS profiles of the 87 phosphopeptides used in this study. 
The purity of the final products was determined by Shimadzu automated reverse phase 
HPLC coupled with IT-TOF spectrometry. Single major peaks (80% purity) and correct 
masses (> 95% of all samples) were obtained. For peptide sequences and ID, please refer 




3.3.2 Determination of Peptide Immobilization Efficiency and Pro-Q Detection 
Linear Range  
 
 To ensure the accuracy of our results, we determined the variability of spots from 
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reading was obtained for the same peptides spotted arcoss different subarrays/slides. We 
noticed, however, different peptides spotted on the same (sub)array, despite a uniform 
spotting concentration (and a high correlation between duplicate spots), registered 
varying degrees of fluorescence reading after Pro-Q treatment (Figure 3.2b). This is 
presumably caused by differential binding affinity of the dye to different peptide 
sequences. The same phenomenon had been reported previously.60 
We also systematically examined the immobilization of peptides and the Pro-Q 
staining method for detection of the peptide dephosphorylation on the array. First we 
tested the immobilization efficiency of TMR-biotin on the array. We found that the 
immobilization of dye on array varies linearly in proportion to dye concentration up to a 
concentration of 100 µM. Above 100 µM, The avidin surface started getting saturated. 
From 500 µM onwards, the avidin surface was completely saturated. The negligible 
change in fluorescent intensity between wash 1 and wash 2 reflects the strong and stable 
biotin-avidin interaction, thus ensuring minimum loss of immobilized peptides during 
microarray process (Figure 3.3).  Subsequently, the immobilization efficiency of peptides 
and Pro-Q detection linaer range is determined by spooting different concentration of 
phosphorylated peptides onto array. Results indicated that the peptide immobilization 
achieved the saturation at around 100uM and complete saturation at 500uM, which 
agreed well with the results obtained with TMR-biotin (Figure 3.4). The linear detection 
range is below 100uM. The spiking experiments with nonphosphorlated peptides also 
proves that the signal generated from Pro-Q staining is proportional to the percentage of 
phosphorylated peptides present in each spot regardless of the immobilization 
concentration of peptides (Figure 3.5). In addition, none of the non-phosphorylated 
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peptides showed any significant fluorescence signal upon ProQ treatment, thus ensuring 
that in our experiments, fluorescence signals detected on the slide originated exclusively 
from the phosphorylated peptides (Figure 3.6). 
 
Figure 3.2 The reproducibility of different subgrids on the array. (a) The 87 
phosphopeptides spiked with 0.1% of TMR-biotin were spotted on a slide containing 3 
identical subgrids and immediately imaged at Cy3 channel (w/o any ProQ treatment). 
The image shows that spots located on different subgrids of the same slide were 
spotted uniformly and consistently. (b) The same 87 peptides (w/o 0.1% TMR-Biotin) 
were similarly spotted, washed, treated with ProQ before scanned for fluorescence. The 
correlationship among different subgrids is more than 0.9 which shows the fluorescence 
images generated from different subarrays on the same slide were highly consistent and 









Figure 3.3 Determination of immobilization efficiency by TMR-biotin. (a) Structure of 
TMR-biotin. (b) Different concentrations of TMR-biotin ranging from 5 mM, 1 mM, 500 
µM, 100 µM, 50 µM, 10 µM, 5 µM, 1 µM, 500 nM, 100 nM, 50 nM, 10 nM, 5 nM, 1 nM, 
500 pM, 100 pM, 50 pM, 10 pM, 5 pM to 1 pM were spotted on avidin slide (from right 
to left). Top to bottom: duplicated spots. The slide was scanned before wash (top image), 
after 1st wash (center image) and after 2nd wash (borrom image). (c) Sigmoidal curves 
were obtained by fitting the data obtained from (b) into a sigmoidal dose-response 
equation (d) Linear relationship was obtained between fluorescent intensity vs. dye 
concentration ranging from 100 µM to 5 µM.  Below 5 µM spotting concentration, the 
fluorescence signals were too weak to be accurately measured (we scanned all our slides 
with a PMT exposure time of 0.5 – 1 sec; it’s possible that for spots < 5µM (peptide 


















































































Figure 3.4 Determination of peptide immobilization efficiency and Pro-Q detection 
linear range. (a) Representative peptides with different dilutions were spotted on array 
and stained with ProQ dye. (b) Sigmoidal curves were obtained by fitting the data into a 






























Figure 3.5 The spiking experiments with nonphosphorylated peptides. Representative 
phosphorylated peptides (E2, E5, L5, K8) were diluted with corresponding non-















Figure 3.6 The Pro-Q image of phosphorylated peptides vs the corresponding 
nonphophorylated peptides. Of the 87 phosphopeptides used in this study, most of their 
non-phosphorylated counterparts (76 in total) were synthesized. Both the phosphorylated 
(left image) and the non-phosphorylated (right image) peptides were spotted on the same 







3.3.3 Time and Concentration Dependent Experiments  
 
     We next investigated whether the peptide microarray could be used for kinetic studies 
of a Ser/Thr phosphatase against its potential substrates. Commercially available Lambda 
phosphatase,105 an enzyme possessing Ser/Thr phosphatase activity from bacteriophage λ 
and distantly related to PP2A and PP1 (also Ser/Thr phosphatase), was used as the model 
protein. Both concentration- and time-dependent experiments were carried out by 
applying different amounts of the enzyme (0 to 8 U) to different subarrays on the glass 
slide, as well as incubating the subarrays for different periods of time under a uniform 
enzyme concentration (Figure 3.8a &3.8b). All experiments were performed in triplicate. 
Results were shown to be highly reproducible. Concomitant fluorescence decreases were 
observed with increasing enzyme concentrations and incubation time, for all active 
peptide spots (that is, spots that show a decrease in fluorescence reading upon treatment 
with Lambda phosphatase). An optimized enzyme concentration was thus obtained and 
used for all subsequent experiments. Inhibition experiments were carried out by 
preincubating Lambda phosphatase with different amounts of Na3VO4 (a general 
phosphatase inhibitor) before being applied to the peptide microarray; a complete 
abolishment of phosphatase activity was observed at 1.4 mM of Na3VO4, indicating the 
specific detection of phosphatase activity on the microarray (Figure 3.8c). To obtain 
kinetic data, the fluorescence data from the time-dependent experiments, representing a 
total of 1044 individual data points (87 peptides x 6 time intervals; in duplicate) was 
quantified, filtered and fitted to the following kinetic profile 
 
          P=So(1-exp(-kobs*t))                                     (Eq.1) 
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where kobs = (kcat/KM)*E, representing the observed kcat/KM under a given enzyme 
concentration (E). P in the equation represents the background-processed fluorescence 
reading of a peptide spot at different time intervals (t) substracted by the fluorescence 
reading at t=0. S0
 
represents the initial fluorescence reading of each peptide (e.g. t = 0). A 
representative fitted curve was shown in Figure 3.7b. Our assay was run under conditions 
in which the enzyme and peptide substrate concentrations were well below the KM, such 
that relative rates of desphorylation (kobs) truly reflect kcat/KM ratios.61,106 The kobs 
obtained from our experiments could therefore allow us to quantitatively compare the 
kinetic profiles of different substrates for the same enzyme (and in future, different 
enzymes for the same substrate). To ensure the quality of kobs obtained, we subjected the 
data to stringent filtering criteria (accuracy curve fits (r > 0.85) and significant 
desphorylation signals (> 40% change from original Pro-Q readings), and were able to 
obtained reasonable kobs for 53 of the 87 peptides (Table 10.2 ). To confirm the accuracy 
of our microarray data (which is based on solid-phase assay), we picked three 
representative peptides having different kobs (high, moderate and low) for independent 
verification using a solution-phase HPLC assay (Figure 3.7c & Table 3.1): results 
confirmed that kobs obtained from the microarray were consistent with those measured 
using the HPLC assay. Furthermore, the microarray assay appeared to be quite sensitive, 
capable of detecting “weak” substrates which would otherwise have eluded the HPLC 
assay. This indicates the potential of the peptide microarray-based approach as a high-




Figure 3.7 Time-dependent experiment with Lambda phosphatase. (a) The six subgrids 
were incubated with Lambda phosphatase at different time intervals (0, 5, 15, 30, 60 and 
120 min). Only one subarray was shown (0 min). “zoomed” images represent time-
dependent images of three peptides (E2, L5 & E8). (b) The kinetic profiles and the fitted 
curves of three representative peptides: E2 ( ), L5 (◊) and E8 (♦). (c) The time-
dependent HPLC assay validation experiment of the three peptides. No noticeable 
dephosphorylation of E8 was detected. (∗) starting peptides, (∗) dephosphorylated 
peptides.  
 
Table 3.1 kobs values obtained from the microarray and HPLC assays  
 
 
Peptide kobs using array kobs using HPLC 
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Figure 3.8 Time, concentration and inhibition dependent experiments with Lambda 
phosphatase. (a) Time-dependent experiment with 1 u of the enzyme. (a) Concentration-
dependent experiments on the array with lambda phosphatase, the 6 girds of peptides 
were incubated with different concentrations of lambda phosphatase (0 u, 0.5 u, 1 u, 2 u, 
4 u, 8 u). (b) Lambda inhibition experiment by different concentrations of Na3VO4 (0 
mM, 0.35 mM, 0.7 mM and 1.4 mM).  
 
 
     To study the relationship between the amounts of immobilized peptides in our 
microarray system and the corresponding kinetic data (e.g. kobs), we also immobilized 
different amounts of the same peptides on one slide and performed the time course 
Time dependent  (min) 
Enzyme concentration (U) 
      Inhibitor concentration (mM) 
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enzyme assay. Results indicated that the kobs value obtained didn’t vary significantly with 
varied spotting concentration (Figure 3.9). This is true because our assay was run under 









































 E2: PVPPGpTPAPPG 
 L5: HSSAApTPNLGP 
 E8: HSESApSPSALS 
(c)    
Spotting Concentration kobs /Peptide E2 kobs /Peptide L5 kobs /Peptide E8 
1000 µM 0.153 0.081 ND* 
500 µM 0.076 0.037 ND 
100 µM 0.104 0.018 ND 
50 µM 0.090 0.048 ND 
Average 0.11 0.05 ND 
10 µM NA 0.151 ND 
5 µM 0.102 NA ND 
   * ND = The kobs value was too small to be determined. NA = Data could not be fitted properly 
 
Figure 3.9 Time-dependent experiment with Lambda phosphatase at different spotting 
concentrations of peptides (a) Time-dependent experiment with Lambda phosphatase (1 
U) at different spotting concentrations of phosphorylated peptides (E2, L5, E8) (left to 
right: 1 mM, 500 μM, 100 μM, 50 μM, 10 μM to 5 μM. (b) The kinetic profiles and 
the fitted curves of two representative peptides (E2 and L5) at different concentrations. (c) 
kobs value obtained from time course experiments of 6 different concentrations of 
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Peptide spotting concentration 
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peptides. At lower spotting concentrations (10 μM, 5 μM), the fluorescence reading of 
the spotted peptides were too weak to be accurately detrmined. As such the 
corresponding kobs values obtained were of little significance. At higher spotting 
concentrations, reasonable fluorescence signals and the corresponding kobs (upon enzyme 
treatment) could be obtained (see table above), showing the  kobs of peptide 





3.3.4 Substrate Fingerpringing of 5 Phosphatases 
 
We next used the peptide microarray to generate the corresponding substrate 
fingerprints against 5 different phosphatases (including Lambda phosphatase). All 
phosphatases tested showed distinct substrate specificities (e.g. “fingerprints”) against 
our peptide microarray (Figure 3.10). Alkaline phosphatase is a “spurious” enzyme 
known to desphorylate a variety of phosphate-containing molecules (including phospho-
peptides/proteins).107 Interestingly, it showed a clear preference towards pSer over pThr 
amongst the phosphopeptides (Figure 3.11), which is a key criteria routinely used to 
distinguish acid/alkaline phosphatases from “genuine” Ser/Thr phosphatases.107 Lambda 
phosphatase dephosphorylated most of the 87 peptide substrates in our microarray,  
which agrees well with its known broad substrate specificity as previously reported.105 Of 
the three mammalian Ser/Thr phosphatases, PP1, PP2B (only the phosphatase subunit of 
PP2B, CnA, was used in our experiments) and PP2A, only PP2A was previously shown 
to be involved in Pin1 regulation pathways.104 PP1, known to play an essential role in 
regulation of glucose metabolism, calcium transport, intracellular transport, protein 
synthesis and cell division,108 was previously reported to show low activity against most 
peptide substrates. Correspondingly, it weakly dephosphorylated most peptides in our 
microarray. Nonetheless, it showed a preference for pThr over pSer peptides as 
previously reported.107 Of the numerous peptides PP1 dephosphorylated, many are 
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derived from known PP1 susbtrate proteins, including Cdc25, Tau and Raf.109 PP2B, also 
called calcineurin, is a heterodimer made of two major subunits, namely CnA and CnB. It 
plays an essential role in controlling the development and the function of immune, 
nervous, cardiovascular, and musculoskeletal systems.110 We expressed the CnA subunit 
(the phosphatase subunit) and tested it against our peptide microarray. Results showed 
that CnA dephosphorylated most peptide substrates. Of the top 6 substrates of CnA 
identified from our results, half of them bear a basic residue at the -3 position (BTK-21, 
C1 & Tau ). This is in good agreement with previous reports regarding the substrate 
specificity of PP2B.111  PP2A, as expected, dephosphorylated many of the peptide 
substrates in our microarray (vide infra), albeit with weak activity in general. Overall, the 
unique fingerprints generated from our experiments not only offers useful information for 
unraveling potential physiological substrates of a target phosphatase, but also facilitates 







Figure 3.10 Substrate fingerprints of 5 different phosphatases (and buffer only as control) 
against the panel of 87 peptides. (a) Original microarray images. (b) Heatmap of the 
extracted data, with selected peptides identified (Table 10.3 ). 
 
 

























Figure 3.11 Further substrate fingerprints analysis by grouping pSer and pThr peptide 
separately. (a) Substrate fingerprints of 5 different phosphatases against the panel of 87 
peptides based on grouping pSer and pThr peptides separately. The graph was generated 
by the data obtained from Table 10.3 (upon proper grouping of pSer and pThr peptides). 
(b) Relative desphorylation rate of pSer-containing peptides vs pThr-containing peptides. 
Data were generated from Table 10.3, by grouping and averaging the dephosphorylation 
rate of all pSer and pThr peptides separately for each phosphatase.  
 
 
3.3.5 Pin1 Regulation Experimet and Cell Based Assay 
 
Pin1 was previously reported to isomerize the p(Ser/Thr)-Pro motif in a number of 
phosphoproteins (e.g. Cdc25 and Tau), and consequently regulate their 
dephosphorylation by PP2A.103, 104, 112 This regulatory mechanism plays an important role 
in a variety of cellular activities and is associated with human diseases including cancer 
and Alzheimer’s disease.103 PP2A is the only phosphatase identified thus far that takes 
part in Pin1-regulated dephosphorylation. We were therefore interested to know whether 
our peptide microarray could be used to investigate Pin1-regulated dephosphorylation 





























physiological protein susbtrates of PP2A could be identified. We carried out the 
dephosphorylation experiment with PP2A, with or without Pin1, on the peptide 
microarray (Figure 3.12a). As shown in Figure 3.12b, by setting +0.1 of Pin1 regulation 
scores as the cut-off thresholds, the affected peptides could be broadly classified into 
different groups: (1) “Expected” (> + 0.1 score) comprise peptides derived from 
previously reported, Pin1-regulated protein substrates of PP2A, including Cdc25 (T286) 
and Cdc25 (T48) (Red bars in Figure 3.12b);104, 112 (2) “Unexpected” (< +0.1 score) 
represent peptides derived from previously known Pin1-regulated protein substrates of 
PP2A, including the two Tau peptides;104, 112 and (3) “New” (> +0.1 score) include 
peptides  derived from proteins not previously known to be Pin1-regulated PP2A 
substrates. They are highlighted with (*) in Figure 3.12b (left to right, respectively), 
including p53, A16, p73, Bcl-2 (S87), p54nrd, Cyclin E, Sil (S699), E6 and Sil (T574). In 
this list, the peptide that caught our immediate attention was Bcl2 (S87) (yellow bar in 
Figure 3.12b) - a phosphopeptide derived from the anti-apoptotic protein Bcl-2 which 
plays a key role in apoptosis and cancer.113 It is known that the activity of Bcl-2 is highly 
regulated by phosphorylation under ER or oxidative stresses, and PP2A may be involved 
in dephosphorylation of Bcl-2.114 Recent studies have also indicated that Pin1 can interact 
with Bcl-2;115 however, the tripartate relationship has not yet been established. In our 
current study, the regulation experiment has provided a rapid and (hopefully) accurate 
means to predict the potential interplay among these three important proteins (e.g. Pin1, 
PP2A and Bcl-2).  To confirm this, we carried out cell-based experiments to investigate 
the effect of Pin1 on Bcl-2 dephosphorylation using Pin1 WT (Pin1+/+) and Pin1 
knockout (Pin1-/-) mouse embryonic fibroblasts (MEFs) (Figure 3.12c). Consistently, 
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both Pin1+/+ and Pin1-/- MEFs showed no difference in the level of Bcl-2 protein 
expression (2nd gel in Figure 3.12c), suggesting that Pin1 did not affect the expression of 
Bcl-2. Importantly, we observed dramatic increase in the phospho-Bcl2 (Ser87) protein 
level in Pin1-/- MEFs (4th gel in Figure 3.12c). These results indicate that in the absence of 
Pin1, PP2A probably displayed significantly reduced phosphatase activity, resulting in an 
accumulation of phospho-Bcl2 (Ser87) protein level. At this moment, we could not rule 
out the possible involvement of other Ser/Thr phosptatases (rather than PP2A) in 
regulating the Bcl-2 dephosphorylation Pin1-/- MEFs. Nonetheless, this result 
corroborates with our microarray-based experiments.  
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Figure 3.12 Pin1-regulated dephosphorylation by PP2A and cell based experiment. (a) 
Array images upon treatment with i: buffer, ii: PP2A only, iii: Pin1+PP2A. The squared 
spots correspond to Bcl-2 (S87) peptide (Yellow) and two of the Cdc25 peptides (Red). 
(b) Pin1 regulation score for PP2A activity against the panel of 87 peptides. See Table 
10.4 for details. A Regulation score of +0.1 was deemed a potentially positive regulation. 
Selected peptides were highlighted by colors or with asterisks.  (c) Cell-based 
experiments with Pin1+/+ and Pin-/- cell lines to confirm the up regulation of Bcl-2 (S87) 
protein dephosphorylation by PP2A in the presence of Pin1. PP2A is endogenously 




In conclusion, we have developed the first peptide microarray platform capable of 
both qualitative and quantitative determination of Ser/Thr phosphatase activities in a 
miniaturized format, in high throughput. The strategy should be amenable for future 
studies of other types of phosphatases. By accurately quantifying the dephosphorylation 
of putative peptide substrates by a target phosphatase and generating the so-called 
substrate fingerprint, we were able to delineate the substrate preferences of the enzyme in 
an in vitro setting and in the presence of regulating proteins. We showed the strategy 
could be used to discover new phosphatase biology in vivo. This was illustrated with the 
example of PP2A, a previously known Pin1-regulated enzyme. This might provide useful 
information for future discovery of potential Pin1 inhibitors. We therefore envisage our 
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14-3-3 proteins are a family of acidic proteins which bind to a maltitude of functionally 
diverse signaling proteins, e.g. kinase, phosphatase and transmembrane receptors. More 
evidence showed they regulate important cellular processes including cell cycle 
progression, DNA damage, apoptosis, etc. For the very first time, we developed a 
fragment-based combinatorial peptide microarray to determine the  substrae binding 
specificity agaisnt seven highly homologous 14-3-3 isoforms in high-throughut. With this 
platform, we were able to unravel the novel consensus binding motifs against all isoforms 





14-3-3 are a family of ~30 kDa acidic proteins expressed in all eukaryotic cells.116 By 
binding, either as homo or heterodimers, to a variety of phosphoserine-containing 
proteins, they regulate important cellular events including cell cycle progression, DNA 
damage, apoptosis, protein trafficking, signal transduction, cytoskeletal rearrangements, 
metabolism and transcriptional regulation. In human, there are seven distinct but highly 
homologous 14-3-3 isoforms, namely β, ε, η, γ, σ, τ and ζ. Thus far, however, the only 
isoform directly linked to cancer has been 14-3-3σ, which is regulated by the major 
tumor suppressor gene, p53.116a Inactiviation of 14-3-3σ is crucial in tumorigenesis. 
Consequently, there have been tremendous interests in the determination of substrate 
specificity of 14-3-3:phosphopeptide binding as well as the structural basis of this 
interaction.117 The elegant work of Yaffe et al was particularly worth noting, where a 
degenerate phosphoserine-oriented peptide library was used to examine the sequence 
requirements for binding to 14-3-3.117a Results confirmed the highly conserved substrate-
binding specificity amongst the 14-3-3 isoforms, giving rise to a consensus hexapeptide 
binding motif, RXXpSXP, which binds strongly to all 14-3-3 isoforms tested. In other 
studies, x-ray crystallography was used to provide the detailed structural information of 
seven human 14-3-3 isoforms bound to a phosphopeptide.117b,117c Interestingly, 14-3-3σ, 
unlike the other six isoforms, was the only protein shown to preferentially form a 
homodimer upon substrate binding. Our ongoing interest in the use of 14-3-3σ as a 
potential cancer target has prompted us to speculate it might be possible to identify 
phosphopeptides that preferentially bind to 14-3-3σ over other isoforms. We report herein 
the first peptide microarray platform made of fragment-based, combinatorial 
phosphoserine/phosphothreonine-containing heptapeptide libraries (P
-3P-2P-1-p(S/T)-
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P+1P+2P+3) for substrate specificity determination of seven mammalian 14-3-3 proteins, 
and the identification of putative 14-3-3σ selective motifs (Figure 4.1).  
     Peptide microarray is a miniaturized screening platform that enables thousands of 
individually addressable peptides to be simultaneously interrogated on a glass slide. 39, 88, 
99,118
 It is well-suited for high-throughput (HT) studies of protein/peptide interactions. 
Compared to other HT peptide-screening approaches, i.e. phage display,119a SPOT™ 
synthesis4b and combinatorial peptide libraries (positional scanning (PS),119b 
degenerate117a and one-bead-one-compound (OBOC)119c), it offers the unique advantage 
that every single spot on the side may be made addressable and quantifiable 
instantaneously.118a In order to obviate the current upper limit of 1,000-10,000 different 
features attainable on a microarray platform, we introduced the concept of fragment-
based combinatorial peptide microarray that enables sufficient coverage of all P
-3P-2P-1-
p(S/T)-P+1P+2P+3 sequences with only 1,000 different spotting features (500 N- and C-
terminal sublibrary each, P+/- represents 10 or 5 individual AAs and X+/- represents an 
isokinetic mixture of 14 AAs; Figure 4.1a);120 by “scanning” fragments (i.e. the 
tripeptides flanking p(S/T)), rather than positions (e.g. in a PS119b or degenerate 
library117a), we retained the “neighboring position effect” ignored by PS/degenerate 
approaches, and ensured a sufficient concentration of peptides was present on the spotted 
array.44b Similar to a PS/degenerate library, screening results obtained from our fragment-
based scanning (Figure 4.1b-d) can be reconstituted to give accurate and relevant 
biological information (Figure 4.1 e-f). To minimize the number of spots on the array, 10 














Figure 4.1 Overall flow of the strategy. (a) Chemical structures of the 1000-member 
fragment-based phosphopeptide library used in this study (residues were numbered 
according to their proximity to p(S/T) and negative if they were located N-terminal to it. 
p(S/T) instead of pS was used so that the peptides could be used to probe other 
phosphopeptide-binding proteins such as Pin1.8 Biotin and a GG linker were introduced 
in each peptide for microarray immobilization. (b) Pro-Q™ image of the 1000-member 
peptide microarray. (c) & (d) Microarray images upon screening with Cy3-labeled Pin1 
and 14-3-3, respectively. (e) & (f) Data analysis. In (e), the 50 p(Ser/Thr)-Pro containing 
peptides were highlighted in blue.  
 
4.3 Results and Discussion 



























































P = 5 or 10 individual AAs
X = an isokinetic mixture of 14 AAs































































































(500 in total) C-terminal sublibrary(500 in total)
Rink amide resin
1000 individual microreactors
(40 mg resin each)
X = isokinetic mixture of 14 AAs





































Scheme 4.1 Peptide synthesis. (a) Peptide synthesis of the two 500-member N- and C-
terminal, mixture-based sublibraries. (b) Scheme of the synthesis of the individual, 
reconstituted peptides, labeled either with biotin or TMR at the N-terminus 
 
The 1000-member phosphopeptide library was synthesized using the IRORI™ split-and-
pool combinatorial approach in two installments, (Scheme 4.1) and subsequently spotted 
(in duplicate) onto an avidin-coated glass slide to generate the corresponding peptide 
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microarray.121 To ensure uniform immobilization, spotted slides were subjected to Pro-
Q™ staining (Figure 4.1b); the image indicates most features (> 99 %) were spotted 
uniformly and consistently, with minimal spot-to-spot and slide-to-slide variations (r > 
0.95). We next assessed if this fragment-based combinatorial microarray could be used to 
obtain substrate specificity of known protein/peptide interactions. Pin1, a well-
documented peptidyl prolyl cis/trans isomerase, is known to bind to p(Ser/Thr)-Pro 
containing peptides with exquisite specificity.103 As shown in Figure 4.1c & 4.1e, of the 
50 p(Ser/Thr)-Pro containing peptide spots in our 1000-member library, 48 bind to Cy3-
labeled Pin1 with substantially higher RF (relative fluorescence) values, unambiguously 
confirming that our fragmented-based peptide microarray could be used for HT 
determination of protein/peptide interactions.  
 
4.3.2 Substrate Fingerprinting of Seven 14-3-3 Isoforms 
     Next, seven mammalian 14-3-3 isoforms were recombinantly expressed, purified, 
fluorescently labeled, and screened with the peptide microarray.  Upon data processing, 
highly reproducible (as judged from duplicated spots/slides), affinity-based fingerprints 
were generated and presented as color heat maps (Figure 4.2a); results indicate that, 
while the overall binding profiles of seven isoforms were quite similar as expected 
(Figure 4.3; r > 0.8 across all isoforms), there were some subtle but distinctive features in 
the fingerprints which differ from one isoform to another, and could be further explored 
to identify 14-3-3σ specific motifs. This clearly highlights the advantage of our array-
based approach over other mixture-based combinatorial methods where only averaged 
data are obtained.117a,119b Further data analysis was carried out using three different 
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methods: (1) position specific scoring matrix (PSSM) to determine averaged binding 
affinity of 14-3-3 across P+/1, P+/2 and P+/3 positions for each amino acid (Figure 4.4); (2) 
top-50 hits identified from each N- and C-terminal sublibrary against individual 14-3-3 
isoforms (Figure 4.5); (3) top-100 hits identified from the 1000-member library 
(irrespectively of N-/C- terminus) against all seven 14-3-3 (Figure 4.6). Results are 
summarized in Table 4.1 and indicate that, regardless of how the data were analyzed, the 
14-3-3 consensus binding motifs derived from our experiments were in excellent 
agreement with previous work using degenerate peptide libraries.117a In addition to the 
general RXXpSXP motif, we uncovered more detailed 14-3-3 binding information. For 
example, R/K were highly preferred at -1 position, and mostly nonpolar residues were 
preferred at -2 and +1 positions. This again agrees well with Yaffe’s work.117a 
Interestingly, we also observed some previously undetected preferences of Pro at -2, Ala 
at -1, Val at +1 and F/L at +3 positions. To confirm these potentially new 14-3-3 binding 
motifs, we made reconstituted peptide sequences of RAApSVPL and RPApSVPL,122 
followed by microarray-based KD determination and fluorescence polarization 
experiments (Figure 4.7); results showed both motifs bind to 14-3-3σ with 
submicromolar affinity, similar to RLSHpSLPG, a well-known 14-3-3 binding peptide.  








-3 P-2 P-1 P+1 P+2 P+3 
Yaffe 
R, K F, S, Y, W, H, A R,K, H 
W, Y, F, 
L, A P, G X 
1 R, P, L, 
F 
A, P, R, 
F, V R, K 
A, V, F, 
L P,A 
F, L, P, 
R 
2 




R A, F, G, P, R, V 
K, R, 


















Figure 4.2 Images of the 1000-member peptide library screened against 7 different Cy3-
labeled 14-3-3 isoforms (left), and the corresponding heat maps (right). For each isoform, 
a total of 10 sub-heat maps were generated by fixing the P+/-3 positions first with their 
respective AAs (5 for P
-3 and 5 for P+3). Within each sub-heat map (zoomed graphs), data 












































Figure 4.3 Scatter plot analysis of the data obtained from the 1000-member peptide 
library. For illustration purpose, 14-3-3 Tau was used to compare with the other six 14-3-
3 isoforms. A good Pearson coefficient (r > 0.8) was obtained in all cases, confirming the 
highly conserved binding patterns of the seven 14-3-3 isoforms against the 1000-member 




























Figure 4.4 Position specific scoring matrix (PSSM) representing averaged binding 
affinity across P+/-1, P+/-2 and P+/-3 positions for each amino acid. The height of each letter 
represents the weighted contribution of that residue to overall peptide binding. The side 
chains are colored according to their properties: hydrophobic/aromatic (black), acidic 





Figure 4.5 Relative binding potency of seven 14-3-3 isoforms across the six permutated 
positions (left to right: in the order of P
-3, P-2, P-1, P+1, P+2 & P+3), as obtained from the 
analysis of top-50 hits from both the N- and C-terminal sublibraries against each 14-3-3 
isoform. Each bar represents the frequency of occurrence of a particular amino acid in the 





































Figure 4.6 Relative binding potency of consensus hits against all seven 14-3-3 isoforms, 
identified from the top-100 list (obtained by analysis of top-100 hits from the 1000-
member library, irrespectively of N- or C-terminus) against each 14-3-3; (a) From the 
top-100 hits against every 14-3-3 (7 x 100 potential sequences in total), Venn diagram 
was used to filter and identify consensus sequences present in all seven isoforms, giving a 
total of 46 unique peptide motifs (I (Beta + Epsilon + Eta) = 63 consensus sequences; II 
(Gamma + Sigma + Tau + Zeta) = 54 consensus sequences; III (I + II) = 46). (b) List of 
the 46 consensus top binders against all seven 14-3-3 isoforms. (c) Bar graph 
representatition of (b), indicating the relative binding potency across the six permutated 
positions (left to right: P
-3, P-2, P-1, P+1, P+2 & P+3). Each bar represents the frequency of 



















Figure 4.7 Quantitative determination of selected peptide motifs binding to 14-3-3σ. (a) 
Microarray-based KD determination of 9 representative peptide motifs selected from the 
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46 consensus binders (numbering of the peptides/spots were based, 5 from the C-terminal 
and 4 from the N-terminal sequences. (b) KD determination of 2 reconstituted peptide 
motifs and a previously reported 14-3-3 binding motif (control). I: microarray-based KD 
determination; II: KD determination using fluorescence polarization experiments with 




4.3.3 Identification of Isoform-specific Binding Motif for 14-3-3σ 
      Due to the highly homologous feature of 14-3-3 proteins, it is extremely challenging 
to identify isoform-specific binding motifs. Given the critical role of 14-3-3σ plays in 
cancer biology,116 our aim was to explore the throughput, sensitivity, reliability, as well 
as the ability to discriminate subtle binding differences, of our peptide microarray for HT 
discovery of 14-3-3σ selective motifs. To do this, we identified six selected sequences 
from the preliminary fingerprinting results (e.g. Figure 4.8a), reconstituted and screened 
them on the microarray using a dual-color ratiometric approach developed 
recently.121,123,124 As shown in 4.8b & c, with the dual-color approach, 14-3-3σ selective 
peptides could be readily and reliably interrogated with another isoform, and visually 
identified (i.e. red spots in Figure 4.8b). A selectivity score of log2(Cy5 σ/Cy3 isoform) 
was obtained for every peptide against the other six 14-3-3 isoforms. As shown in Figure 
4.8c, of the eleven peptides studied, A1, A2 & A3 are RLSHpSLPG, RAApSVPL and 
RPApSVPL, respectively, which expectedly bind to most 14-3-3 isoforms 
indiscriminately. Six out of the other eight reconstituted peptides showed some degrees 
of preference toward 14-3-3σ binding. Among them, B1 (LFGpSLLR) and B2 
(LFGpSLVR) preferentially bind to σ at least twice as strongly as almost all other 
isoforms. To further confirm these results, we carried out experiments using Surface 
Plasmon Resonance (SPR) (Figure 4.9); results confirmed that B1 indeed binds to 14-3-
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3σ preferentially (KD = 0.54 µM) over the other six 14-3-3 isoforms (KD > 10 µM). 
















Figure 4.8 Affinity-based fingerprinting of seven 14-3-3 isoforms. (a) Colored heat maps 
displaying binding of the 1000-member peptide library against seven Cy3-laleled 14-3-3, 
sorted in the order of P+/-3>P+/-2>P+/-1 amino acids. (insert) Six putative σ-specific 
peptides were identified. (b) Dual-color ratiometric screening using a protein mixture 
containing Cy5-labeled σ and a Cy3-labeled 14-3-3 isoform. A new microarray was used 
in which 11 peptides were spotted (in duplicate vertically). As a control (σ/σ), the first 
slide was treated with an equal amount of Cy5- and Cy3-labeled σ. All spots appeared 
orange indicating equal RF in both channels. σ-specific spots appeared red. (c) Bar graph 
representing the selectivity scores, log2(Cy5 σ/Cy3 isoform), of the 11 peptides from (b). 
Score “0” indicates no selectivity and “+” indicates σ-preferred peptides. An arbitrary 
threshold of “1” was set (dashline), to highlight motifs binding to σ at least twice as 





























Figure 4.9 KD obtained from SPR experiments. (a) Summary of KD obtained from SPR 
experiments. (b) SPR profiles of B1 against each of the seven 14-3-3 isoforms and the 
corresponding fitted curves.  
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4.4 Conclusion 
     In conclusion, we have developed the first fragment-based combinatorial peptide 
microarray that enables high-throughput determination of substrate binding specificity 
and rapid discovery of isoform-selective motifs against the highly homologous 14-3-3 
proteins. By introducing the concept of fragment-based scanning in a peptide microarray 
for the first time, our platform was able to cover a large peptide sequence space using a 
manageable number of spots/peptide libraries, without the loss of detailed and subtle 
information on protein/peptide interaction. We have uncovered novel putative binding 
motifs of 14-3-3σ whose biological relevance needs to be further validated. We foresee 





















  PTPs have become important therapeutic targets in recent years. However, the 
PTP active site is highly conserved across the whole PTP families, which present a 
dauting task to design selective and potent inhibitors targeting to each PTP. The 
successful development of PTP inhibitors relies on a detailed undertanding about the 
molecular mechanism of PTP catalysis as well as substrate specificity. In our approach, 
we applied the fluorescently labeled PTP mutants onto pTyr peptide array and studied the 
substrate specificities of different PTPs. By using this approach, we were able to 1) 
generate the unique and comparative affinity-based substrate fingerprints against 
different PTPs, 2)obtain quantiative KD  values of a given phosphatase against different 
substrates on a single slide, and 3) simultaneously screen multiple PTPs under different 
fluorescence channels by a single doube labeling assay.   
 5.2 Introduction 
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  Protein phosphorylation and dephosphorylation reactions are employed by living 
organisms for the regulation of innumerable cellular processes. The protein tyrosine 
phosphatases are the classe of enzymes that act as catalysts in the dephosphorylation of 
the phosphotyrosine residues in their protein substrates. More than 100 PTPs are encoded 
in the human genome. PTPs play a crucial physiological role in variety of mammalian 
tissues and cells. Tyrosine phosphorylation accounts for only 0.01-0.05% of total protein 
phosphorylation. However, upon oncogenic transformation or growth factor stimulation, 
the level of tyrosine phosphorylation increases to 1-2% in the cell.125  Defective 
regulation of PTPs leads to various human diseases like cancer, diabetes, and immune 
disorders.126 PTPs have increasingly become important therapeutic drug targets. Many 
inhibitors targeting to PTPs have been made and investigated in recent years. However, 
the PTP active site is highly conserved which presented a daunting task as well as 
significant challenge for designing selective and potent inhibitors targeting to a given 
PTP.  
  PTP 1B shares 74% sequence homology with TCPTP in their catalytic domain, 
however, their substrate specificity has implicated these enzymes in various signaling 
pathways.127 SHP1, is implicated as a negative regulator in haemopoietic signalling.128 
SHP2 is very similar to SHP1 in terms of sequence homology. However, their fucntions 
are very different. Deletion of this gene will result in death which indicates SHP2 is 
critical for regulation of cellular function. SHP2 is also implicated in the cancer 
development due to the mutation.129 LMW PTP is a small size PTP which is composed of 
around 157 amino acid residues. The little sequence similarity between LMW PTP and 
other PTPs indicates that this enzyme is belonging to a novel class of PTPs.130 
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      In recent years, there have been numerous examples of extensive biochemical and 
structual studies on PTP family, which leads to a better understanding about the 
molecular mechanism of PTP catalysis. However, the molecular basis by which PTP 
distinguish and recognize the diverse substrates in cellular environment remains largely 
unknown. Currently, there are few methods which allow high-throughput and 
comprehensive studies on substrate specificity of PTPs. Only very recently, Waldmann 
and our group independently report the feasibility of using peptide microarray for large-
scale phosphatase substrate specificity studies.99,121b Compared to other standard 
approaches, i.e. membrane59a, SPOT40, phage display119a, peptide array offers the unique 







Scheme 5.1 The two approaches employed in our study. (a) The PTP mutants were 
fluorescently labeled and used to probe the binding affinity towards the pTyr array (b) 
The p(CAP) was incoporated into peptides and used for detecting PTP substrate 
















  In our approach, we developed an innovative array technique based on PTP 
substrate-trapping mutant131(Scheme 5.1a). The method is based on the ability of PTP to 
bind to its cognate substrate during dephosphorylation. When the critical active site 
residue is mutated, e.g. Cys to Ser, the substrate retains the ability to bind to PTPs; 
whereas the nucleophile attack on the phosphatae cannot occur. The subtstrate-trapping 
mutant approach has been utilized extensively for the identification of a number of 
putative PTP substrates both in vitro and in vivo. By integration of microarray and PTP 
substrate mutant approach, it allows one to 1) generate the unique and comparative 
affinity-based substrate fingerprints against different PTPs, 2)obtain quantiative KD 
values of a given phosphatase against different substrates on a single slide, and 3) 
simultaneously screen multiple PTPs under different fluorescence channels by a single 
doube-labeling assay.  We envisage this approach will be able to quickly discern the 
substrate difference of  highly homologous PTP pair, e.g.  PTP1B and TCPTP, SHP1 and 
SHP2. These information will greatly help to design the highly specific inhibitors for a 
given phosphatase. Unlike the activity based assays for highthroughput screening of PTP 
inhibitors which suffer from the highly reactive oxidizing and alkylating reagents might 
surface as hits, our approach eliminates the potential false positives by mutation of the 
sensitive cysteine residue into serine.132 
      In another supplementary approach, we also explored the feasibility to study the 
substrate specificity of PTPs by replacing the pTyr with unnatural fluorogenic analogue 
P(CAP) in peptide sequence (Scheme 5.1b). p(CAP) has been proved as a sensitive probe 
to detetct the PTP activity in the microplate assay.133 Herein we seek to extend this 
approach onto array to study the substrate specificity of PTPs. The advantage of p(CAP) 
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approach lies in that it allows the real time monitoring phosphatase activity by recording 
the increased fluorescent intensity. we synthesized 16 putative peptides with 5 aas on 
both sides of p(CAP) to probe the substrate specificity of PTPs on the array as the very 
preliminary step.   
5.3 Results and Discussion 
5.3.1 Peptide Library Synthesis 
We synthesized 144 putative peptide substrates of PTPs, each containing 11 
amino acid residues with a central located pTyr moiety flanked by 5 amino acid residues 
on each side. The peptide sequence is derived from potential PTP protein substrates by 
data mining from the website: www.hprd.org. The peptides were individually synthesized 
by standard solid-phase peptide chemistry and characterized by LC-MS (Table 10.5). An 
extra hydrophilic linker and biotin were introduced at the N-terminus of each peptide, 
which was then subsequently immobilized onto an avidin-coated glass slide to generate 
the corresponding peptide microarray. To ensure uniform immobilization, spotted slides 
were subject to Pro-Q dye treatment. The image indicated most of the peptides were 


































































































Figure  5.1 The Pro-Q image of 144 pTyr peptide library. (a) The microarray image after 
staining with Pro-Q dye. (b) The spotting format in our study. 
 
5.3.2 Substrate Fingerprinting of PTP Mutants 
Next the active site mutants of 5 different PTPs (PTP1B, TCPTP, SHP1, SHP2 
and LMWPTP) were mutated by using the commercially available site directed 
mutagenesis Kit. Subsequently, these PTP mutants were expressed, purified, 
fluorescently labelled and applied onto array. Highly reproducible data were obtained 
across different slides. (r>0.9) All PTPs tested showed distinct substrate specificities 
against our peptide microarray (Figure 5.2a & Table 10.6). The peptide AELEFpYMDYEA 
which was previously reported as a potent substrate for PTP1B98d showed the strong 


















approach for identifying the potent substrates. PTP1B and TCPTP displayed very similar 
binding pattern which proved that they are highly homologous to each other. SHP1 and 
SHP2 which share high sequence homology also clustered together (Figure 5.3). LMW 
PTP is implicated as a novel class of PTP which showed the most unique binding pattern 
among the 5 PTPs investigated. SHP1 and SHP2 are well known to bind to ITIM motif. 
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 Further data analysis with the frequency of occurrence of a particular amino acid at N-
3 and C+2 positions were carried out with the top 69 binders selected from both SHP1 
and SHP2 binding experiments. Results indicated that SHP phosphatase indeed prefers 
the amino acid residue “Ile”, “Leu”, “Thr” and “Val” at N-3 and C+2 position (Figure 
5.2c). Interestingly, the top binders for SHP1 and SHP2 identified from our array 
experiments closely matched with the literature which reported the relevant experiments 
showing their interaction in vitro or in vivo (Figure 5.4). Nevertheless, this didn’t apply to 
PTP1B and TCPTP, which probably could be due to the reason that there might be other 
factors which determine the substrate specificity, e.g. subcellular localization or the 
protein sequence other than catalytic domain which is responsible for binding occur. In 
the mean time, the denatured fluorescently labelled protein didn’t show any binding 
towards our array which indicated our affinity assay is activity dependent. The 14-3-3 
protein which contains the GST tag served as a negative control and didn’t show any 
obvious binding towards our array. It indicated that GST tag didn’t contribute any 
binding to our array. On the other hand, it also proved the pSer/Thr binding proteins 
didn’t bind to pTyr peptides. The previous reported pSer/Thr peptide array also didn’t 










Figure 5.2 Substrate fingerprints of 5 different PTP mutants. (a) Microarray image of 5 
different PTP mutants. (b) Substrate fingerprintof 5 different PTP mutants in “Tree view” 
format. (c) The summary of amino acid frequency at N-2 and C+3 position of Top 69 




Figure 5.3 Calodograms of  PTPs based on substrate fingerprint obtained from pTyr 
peptide array. The panel was clustered according to the fluorescence data set of 144 
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Figure 5.4 The venn diagram from top 59 binders of SHP1 and SHP2. It shows that 32 
peptides which sequence are derived from SHP1 or SHP2 protein substrates are in the list. 




















Figure 5.5 Proof–of-concept experiments with pTyr peptide array. (a) The denature 
experiment of PTP mutants. The top panel showed the image obtained with denatured 
fluorescently labeled mutants. The bottom panel showed the image obtained with the 
corresponding fluorescently labeled mutants. (Left, SHP1, right PTP1B) (b) The 
microarray image of 14-3-3 protein against pTyr peptide array. 14-3-3 protein, which is 
previously shown to binding to a pSer/Thr peptide microarray, didn’t show measurable 
specific binding to any of the pTyr peptides on the array, indicating our pTyr peptide is 
highly specific for screening of PTP mutants.  
 
5.3.3 Dual Labeling Assay 
      Next we went on further to investigate the substrate specificity difference 
bewteen the highly homologous pairs by using dual labeling approach. Due to the high 
degree of homology between PTP1B and TCPTP, it is extremely challenging to identify 
the selective substrates or inhibitors towards PTP1B or TCPTP. To discriminate the 
subtle difference between these two enzymes, we carried out the dual labeling assay and 
identified several comparatively selective peptides against PTP1B (by setting the 
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Figure 5.6 Dual labeling assay with PTP1B and TCPTP. (a) The microarray image of 
PTP1B Cy5 vs TCPTP Cy3, (b) The summary of selectivity ratio results of PTP1B 
against TCPTP. The higher the value, the more selective towards PTP1B. 
Subsequently, we picked up 3 of the selective peptides and verified the selectivity by 
microplate activity assays. The results indicated that the peptides were indeed specific 
towards PTP1B (Table 5.1). 
Table 5.1  The kobs of PTP1B-selective peptides against PTP1B and TCPTP. 




kobs /PTP1B kobs /TCPTP 
B15 IESDIYAEIPD Type 12 0.14 0.048 
D12 SSTVQYSTVVH SHP2 0.215 0.11 
D24 YFMTEYVATRW Mitogen kinase 0.040 0.017 
       
  SHP phosphatase is known to contain two N terminal SH2 domain and catalytic 
domain. SH2 domain is also known to bind to pTyr containing peptides. To explore 
whether the binding affinity comes from SH2 domain itself or PTP catalytic domain 
alone, we overexpressed proteins of SH2 domain and catalytic domain from SHP2 
respectively and applied fluorescently labeled proteins onto array. Results indicated that 
both of SH2 domain and catalytic domain has the binding affinity towards our pTyr 
peptide array. Further data analysis also indicated that the full length SHP phosphatase 
binding affinity comes from both SH2 domain and catalytic domain together (Figure 
5.6a).  On the other hand, SHP1 and SHP2 are interesting homologous PTP pair under 
our investigation. They share 61% homology in their catalytic domain and 64%, 55% 
similarity in their two N terminal SH2 domains respectively135, however, their cellular 
functions are very different. SHP1 is a potential anti-oncogene and inhibits the growth of 
tumor by negatively regulation of c-Kit gene. Whereas SHP2 was defined as a bona fide 
oncogene which arouses much interest to develop the selective inhibitors targeting to 
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SHP2. 136 In our dual labeling assay , we were able to identify several peptides selective 
to SHP1 or SHP2 respectively (Figure 5.7). As the figure showed, 5 out of them showed 
the strong selectivity towards SHP1 and 7 out of them showed strong selectivity towards 
SHP2.  Interestingly, peptide B6 derived from c-Kit Tyr569 was found selective to SHP1. 
Previous reports has identified the Tyr 569 as the major site for binding of SHP1 to c-Kit 
whereas Tyr567 is involved with SHP2.137 This agrees well with our results which also 
suggests the Tyr 569 is selective towards SHP1. The cadherin and catenin complex was 
tyrosine phosphorylated and associated with cytosolic SHP1138, although the detailed 
anchoring part is still unknown. Our studies with peptide A18 indicated that Tyr654 
might serve as a specific anchoring site for association with SHP1. FAK2 is demonstrated 
as a direct substrate for SHP1 in vitro.139 FRS-2 was reported to form a complex with N-
terminal SH2 domain with SHP2 in response to FGF stimulation. 140 Gab-1 is tyrosine 
phosphorylated and forms a complex with SHP2 upon stimulation with gp130 or 
interleukin-3 receptor. 141 Tyr 1009 phosphorylation in the C-terminus of PDGFR is 
required for the stable association with SHP2. 142 SIRP was suggested as a potential 
substrate for SHP2.143 Phosphorylated MYELIN PZR was associated with SHP2.144 
SHP2 binds to IRS-1 via SH2 domains in response to insulin.145 All these reported 
examples have matched with our results pretty well, which might indicate that the 
particular phosphorylation site identified from our studies potentially serve as selective 
anchoring site for differentiation between SHP1 or SHP2 in vivo. 
  It was suggested that the catalytic domain directly contributes the substrate 
specificity to the highly conserved SHP1 and SHP2 PTPs.128, 135 To explore whether the 
substrate specificity of full length PTP comes from catalytic domain or SH2 domain, both 
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catalytic domains of two SHP PTPs were cloned, expressed, fluorescently labeled and 
applied onto our array respectively. The dual labeling experiments showed that the 
selective peptides identified from SHP1 catalytic domain closely matched with those 
peptide previously identified from the full length PTP experiments (Figure 5.8 & Table 
5.2).  Although at current stage we cannot rule out the possbilities that SH2 domain might 
aslo confer the substrate specificity to some extent considering the difference between 
two sets of selectivity ratio data, we were able to pinpoint the catalytic domain of PTP 












Figure 5.7 Substrate fingerprints of SH2 domain and catalytic domain of SHP2 mutants 
and dual labeling assay with SHP1 and SHP2 full length mutants. (a) The fingerprinting 
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microarray image of SHP1 full length and SHP2 full length mutants. (c) The summary of 









Figure 5.8 Dual labeling assay with SHP1 and SHP2 catalytic domain. (a) Microarray 
image of SHP1 catalytic domain Cy5 and SHP2 catalytic domain Cy3. (b) The summary 
of selectivity ratio of SHP1 catalytic domain against SHP2 catalytic domain. 
Table 5.2 The summary of SHP1 catalytic domain-selective peptides 
384 well Peptide Sequence Enzyme Protein Source SHP1/SHP2 Catalytic 
Domain Ratio 
A18 EGVATYAAAVL SHP1 CATENIN 7.6 
C19 PSFSEYASVQV SHP2 SIRP 4.3 
E19 AELEFYMDYEA  Alanine scanning 6.6 
B6 GNNYVY IDPTQ SHP1 KIT 4.0 
B15 IESDIYAEIPD Type12  4.5 
 
To study the strength of binding interactions, we next performed the KD 
experiments on the array with three PTPs, namely PTP1B, SHP1 and SHP2. The data 
were fitted to a saturation dynamics reaction, which assumes that when equilibrium is 
achieved, KD information could be extracted from the resulting curves. Upon subjecting 
the data to the stringent filtering criteria (r>0.9) and significant binding intensities, we 
were able to obtain the KD data which showed a good affinity on the array (Table 10.7). 
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previously. Results indicated that the KD value could also reflect the selectivity between 
SHP1 and SHP2. The
 
smaller KD, and the higher affinity against one of enzyme (Table 



















KD /SHP1(µM) KD /SHP2(µM) SHP1 
/SHP2 
ratio 
A18 EGVATYAAAVL SHP1 CATENIN 654 0.96 1.1 9.4 
E19 AELEFYMDYEA  Alanine 
scanning 
 0.41 ND 17.7 
E21 GPQDIYDVPPV  P130cas  1.1 ND 12.7 
B6 GNNYVY IDPTQ SHP1 KIT 570 ND ND 5.3 
B15 IESDIYAEIPD Type12 FAK2  0.2 ND 27 
ND the fluorescent value was low and KD was unable to be determined. 
Too high signal means signal reached saturation point at very low concentration. 
 
 










KD /SHP1(µM) KD /SHP2(µM) SHP2/SHP1 
ratio 
A9 DKQVEYLDLDL SHP2 GAB1 657 4.7 0.96 5.1 
A17 EDTLTYADLDM SHP2 SIRP 470 7.9 4.1 7.0 
A20 ENGLNYIDLDL SHP2,PTP1B IRS1 1179 ND 0.18 4.8 
C22 QGPVI YAQLDH SHP2 MYELIN 241 1.3 0.14 8.4 
B11 HRQLNYIQVDL SHP2 FRS2 436 1.4 0.42 4.5 
D18 TSSVLYTAVQP SHP2 PDGF 1009 ND 0.095 4.1 
ND the fluorescent value was low and KD was unable to be determined. 
 
 
5.3.4 p(CAP) Peptide Array 





     The synthetic route for p(CAP) building block was based on the reported procedure 
with minor modifications.133a First the commecialy avaliable Fmoc-Asp(Otbu)-OH was 
protected with Tce group with the main chain carboxylic acid. The tbu group of side 
chain was deprotected and acylated by using DCC and meldrum’s acid. Due to the 
reagent isobutene is too expensive, we employ the common coupling reagent DCC to 
replace the isobutene with the original protocol. Subsequently the β-ketoester was 
condensed with resorcinol to form the coumarin under the catalysis of methane sulfonic 
acid. The phenolic OH of coumarin was protected with diethylchlorophosphate or 
monobenzylphosphate to yield the phosphorylated coumarin.  Finally the Tce group was 
deprotected with Zn dust in 50% acetic acid.  
  The diethyl protected p(CAP) 9 was labile during the peptide synthesis, which 
caused the fluorescence background without addition of enzyme. Next the monobenzyl 
protected p(CAP) 11 was syntheized and assembled on the solid phase synthesis. The 
crude peptide profile obtained from monobenzyl protected p(CAP) 11 was not as clean as 
the diethyl protected p(CAP) 9. Thus we decided to employ diethyl protected p(CAP) 9 
as the building block for p(CAP) peptide synthesis and purify the final products by HPLC.  
16 p(CAP) peptides with sequence derived from different putative PTP substrates were 
synthesized and purified by HPLC. The peptides after HPLC purification were all 















Figure 5.10 Schematic representation of p(CAP) buidling block synthesis. a. 
CCl3CH2OH, DCC, DMAP, 15h, 97%; b. 50% TFA in DCM, 0.5h, 99%; c. Meldrum’s 
acid, DCC, DMAP, 4h; d. MeOH, reflux, 2h, 40%; e. CH3SO3H, resorcinol, 60%; f. 
(EtO)2POCl, DIEA, 14h, 80%; g. Zn dust, 6h, 99%; h. iPr2NP(OBzl)2, Tetrazole,  t-butyl  
hydroperoxide  THF, rt, 4h, 70%. (i)NaI, CH3CN, reflux , 2h, 80%; j. Zn dust, 6h, 99%.  
 
Table 5.5 List of 16 p(CAP) peptides used in the  peptide microarray 
Peptide NO. Sequence Enzyme Mw LC-MS 
1 DEGIHp(CAP)SELIQ SHP1 1790 y 
2 GSAAP p(CAP)LKTKF TCPTP 1670 y 
3 KAVDG p(CAP)VKPQI SHP2 1592 y 
4 LNSDG p(CAP)TPEPA LMW 1650 y 
5 LPPEG p(CAP)VVVVK SHP2 1686 n 
6 NSDVQ p(CAP)TEVQV SHP1 1770 y 
7 PEGHE p(CAP)YRVRE PTP1B 1922 y 
8 PQDKE p(CAP)YKVKE SHP2 1914 y 
9 VDADE p(CAP)LIPQQ SHP2 1778 y 
10 ELEF p(CAP)MDYEA PTP1B 1798 y 
11 EDGGV p(CAP)SSSGL FER kinase 1598 y 
12 EGVAT p(CAP)AAAVL SHP1 1552 n 
13 ESDGS p(CAP)QKPSY SHP2 1748 y 
14 IESSN p(CAP)MAPYD PTP1B 1778 y 
15 TSKLI p(CAP)DFIED type12 1832 y 


















































































  The peptides were first screened with different PTPs including PTP1B, TCPTP 
and YOP via microplate assay. The microplate assay indicated that all enzymes tested 
showed activity towards most of the p(CAP) peptides. Subsequently we carried out the 
PTP assay on microarray. Two groups of peptides : p(CAP) peptide and  corresponding 
pTyr peptide were spotted together onto the same slide.  Pro-Q staining was first carried 
out to prove that the both of the peptide were successfully immobilized onto slide. After 
applying PTP1B enzyme, the signal increased in ACC channel was relatively weak and 
difficult to discern (Figure 5.11). This intrincic low fluorescent intensity of ACC 
fluorophore hinders the direct visulization of enzyme activity from the array and makes it 
difficult for the development of real time assay for PTPs. 
 Table 5.6 The summary of microplate assay with p(CAP) peptide against 3 PTPs. 
Fluorescence intensity Peptide NO Peptide Sequence 
Bkg PTP1B TCPTP YOP 
1 DEGIHp(CAP)SELIQ 959 1221 1684 3466 
2 GSAAP p(CAP)LKTKF 2628 2751 3523 3412 
3 KAVDG p(CAP)VKPQI 422 491 391 501 
4 LNSDG p(CAP)TPEPA 393 870 1289 1844 
5 NSDVQ p(CAP)TEVQV 130 214 233 698 
6 PEGHE p(CAP)YRVRE 294 365 354 343 
7 PQDKE p(CAP)YKVKE 559 844 621 490 
8 VDADE p(CAP)LIPQQ 417 529 572 3677 
9 ELEF p(CAP)MDYEA 502 593 450 1719 
10 EDGGV p(CAP)SSSGL 241 382 451 826 
11 ESDGS p(CAP)QKPSY 494 527 605 959 
12 IESSN p(CAP)MAPYD 292 448 499 1819 
13 TSKLI p(CAP)DFIED 572 1283 1435 2131 
14 AEKPF p(CAP)VNVEF 172 164 190 149 
15 (Control)DIMUFP 393 17067 17153 17668 
 
 




 In conclusion, we have developed an affinity-based array capable of determination of  
the substrate specificity against various PTPs. The information obtained should allow us 
to shed light on the molecular mechanism of protein-protein interactions in the signalling 
proteome. More importantly, by using the dual labeling approach, we were able to 
differentiate the subtle differences between the closely homologous PTP pairs, e.g. 
PTP1B and TCPTP, SHP1 and SHP2. We envisage this approach will greatly accelerates 
inhibitor development towards PTPs.  





























A Novel Strategy for SrtA-Mediated Site-Specific 







Fluorescence labeling of proteins in vivo has potential applications including  the 
study of temporal and spatial regulation of genes and protein trafficking. Our group has 
explored different approaches to site specifically label proteins in live cells. Herein we 
present a novel approach mediated by SrtA for site-specific protein labeling.  SrtA 
catalyses a transpeptidation reaction by aminolysis of the T-G bond in the sorting motif 
LPXTG of proteins, to form LPXT –Gn peptide (n = 1 to 5) conjugates in the presence of 
a Gn containg peptide. The advantage of our approach lies in that it utilizes a small 
peptide motif which could be conveniently tagged onto target protein while the small tag 
won’t perturb the original conformation and activity of proteins. Moreover, the tag is 
very specific and can be only recognized by SrtA. We have successfully shown that SrtA 
catalyses the transpeptidation reaction site-specifically in vitro. However, due to the low 
turn over rate of SrtA, we haven’t been able to extend this strategy for live cell imaging. 
The future endeavour for engineering a highly active version of SrtA mutant is strongly 
encouraged before it is applied to bioimaging field.  
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 6.2 Introduction 
Studying the dynamic movement and interactions of proteins inside living cells is 
enthusiastically investigated recently due to its critical role in understanding the cellular 
mechanism and functions. Traditionally, this has been done by genetic fusing the 
fluorescent protein gene to the protein of interest. However, the inherent property of 
fluorescent proteins (~27kDa) has hindered the development of this approach due to its 
bulky size, the dimmer or trimmer formation, the long maturation time, the limited 
number of “color”, which will affect the conformation and activity of native proteins 
greatly, especially considering that enzymes are very sensitive with the macromolecule 
fusion. More recently, the small-molecule probes for site-specific labeling of the proteins 
have been developed to address these problems and proven useful in protein chemistry. 
The advantages of small-molecule probes lie in that: 1. They are less sterically bulky 
compared with the protein fusions. 2. The labeling rate is fast considering the EGFP 
protein requires long maturation time (>20hs) 3. The small molecule probes can be 
modified for a wide spectrum colors by combinatorial chemistry.  Although this field has 
witnessed a tremendous development over these years,80-84 many approaches employed 
still require the use of large protein domains fused to target protein.81, 84 Thus it is still 
imperative to develop the small-molecule approach for labeling  proteins in vivo. 
SrtA, found in 1999, was reported to catalyze the anchoring of surface proteins of 
Staphylococcus aureus to bacterial cell wall and cause infection.146 (Figure 6.1a) First, 
SrtA cleaves the polypeptides between “T” and “G”, resulting in the thioester linkage 
between the carboxyl group of theronine and sulfhydryl of enzyme. Subsequently, the 
acyl-enzyme intermediate was resolved by nucleophilic attack by the amino group of 
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pentaglycine crossbridge of cell wall (Figure 6.1b). Through this reaction, the surface 
proteins which contain “LPXTG” motif could be covalently anchored onto the bacterial 
cell wall.147 Strong nucleophiles like hydroxylamine could substitute the pentaglycine 
both in vitro and in vivo. In the absence of nucleophiles, SrtA slowly hydrolyzes the 








Figure 6.1 (a) Schematic of SrtA catalyzing the anchoring of surface proteins onto the 
staphylococcal cell wall. (Schneewind et al) (b) Equations depicted the intermediate and 
product formation during SrtA catalysis. 
 
In our approach, a protein target is overexpressed with “LPETG” sequence at its 
C-terminus, in the presence of SrtA and a small molecule-based labeling reagent Gn-tag 
(n=1-5), which undergo the “transpeptidation” reaction, by cleaving between threonine 
and glycine in the protein and subsequently joining the carboxyl group of threonine to an 
amino group of the “tag”. The advantage of our approach is that it utilizes a small peptide 
motif, which could be conveniently tagged onto target protein while the small tag won’t 
perturb the original conformation and activity of proteins. Moreover, the tag is very 












R1-LPXT(CO-NH)-G-R2 + E-SH R1-LPXT(CO-S)-E + NH2-G-R2





the in vitro SrtA-mediated ligation of proteins to peptides as well as non-peptides.148 We 
also successfully validated this strategy and further proved the feasibility of site-specific 
labeling of proteins via SrtA transpeptidation in the crude cell lysates (this work has been 
done in 2005). Recently Polegh et al. has extended this approach to label the proteins on 
the cell surface.149 
Four different types of probes were synthesized and used to study the protein 
labeling via SrtA. Probe I and  II are the physiological nucleophiles conjugated with 
fluorophores. Probe III and IV are the modified version with amino group replaced by 
strong nucleophile hydroxyl amine. Different fluorophores (TMR and RhoB) were 







Scheme 6.1 SrtA-mediated labeling approach. (a) The schematic representation of SrtA-
mediated protein labeling approach. (b) The chemical structure of 4 types of probes used 
in this study. I and II represents the natural substrate of SrtA, III and IV represents the 
hydroxyl amine version of modified substrate.  
 
 It is noteworthy that early studies postulated that the rate determine step is the 
acyl-enzyme intermediate formation during the transpeptidation reaction.150 Stimulated 
by this point, we also generated protein thioester intermediate by exploiting intein 












favorable for the reaction. The strategy is utilized an enzyme called intein, which is 
known to occur the self splicing and rejoin the remaining parts with amide bonds (Figure 
6.2). Intein was found within genes of other proteins. After translation as a single 
polypeptide chain, intein initiates the autocleavage process by cleavage itself and join in 
the flanking host segments with a peptide bond.151
 
     By using site directed mutagenesis techniques, we successfully mutated the last four 
amino acids of EGFP gene into SrtA recognized motif “LPET” in the construct of 
pTYB1-EGFP. In this construct, the intein is located at the C-terminal of EGFP. Through 
intein self-splicing, the EGFP protein with C terminal LPET thioester could be obtained, 





























Scheme 6.2 The scheme of protein labeling via combination of EPL and SrtA approach. 
The purpose is to probe whether protein thioester intermediate would serve as a better 
substrate of SrtA. 
 
     The preliminary in vitro labeling experiments in our lab have shown that SrtA could 
catalyze the labeling of target proteins fused to LPETG sequence by Gn containing 
fluorophores  site specifically. However, due to the low turn over rate of SrtA, we haven’t 
been able to extend this approach inside the living cells. The reported kcat for SrtA 
transpeptidation reaction was 0.096 min-1. Based on our kinetic analysis, the SrtA is not a 
very active enzyme as well. In the Polegh’s approach, the concentration of SrtA using is 
unexpectedly high---200 µM. Whereas in living cells, the local concentration of SrtA 
certainly cannot achieve such high concentration. On the other hand, the newly formed 
ligated product have the susceptibility to occur the second cleavage in the absence of 
nucleophiles. This might happen once the excess probe is washed away after the labeling 
process is complete. All these trigger us to seek an improved version of SrtA mutant with 
high catalytic activity and without proteolytic activity.  For genetics approach, there are 




directed evolution. The most successful mutagenesis example is “subtiligase” enzyme,  in 
which the Ser221 is mutated to Cys and Pro225 is changed to Ala. In their very first step, 
they mutated the Ser221 to Cys and obtained the thiosubtilisin with high amidase vs 
esterase activity. However, the enzyme catalytic efficiency was much lower compared 
with the wild type. After reexamine the enzyme structure carefully, they mutated Pro225 
to Ala to replace the bulky residue which might affect the enzyme binidng site with a 
small residue. With the modified subtiligase, the stability, the amidase vs esterase activity 
and the proteolytic activity were all improved.152 If the specificity and enzyme structure 
are not understood thoroughly, one can use the random approach---in vitro directed 
evolution. By using the random mutation and recombination technology, the gene 
encoding enzyme mutants can be subject to several rounds of mutagenesis, screening and 
selection until a desired level of improvement has been achieved. 153 
     We have displayed SrtA as a fusion to the capsid protein of the bacteriophage T7, with 
the sorting motif LPETG, as a C terminal fusion (Figure 6.3). Upon displayed on phage, 
SrtA was shown to catalyze the transpeptidation of a peptide fluorophore conjugate onto 
itself (unpublished result Yao et al).  The random SrtA gene mutants are generated by 
using DNA shuffling approach and subsequently inserted into the phage vector. Active 
SrtA mutants capable of ligating a Gn-Biotin moiety onto themselves would be pulled 
down by passing through avidin beads and the inactive ones would be washed away. 
Following these, potential candidates can be screened for increased activity.  
A real time FRET assay was developed to monitor the hydrolysis and 
transpeptidation activity of SrtA or SrtA mutants simultaneously. The HPLC assay 
commonly utilized suffers from low sensitivity and low throughput, whereas the 
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microplate assay provides a convenient yet highly sensitive method for detecting the 
enzyme activity. As described in the graph (Figure 6.4), before hydrolysis reaction occurs, 
the donor fluorophore is strongly quenched by the quencher and no fluorescence should 
be observed at this stage. After addition of enzyme, the quencher is released from the 
substrate by enzyme cleavage and the donor fluorescence can be observed. By addition of 
nucleophiles GGG-probe, it will form the ligation product with FRET pairs. The acceptor 
fluorescence can be observed by excitation with the donor channel. This assay can serve 
as a real-time assay for monitoring the hydrolysis and transpeptidase reaction of SrtA and 




























Figure 6.4  Real-time FRET assays designed for screening SrtA or SrtA mutants. The 
assay could be used to monitor the hydrolysis and transpetidase activity of SrtA. 
 
6.3 Results and Discussion 
The EGFP protein serves as the model protein in this study. The EGFP gene and 
SrtA gene were cloned into pdest17 vector by using the GatewayTM cloning technology. 
6.3.1 Cloning of Target Genes 
     The general feature of pdest17 vector is as followed (Figure 6.5). Transcription of the 
gene was initiated by the T7 promoter. A His tag was put at the C-terminal of gene for 
future protein purification purpose. Ampcilin was the gene resistance. The advantage of 
using GatewayTM cloning technology lies in that it provides a versatile system for 
transferring the gene between numerous vectors. This system utilizes the site-specific 
recombination reactions of bacteriophage λ in E.coli. 
 attB x attP      attL x attR (where “x” signifies recombination) 
 
The above equation stands for the basis of GatewayTM cloning technology. The entry 




















ccdB gene. The DNA sequence is amplified with PCR by using primers containing two 
recombination sites attB1 and attB2. The PCR product was then cloned into the entry 
vector pDONR 201 by an enzymatic recombination reaction (BP reaction), in which the 
attB-PCR product recombines with a donor vector containing attP sites .  The  toxic ccdB 
gene would be replaced upon the successful cloning the target gene into entry vector. The 
vector with the insert was transformed into Top 10 cells and cultured in LB+ Kanamycin 
plates. pdest17 vector is an expression vector containing two recombination sites attR1 
and attR2 which  flank a toxic ccdB gene. Similarily, another recombination recation (LR) 
was carried out to recombine the gene with ccdB gene in the destination vector. The 
vector was transformed into Top 10 cells and cultured in LB Ampicilin plates. Colony 
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Figure 6.5 Schematic representation of gateway cloning technology.(a) representation of 
cloning gene EGFP by using gateway cloning strategy; (b) the vector map of entry vector 




6.3.2 Protein Expression and Purification 
 
The protein expression level is greatly influenced by the concentration of inducing 
reagent, temperture  and inducing time. Different conditions were tested out to optimize 
the two protein expressions. Bl21 AI is an expression starin which is compartible with T7 
promoter vector which allows the tightest gene expression control and maximum protein 
expression. It turns on the protein expression with 0.2% arabinose.  Results inidcated that 
EGFP could get an optimum yield  at OD = 0.6,  room temperature for 12hrs while SrtA 
expressed quite well at OD = 0.4, 37°C for 3hrs. Western blot was carried out to verify 
both protein expressions by using anti-His tag antibody. The image showed that both of 
the genes were expressed pretty well and under tight control. It was observed there was 
some basal level of EGFP expression without arabinose induction (Figure 6.6b). 
 
             -arabinose +arabinose             -arabinose +arabinose 
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Figure 6.6 Western blot analysis of protein expression. (a) Western blot of SrtA 
expression by using anti-His antibody. Lane 1, OD= 0.4 without arabinose; Lane 2, 
OD=0.4 with 0.2% arabinose. (b) Western blot of EGFP-V5 expression by using anti-His 
antibody. Lane 1, OD=0.6, without arabinose; Lane 2, OD=0.6, with 0.2% arabinose. 
 
 
Figure 6.7 His tag protein purification. (a) EGFP-V5 purification. From left to right, 
Lane 1, CL (Crude cell lysates); Lane2, FT(Flow through); Lane 3, W1(Wash 1); Lane 4, 
E1(Elution 1). (b) His tag purification of SrtA. Lane 1, CL (Crude cell lysates); lane 2, 
M(Protein marer); lane 3, FT( Flow through); lane 4-6, E1-E3 (Elution1-3). 
 
6.3.3 Site-Directed Mutagenesis of pTYB1-EGFP 
 
The pTYB1-EGFP construct was prepared by Rina et al.  which contains an EGFP 
gene fused to intein tag via its C-terminal residue. The pTYB1-EGFP mutant was 
generated by mutation of the last 4 amino acid residues of EGFP gene into the SrtA motif 
“LPET” in the template through quick site directed mutagenesis Kit. After confirming 
with DNA sequencing, western blot analysis was carried out to verify the gene expression. 
Results indicated that most of the fusion protein occurred self-splicing during protein 
expression. Consequently, we transformed the fusion gene into different host cells and 
compared with the self-cleavage efficiency. Western blot analysis indicated that most of 
the fusion proteins were cleaved with Bl21-AI strain whereas the fusion proteins remain 
as the major protein in ER2566 (Figure 6.8). Consequently we used ER2566 as the 
expression host in the following experiments. 




                                  
 
Figure 6.8 Western blot analysis of pTYB1-EGFP mutant expression by using anti-
EGFP antibody. From left to right, Lane 1, ER2566 strain with 0.3mM IPTG induction; 
Lane2, ER2566 strain without IPTG induction; Lane 3, Bl21-AI strain with 0.2% 
arabinose induction; Lane 4, Bl21-Ai strain without arabinose induction. 
 






















Figure 6.9. The chemical synthesis of several dyes in this study. a) Di-t-butyl dicarbonate, 
DCM, 19h, 85%; b) trimellitic anhydride, toluene, 12h, 36%; c) (i) tert-butyl 2-
                             ER2566            Bl21-AI 
                       +IPTG -IPTG +arabinose -arabinose 




















































aminoethylcarbamate 14, EDC, DIEA, 8h, (ii) TFA/DCM, 1h, 65%; d) piperizine, AlMe3, 
reflux, 10h, 81%; e)(i) trimellitic anhydride, CH3SO3H, 12h, (ii) acetic anhydride, DCM, 
15min, 53%; f) ammonium hydroxide, THF/MeOH, 2h, 78%; g) (i) tert-butyl 2-





















Figure 6.10 The chemical synthesis of TMR derivated probes in this study. a) (i) (Boc)-
aminooxy acetic acid, EDC, DIEA, 8h; (ii) TFA/DCM, 1h, 67%; b) (i) (Boc)-Gly-OH, 
EDC, DIEA, 8h; (ii) TFA/DCM, 1h, 75%; c) (i) (Boc)-Gly-OH, EDC, DIEA, 8h; (ii) 




















































































































Figure 6.11 The chemical synthesis of RhoB-derevatived probes. a) (i) (Boc)-aminooxy 
acetic acid, EDC, DIEA, 8h; (ii) TFA/DCM, 1h, 78%; b) (i) (Boc)-Gly-OH, EDC, DIEA, 
8h; (ii) TFA/DCM, 1h, 83%; c) (i) (Boc)-Gly-OH, EDC, DIEA, 8h; (ii) TFA/DCM, 1h, 















Figure 6.12 The chemical synthesis of GGG-Fluorescein. a) (i) Glycine ester, EDC, 
DIEA, 8h; (ii) TFA/DCM, 1h, 93%; b) (i) (Boc)-Gly-OH, EDC, DIEA, 8h; (ii) 




6.3.5 Protein Labeling  
 
In a very first step, we carried out in vitro labeling experiments with SrtA. The 
distinct labeling protein band could be observed within 1h at room temperature. On the 
other hand, the negative control didn’t show any labeling, which indicated the labeling 
reaction was enzyme dependent and the background was low (Figure 6.13). Further 
experiments indicated Ca2+ could enhance the enzyme-mediated labeling as well (Figure 
6.14). Encouraged by these results, we further investigated the labeling with the crude 
cell lysates which expressed EGFP-V5 protein substrate. Results clearly indicated only 
the target protein was labeled which indicated the reaction was highly sequence specific 
even in the presence of a large number of other proteins (Figure 6.15). The 
hydroxylamine version of probes were used to probe whether the strong nucleophiles 














































could serve to accelerate the reactions compared with the physiological substrates of SrtA. 
Results showed that the physiological substrate was more preferred by SrtA than the 

















Figure 6.13 Labeling experiment via SrtA mediated labeling. Lane 1: Marker; lane 2, 
















Figure 6.14 Labeling experiment with strong nucleophile probe. Lane 1: NH2O-TMR, 
SrtA, EGFP only; Lane 2, NH2O-TMR, SrtA, EGFP, 5mM Ca2+; Lane 3, GG-TMR, SrtA, 
EGFP only; Lane 4, GG-TMR, SrtA, EGFP and 5mM Ca2+; Lane 5, G-TMR, SrtA, 
EGFP only; Lane 6, G-TMR, SrtA, EGFP and 5mM Ca2+; Lane 7, Marker 
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Figure 6.15 The crude cell lysate labeling. The crude cell lysate expressed with EGFP 
was labeled with G-TMR probe. Lane 1, Marker; lane 2, crude cell lysate and G-TMR 
probe; lane 3, crude cell lysate, SrtA and G-TMR probe. 
 
To first determine whether the thioester intermediate of EGFP protein was generated, 
cysteine conjugated TMR was synthesized and used to label the protein after cleavage. 
The image indicated that the protein thioester intermediate was generated during the thiol 
induced intein cleavage (Figure 6.16). Different cleavage reagents including 2-Me, dTT 
and MESNA were used to optimize the cleavage efficiency. Results indicated that dTT 
was the best cleavage reagents in this study. Subsequently we carried out the labeling 
experiments with G-TMR through SrtA mediated catalysis. As the image showed, only 
pTYB1-EGFP mutant showed distinct labeling, which indicated the reaction was enzyme 
dependent (Figure 6.16). However, the labeling efficiency of pTYB1-EGFP mutant was 






















Figure 6.16 Cysteine-TMR labeling test. This assay was used to test whether thioester 
intermediate was generated by intein cleavage. Lane 1 , pTYB1 mutant cleaved with dTT;  
Lane 2, pTYB1 mutant cleaved with MESNA; Lane 3, pTYB1 mutant cleaved with 2-Me; 
lane 4, pTYB1 cleaved with dTT; Lane 5, pTYB1 cleaved with MESNA; Lane 6, pTYB1 

















                 
           
Figure 6.17 Labeling experiment with G-TMR after intein cleavage. Lane 1 (from left to 
right), pTYB1and G-TMR, Lane 2, pTYB1, SrtA and G-TMR; Lane 3, pTYB1 mutant 
and G-TMR; Lane 4, pTYB1 mutant, SrtA and G-TMR.  
 
       1           2            3           4 
 
                     Marker   1      2      3      4       5       6 
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Figure 6.18 Comparison of labeling efficiency among different probes. Lane 1 (from 
right to left), EGFP, SrtA and G-TMR; Lane 2, EGFP, SrtA and GG-TMR; Lane 3, 
EGFP, SrtA and aminooxy-TMR; Lane 4, EGFP-LPET-SR, SrtA and G-TMR; Lane 5, 
EGFP-LPET-SR, SrtA, GG-TMR; Lane 6, EGFP-LPET-SR, SrtA, aminooxy-TMR. 
 
6.3.6 FRET Assay for SrtA and SrtA Mutants 
 
     Due to the susceptibility of second cleavage of ligation product by SrtA, we seek to 
generate the SrtA mutant which ligates other amino acid instead of glycine as well as has 
high catalytic activity. To select the active SrtA mutants, we constructed a novel FRET 
assay for selection of the SrtA mutants. In a very first step, the transpeptidation product 
was isolated by HPLC separation and confirmed with mass spectrometry (Figure 6.19). 
The ligation product was subject to wavelength scan with proper control. The wavelength 
scan experiment of ligation product clearly indicated that FRET occurred (Figure 6.20). 
Under different substrate concentrations, the hydrolysis curve increased with 
concentration of substrate (Figure 6.21a). Subsequently different concentrations of 
nucleophiles were added to test the transpeptidation reaction with the same concentration 
of substrate and enzyme (Figure 6.21b). Stronger signal was observed compared with the 
hydrolysis reaction, which indicated the reaction accelerated in the presence of 
nucleophiles. This is in accordance with the reported literature, the rate of SrtA-mediated 
cleavage at the LPETG motif was increased in the presence of amino group donors. 
  6       5       4       3      2     1     M 
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Subsequently we carried out the real time assay monitoring the WT SrtA hydrolysis and 
transpeptidase activity in dual channel. As figure 6.22a showed, in the absence of GGG-
FITC, the peptide ACC-GLPETG-Dabcyl was hydrolyzed and yield the fluorescence 
readout at ACC channel only. In the presence of nuceophiles GGG-FITC, FRET occurred 
and the acceptor fluorescence was observed when excited with the donor channel (Figure 
6.22b). With increased concentration of nucleophiles, more FRET signal was observed 
(Figure 6.22c&d). This assay could be potentially adapted as real time assays for 





Figure 6.19 HPLC profiles of SrtA transpeptidation reaction. a, 1 mg GTEPLG-ACC, 3 
mg GGG-FITC, Total Volume: 100ul (50mM Tris buffer), Figure b, 1mg GTEPLG-ACC, 
3mg GGG-FITC, Total Volume: 100ul (50mM Tris buffer), 10ul SrtA (5mg/ml), Both 























Figure 6.20  The wavelength scan for transpeptidation product. (a) the negative control 
FITC ( Ex: 350nm, Em: 350-750nm), (b) the ligation product, FITC-GGGTEPLG-ACC 
( Ex: 350nm, Em: 350-750nm). (c) the negative control  FITC ( Em: 530nm, Ex: 250-


























       Figure 6.21 Progress curves of hydrolysis and transpeptidation reaction of SrtA.(a) 
Progress curves of Hydrolysis reaction at different concentration of ACC-GLPETG-
Dabcyl (40 µM, 20 µM, 16 µM, 8 µM, 4 µM, and 2 µM), (b) Progress curves of 
Hydrolysis reaction at different concentration of nucleophiles GGGG (0 µM, 1 µM, 5 µM, 





Figure 6.22 Dual wavelength real time monitoring of SrtA hydrolysis and 
transpeptidation reaction. Blue color, ACC channel Ex: 355 nm, Em: 460 nm, Red color, 
FRET channel: Ex: 355 nm, Em: 530 nm. (a). Dabcyl-LPETG-ACC 20 µM, GGG-FITC 
0 µM, SrtA; (b). Dabcyl-LPETG-ACC 20 µM, GGG-FITC 1 µM, SrtA; (c). Dabcyl-
LPETG-ACC 20 µM, GGG-FITC 5 µM, SrtA; (d) Dabcyl-LPETG-ACC 20 µM, GGG-




     In conclusion, we have successfully developed a SrtA-mediated protein labeling 
approach in vitro. The highly specific lableing with the crude cell lysate further proved it 
has great potential in the application of bioimaging. Out of the four probes, the GG-TMR 
worked as the best nucleophile which proved that SrtA prefers the physiological 
nucleophiles rather than nonphysiological strong nucleophiles. The thioester intermediate 
generated from intein mediated splicing didn’t improve the kinetics of lableing which 
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could be due to the kinetic step is the last step. The novel real time FRET assay should 
add useful tools for selction of the evolved SrtA mutants. All these studies should lay 




































Chapter 7. Experimental Procedures 
 
7.1 General Procedure 
 
7.1.1 Materials 
All chemicals were purchased at the highest grade and used without further 
purification, unless otherwise noted. Fmoc-amino acids, HOBT, HBTU, TIS, TFA were 
from GL Biochem (China). Piperidine was from Merck (USA). All proteases (Sigma Cat 
No.) used were from Sigma. They include chymopapain (C-8526), papain (P-4762), a-
chymotrypsin (C-4129), β-chymotrypsin (C-4629), ficin (F-6008), subtilisin (P-3910), 
trypsin (T-8003), thermolysin (T-7902), actinase E (P-8811), achromopeptidase (A-3547), 
thrombin (T-3399), bromelain (B-4882), proteainase K (P-8044), pepsin (77152), rennin 
(83553), and bovine serum albumin (B-4287). TEV was obtained from Invitrogen. 
Lambda phosphatase, PP1 was from NEB.  All seven 14-3-3 bacterial expression 
constructs are commercially available (www.addgene.org) Pin1, 14-3-3 isoforms, CnA, 
SrtA and all PTP mutants were expressed and purified in house. Plain glass slides were 
purchased from Sigma Aldrich (USA), and modified to generate the corresponding 
avidin-coated surface as previously described. Pro-Q™ Diamond dye was bought from 
Invitrogen (USA). The EnzChek Protease Assay Kit comprising the bodipy casein 
substrate was obtained from Molecular Probes, Invitrogen (California, USA). Microplate 
experiments were performed in black flat-bottom polypropylene 384 well plates (Nunc, 
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USA). Glass slides used for microarrays were 75mm X 25mm microscope glass slides 
from Sigma-Aldrich (Milwauki, USA), unless indicated otherwise.   
   
7.1.2 Instrumentation 
Microplates were scanned using a SpectraMaxTM Gemini XS fluorescence plate 
reader (Molecular Devices, USA). Where indicated, liquids were dispensed robotically 
using an automated liquid handler with 8-channel dispensing capability. (Precision XS, 
Biotek, Vermont, USA). Microarrays were printed using a contact arrayer (Virtek 
Chipwriter, Ontario, Canada). Microarrays were scanned on an ArrayWoRxTM 
microarray scanner (Applied Precision, USA) equipped with the relevant filters for 
coumarin (λex/em: 360/457 nm), fluorescein (λex/em: 490/528 nm), Cy3 (λex/em: 548/595 nm) 
and Cy5 (λex/em: 633/685 nm). Gels were scanned on a Typhoon fluorescence gel scanner 
(GE Healthcare, USA). Surface plasmon resonance measurements were performed on a 
Biacore 3000 instrument (Biacore AB, Uppsala, Sweden). Fluorescence polarization 
experiments were performed on fluorescence plate reader (Tecan, USA) installed with 2 
pairs of polarizers ((λex/em: 540/590 nm). ESI mass spectra were acquired in both the 
positive and negative mode using a Finnigan/Mat TSQ7000 spectrometer. HPLC profiles 
and ESI mass spectra were acquired in the positive or negative mode by using a 
Shimadzu IT-TOF. Analytical and semi-preparative RP-HPLC separations were 
performed on Phenomex C18 analytical (150 x 3.0 mm) and semi-preparative (250 x 21.2 
mm) columns, respectively, using a Shimadzu Prominence HPLC system equipped with a 
Shimadzu SPD-20A detector. Eluents A (0.1 % TFA/acetonitrile) and B (0.1 % 
TFA/water) were used as the mobile phases.  
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7.2 Solution Phase Synthesis 
Dabcyl-NHS (1). N-hydroxysuccinimide (1 g, 8.6 mmol) and DCC (3 g, 14 mmol) were 
added to a solution of p-(p-dimethylaminophenylazo) benzoic acid, sodium salt (2 g, 6.8 
mmol) in HPLC-grade DMF. The mixture was stirred at room temperature overnight and 
concentrated in vacuo to yield a dark, red solid. The solid was purified by flash 
chromatography (DCM:methanol =8:1) and characterized by 1H NMR. Yield: 85%. 1H 
NMR (300 MHz, CDCl3) δ 8.23 (d, J = 8.4, 2H), 7.91 (d, J = 8.8, 4H), 6.76 (d, J = 9.2, 
2H), 3.12 (s, 6H), 2.91 (s, 4H). 
 
Fmoc-Lys-(Dabcyl) (2). Ten milliliters of a TFA/DCM mixture (1:1) was added to a 
roundbottom flask containing Fmoc-Lys(OtBu) (2.53 g, 5.4 mmol), and the reaction 
mixture was stirred for 1 h at room temperature and concentrated in vacuo. Dabcyl-NHS 
dissolved in DMF (10 ml) was added followed by DIEA (1.03 ml, 5.94 mmol). The 
reaction mixture was stirred at room temperature overnight. The resulting solution was 
concentrated in vacuo and purified by flash chromatography (DCM: Methanol=4:1) to 
afford Fmoc-Lys-Dabcyl as a dark red solid. Yield: 60%. 1H NMR (300 MHz, CDCl3): δ  
7.79 (d, J= 7.65, 4H), 7.69 (s, 2H), 7.58 (d, J= 6.42, 2H), 7.25–7.12 (m, 4H), 6.62 (d, J = 
8.43, 2H), 4.27 (br, 2H), 4.04 (br, 1H), 3.27 (br, 2H), 2.99 (s, 6H), 1.46–1.27 (m, 6H). 
ESI-MS:m/z [M-H]- = 618.1. 
 
Biotin-NHS (3). To a solution of D-biotin (2.4 g, 10 mmol) in DMF was added 
Nhydroxysuccinimide (1.4 g, 12 mmol) and EDC (2.3 g, 12 mmol). The reaction was 
allowed to proceed overnight. The resulting mixture was concentrated in vacuo, giving a 
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gel-like residue, which was recrystallized from EtOH/acetic acid/H2O (95:1:4) to afford 
biotin- NHS as a white solid (2.9 g, 85% yield). 1H NMR (300 MHz, CD3OD) δ  6.40 (br 
s, 1H), 6.35 (br s, 1H), 4.33–4.29 (m, 1H), 4.17–4.13 (m, 1H), 3.12–3.08 (m, 1H), 2.86–
2.81 (m, 5H) including 2.81 (s, 4H), 2.67 (t, J = 7.2, 2H), 2.61–2.59 (m, 1H), 1.70–1.24 
(m, 6H). ESI-MS: m/z [M + Na] + = 367.1. 
 
Synthesis of Fmoc-Lys-(Biotin) (4). To a solution of Fmoc-Lys(Boc)-OH (3.98 g, 8.5 
mmol) in DCM (4 ml) was added TFA (4 ml). The reaction was stirred at room 
temperature for 1 h and concentrated in vacuo. The oil residue was dissolved in an 28 ml 
of dioxane/water mixture (1:1), and the pH of the solution was adjusted to 8–8.5 (using 
4M NaOH) at 0ºC. Biotin- NHS (2.9 g, 8.5 mmol) was subsequently added, and the 
reaction mixture was stirred at room temperature overnight. To the resulting gelatinous 
solid was added ether and stirred for 5 min, then the supernatant ether was decanted off. 
Acetone was subsequently added. The pH of the solution was adjusted to 3 (using 2M 
HCl) at 0 ºC. Finally, the solid was filtered, washed several times with MeOH to afford 
the pure Fmoc-K(Biotin)-OH as a white solid (4.15 g, 82%). 1H NMR (300 MHz, 
CD3OD) δ  7.89 (d, J = 7.6, 2H), 7.72 (d, J = 7.7, 2H), 7.42 (t, J = 7.3, 2H), 7.33 (t, J = 
7.3, 2H), 6.41 (br s, 1H), 6.35 (br s, 1H), 4.31–4.22 (m, 4H), 4.13–4.09 (m, 1H), 3.91–
3.84 (m, 1H), 3.10–3.00 (m, 3H), 2.80 (dd, J = 4.9, J = 12.2 , 1H), 2.56 (d, J = 12.5, 1H), 
2.03 (t, J = 7.3, 2H), 1.61–1.29 (m, 12H). ESI-MS: m/z [M + Na]+ = 618.2. 
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-succinic acid 4-tert-butyl ester 1-(2,2,2-
trichloro-ethyl) ester (5). A solution of compound Fmoc-Asp(Otbu) (1.64 g, 4 mmol) in 
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anhydrous dichloromethane was cooled to 0 °C. 2,2,2-trichloroethanol (0.5ml, 13.eq), 
DMAP (0.244g, 0.5 equiv) and  DCC (1.07g, 1.3 equiv) was sequentially added and the 
mixture was reacted at 0 °C till the starting material disappeared. Upon completion of the 
reaction, the precipitates were filtered to remove DCU. The filtrate was diluted with ethyl 
acetate and the resulting solution was washed sequentially with 10% aqueous citric acid, 
water, saturated NaHCO3, water and brine. The solvent was evaporated and yield a white 
solid. The compound can be purified by column chromatography over silica gel eluting 
with (3:1) hexane/ ethyl acetate. Yield: 97%. 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J 
=7.65, 2H), 7.60 (d, J =6.96, 2H), 7.37 (t, J =7.32, 2H), 7.31 (t, J = 6.6, 2H), 5.86 (d, J = 
8.75, 1H), 4.86 (d, J =11.8, 1H), 4.77 (m, 1H), 4.36-4.44 (m, 2H), 4.26 (t, J = 7.0, 1H), 
3.02- 3.09 (A part of an ABX system, JAB=17.4 Hz, JAX=4.5 Hz, 1H), 2.81- 2.88 (B part 
of an ABX system, JAB =17.4 Hz, JAX =4.5 Hz, 1H), 1.45 (s, 9H). ESI-MS: m/z [M + Na]+ 
= 564.0. 
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-succinic acid 1-(2,2,2-trichloro-ethyl) 
ester (6). A solution of 5 (0.523 g, 0.96 mmol)in dichloromethane (7 mL) was treated 
with an equal volume of trifluoroacetic acid (TFA). The resulting mixture was stirred at 
room temperature for 30 min. Followed by the evaporation of solvent in vaccuo, the 
residue was precipitated by addition of cold water (10 mL). The precipitate was filtered 
through a Buchner funnel, and dried to obtain a white solid in quantitative yield. 1H NMR 
(300 MHz, CDCl3) δ 7.75 (d, J =7.32, 2H), 7.59 (d, J =7.32, 2H), 7.40 (t, J =7.32, 2H), 
7.33 (t, J = 7.2, 2H), 5.88 (d, J = 8.7, 1H), 4.69-4.82 (m, 3H),  4.31- 4.43 (m,2H), 4.21 (t, 
J = 7.0, 1H), 3.36- 3.43 (A part of an ABX system, JAB=17.4 Hz, JAX=4.5 Hz, 1H ), 3.17- 
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3.24 (A part of an ABX system, JAB=17.4 Hz, JAX=4.5 Hz, 1H ). ESI-MS: m/z [M + Na] + 
= 508.  
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-oxo-hexanedioic acid 6-methyl ester 
1-(2,2,2-trichloro-ethyl) ester (7). A solution of 6 (0.487g, 1 mmol), Meldrum’s acid 
(1.3 equiv) and DMAP (2 equiv.) in 5 mL anhydrous dichloromethane was cooled in an 
ice-salt bath. To this reaction mixture, a solution of DCC (1.1 equiv) in 2 mL 
dichloromethane was added very slowly with vigorous stirring under nitrogen. The 
reaction mixture was stirred in ice till the starting material disappeared. Upon completion, 
6 mL of a 5% citric acid was added to quench the reaction. After dilution with 
dichloromethane, the organic fraction was washed with water, brine and dried over 
Na2SO4. Evaporation of the solvent gave the Meldrum’s acid adduct, which was 
dissolved in methanol and heated under reflux for 4 h. After evaporation of the solvent, 
the product can be purified by column chromatography to obtain 0.22 g (40%) compound 
7 as colorless oil. 1H NMR (300 MHz,CDCl3) δ 7.74 (d, J =7.7, 2H), 7.58 (d, J =7.0, 2H), 
7.38 (t, J =7.32, 2H), 7.29 (t, J = 7.29, 2H), 5.93 (d, J = 8.4, 1H, NH), 4.72-4.81 (m, 3H), 
4.30- 4.45 (m, 2H), 4.21 (t, J = 7.0, 1H),  3.70 (s, 3H), 3.48 (s, 2H), 3.34-3.41 (A part of 
an ABX system, JAB= 18.8, JAX= 4.53, 1H), 3.16- 3.24 (B part of an ABX system, JAB= 
18.8, J BX= 4.53, 1H). ESI-MS: m/z [M + Na] + = 564.1.  
 
3-(7-hydroxy-2-oxo-2H-chromen-4-yl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-
propionic acid 2,2,2-trichloro-ethyl ester (8). Resorcinol (5, 0.162 g, 1.47 mmol) was 
added to a solution of compound 7 (0.795 g, 1.47 mmol) in methanesulfonic acid in an 
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ice bath. The resulting solution was stirred at 0°C for 6 h, and kept at 0°C for 15 h. After 
completion of the reaction, the mixture was poured into ice-cold water and the 
precipitates were filtered to obtain a white solid. The crude product was purified by 
column chromatography eluting with hexane: ethyl acetate (2:1) gave 6 as a white solid 
in 60% yield. 1H NMR (300MHz,CDCl3) δ 8.76 (s, 1H), 7.66 (d, J =7.6, 2H), 7.48-7.56 
(m, 3H), 7.31 (t, J =7.38, 2H), 7.22 (t, J = 7.41, 2H), 6.79 (m, 2H), 6.16 (s, 1H), 6.07 (d, J 
= 8.2, 1H), 4.83 (m, 2H), 4.68 (d, J =12, 1H), 4.14 (d, J = 7.1, 2H), 4.08-4.15 (m, 1H), 
3.37- 3.40 (m, 1H), 3.04- 3.11 (m, 1H). ESI-MS: m/z [M + Na]+  = 624.1.  
 
3-[7-(Diethoxyphosphoryloxy)-2-oxo-2H-chromen-4-yl]-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-propionic acid 2,2,2-trichloro-ethyl ester (9). To a solution 
of 8 (1.400 g, 2.0 mmol ) in 60 mL anhydrous CHCl3, DIPEA (0.646 g, 5.0 mmol) and 
diethyl chlorophosphate (0.518 g, 0.43 mmol) were added. The resulting mixture was 
stirred at room temperature, under nitrogen for 4 h. Upon completion of the reaction, the 
reaction was washed with 5% citric acid, 10% NaHCO3, water and brine. Evaporation of 
the solvent gave the desired product as a white solid. The compound was purified by 
column chromatography over silica gel, eluting with 1:1 (Hexane: ethyl acetate) gave 
1.196 g of 7 (85%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.69-7.76 (m, 3H), 
7.54 (d, J =7.2, 2H), 7.35 (t, J =7.1, 2H), 7.21-7.28 (m, 4H), 6.34 (s, 1H), 6.21(d, J =8.2, 
1H), 4.68-4.88 (m, 3H), 4.35 (d, J = 7.1, 2H), 4.25 (m, 5H), 3.36- 3.41 (m, 1H), 3.15- 




ylmethoxycarbonylamino)-propionic acid (10). The compound 9 (0.274g, 0.372 mmol) 
was dissolved in 20 mL THF/ acetic acid (1:1), and stirred at room temperature under 
nitrogen. Zinc dust (0.149g, 2.23 mmol) after fresh treatment with HCl was added to the 
reaction mixture and allowed to stir vigorously for 2 h. The reaction mixture was then 
filtered to remove Zn dust. The filtrate was poured into water and extracted with diethyl 
ether. The combined ether fractions were washed with water and  brine ,dried and the 
solvent was evaporated to get the product, which can be further purified using column 
chromatography on silica gel, eluting with 1:10 (MeOH : DCM) to get 0.224g of 8 (99%) 
as a white solid. 1H NMR (300MHz CDCl3) δ 7.79 (d, J = 8.7, 1H), 7.70 (d, J =7.3, 2H), 
7.51-7.54 (m, 2H), 7.31-7.36 (m, 2H), 7.17-7.27 (m, 4H), 6.34 (s, 1H), 6.16 (d, J =8.0, 
1H), 4.68-4.70 (m, 1H), 4.11-4.34 (m, 7H), 3.12-3.37 (m, 2H), 1.35 (t, J =6.8, 6H). ESI-
MS: m/z [M -H] - = 606.2 . 
 
3-[7-(Dibenzylphosphoryloxy)-2-oxo-2H-chromen-4-yl]-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-propionic acid 2,2,2-trichloro-ethyl ester (11).  To a 
solution of 8 (0.181g, 0.3mmol) and tetrazole (0.074g, 1.05mmol) in THF was added  
dibenzyl diisopropylphospho (0.6mmol, 0.207g) and. The reaction was allowed to stir at 
room temperature for 2h and then the reaction mixture was chilled down to 0 °C. BuOOH 
(0.9mmol, 0.133ml) was added to the chilled solution and the reaction was stirred for 2h 
at 0 °. After the reaction was complete, the THF was evaporated and redissolved in Ethyl 
acetate. The resulting solution was washed with 5% KHSO4, H2O and brine. The organic 
layer was dried over Na2SO4. The compound can be purified by column chromatography 
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over silica gel eluting with (3:1) hexane/acetone.  1H NMR (CDCl3, 300MHz) δ 7.63-
7.69 (m, 3H), 7.52 (d, J =7.32, 2H), 7.21-7.35 (m, 14H), 7.07(d, J =10.5, 2H), 6.31 (s, 
1H), 6.16 (d, J =8.01, 1H), 5.12 (d, J = 9.06, 4H), 4.66-4.86 (m, 3H), 4.33 (d, J =7.0, 2H), 




ylmethoxycarbonylamino)-propionic acid 2,2,2-trichloro-ethyl ester (12). To a 
solution of 11 (1.2g)  in CH3CN was added 2eq NaI (0.43g). The reaction was stirred 
under reflux conditions for 3h. After the reaction was complete, the reaction mixture was 
concentrated and redissolved in H2O. The compound was extracted into ether layer. The 
combined ether fractions were washed with water and brine, dried and the solvent was 
evaporated to get the product.  1H NMR (300MHz, CDCl3) δ 8.17 (d, J=8.04, 1H), 7.79 
(d, J =7.38, 2H), 7.65 (m, 3H), 7.15-7.42 (m, 10H), 6.28 (s, 1H), 4.95 (d, J =4.92, 2H), 




ylmethoxycarbonylamino)-propionic acid (13). The compound 12 (0.274g, 0.372 
mmol) was dissolved in 20 mL THF/ acetic acid (1:1), and stirred at room temperature 
under nitrogen. Zinc dust (0.149g, 2.23 mmol) after fresh treatment with HCl was added 
to the reaction mixture and allowed to stir vigorously for 2 h. The reaction mixture was 
then filtered to remove Zn dust. The filtrate was poured into water and extracted with 
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diethyl ether. The combined ether fractions were washed with water and  brine ,dried and 
the solvent was evaporated to get the product, which can be further purified using column 
chromatography on silica gel, eluting with 1:10 (MeOH : DCM) to get 0.224g of 8 (99%) 
as a white solid.1H NMR (300MHz, CDCl3) δ 8.17 (d, J =8.04, 1H), 7.79 (d, J =7.38, 2H), 
7.65 (m, 3H), 7.15-7.42 (m, 10H), 6.28 (s, 1H), 4.89 (d, J =8.1, 2H), 4.15-4.35 (m, 4H), 
3.15 (m, 2H). MS (ESI): m/z [M-H]-= 640.2 
 
N-tert-Butoxycarbonyl-1,2-diaminoethane (14). To a chilled solution of ethylene 
diamine in DCM was added dropwise a solution of Di-t-butyl dicarbonate. The reaction 
mixture was stirred for 30min at 0°C, then at room temperature for 19h. After 
evaporation of the solvent, the residue was redissolved in EA and washed with 5% 
NaHCO3 until the starting material disappearing. The organic layer was then washed 
with H2O and brine subsequently and dried with anhydrous NaHCO3. The resulting 
organic solvent was concentrated with reduced pressure to yield a gelatinous of liquid. 
Yield: 85%. 1H NMR (300 MHz, CDCl3) δ 5.01 (b, 1H), 3.09-3.13 (m, 2H), 2.73-2.77 (m, 
2H), 1.4 (s, 9H) . MS (ESI): m/z [M-H]-= 160.9.  
 
5-Carboxy-tetradiethylrhodamine (TMR) (15). Trimellitic anhydride (1.00 g, 5.2 
mmol) and 3-diethylaminophenol, (0.72 g, 10.5 mmol) was refluxed in toluene (50 ml) 
for 12 hours. Upon cooling to RT, the resulting precipitate was collected by filtration, and 
further purified by flash chromatography (silica gel, dichloromethane/methanol/acetic 
acid = 8:1.9:0.1) to afford pure (1) as a dark purple solid (0.811 g, 36%). 1H NMR (300 
MHz, CDCl3) δ 8.82 (s, 1H), 8.33 (d, J = 8.61 , 1H), 7.49 (d, J = 7.62 , 1H), 6.83 (m, 2H), 
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6.17 (s, 2H). 6.07 (d, J = 5.61 , 2H), 3.36 (q, J =6.84, 8H), 1.19 (t, J =6.96, 12H) . MS 
(ESI): m/z [M+H]+ = 487.4. 
 
TMR-linker (16). To a solution of TMR acid 15 in DMF was added tert-butyl 2-
aminoethylcarbamate followed by EDC (1.2eq) and HOBT (1.1eq), the reaction was 
allowed to react at room temperature for overnight and concentrated in vacuo to yield a 
dark red solid. The resulting solid was redissolved in DCM and washed with with 5% 
NaHCO3, H2O and brine respectively. The organic layer was dried with anhydrous 
Na2SO4 and concentrated under reduced pressure to afford a crude mixture, which was 
further purified with flash chromatography with 4:1 (DCM: methanol) elution condition. 
Subsequently the compound was deprotected with 1:1 TFA/DCM. The reaction mixture 
was stirred for 1h at room temperature. The resulting mixture was concentrated at 
reduced pressure and redissolved in DCM. The organic layer was washed with H2O and 
brine successively. And the resulting organic solvent was dried with anhydrous Na2SO4 
and concentrated at reduced pressure. Yield: 65%. 1H NMR
 
(300 MHz, CDCl3) δ 8.57 (b, 
1H), 8.14-8.33 (m, 1H), 7.67 (s, 1H), 7.13-7.26 (m, 1H), 6.75-6.77 (m, 2H), 6.45-6.48 (m, 
3H), 3.23-3.5 (q, J=6.84, 8H), 2.92 (s, 2H), 2.84 (s, 2H), 1.1-1.27(t, J =6.84, 12H). MS 
(ESI): m/z [M+H]+= 529.3. 
 
Rhodamine B base (17).  Rhodamine B was dissolved in EtOAc and extracted with 1M 
NaOH. After the isolation of organic layer, the aqueous layer was extracted with EtOAc 
twice. The resulting organic layer was washed with NaOH and brine successively. 
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Followed by drying with anhydrous Na2SO4, the organic layer was concentrated under 
reduced pressure to afford a pink foam product.  
 
Rhodamine B piperazine amide (18).  To a solution of piperizine in DCM was added 
the trimethyl aluminum in toluene dropwise in a dropping funnel. After stirring for 1h at 
room temperature, a solution of rhodamine B base in DCM was added dropwise to the 
reaction. The reaction was allowed to react under reflux for 24 h. a 0.1 M HCl was added 
to quench the trimethyl aluminum until the gas evolution ceased. The heterogeneous 
solution was filtered and the retained solid was rinsed with 4:1 DCM/MeOH solution. 
The combined filtrate was concentrated and the residue was dissolved in DCM and 
filtered to remove the insoluble residue. The organic layer was concentrated, dissolved in 
EtOAc and extracted with 5% NaHCO3. After isolation of organic layer, the aqueous 
layer was washed with EtOAc to remove the starting material. The combined aqueous 
layer was  saturated with NaCl, acidified with 1M HCl, and then extracted with several 
times of 2: 1 iPrOH/DCM until the aqueous layer become a faint pink. The organic layers 
were then washed with brine, dried with anhydrous Na2SO4 and concentrated under 
reduced pressure to afford a dark purple solid, which was further purified by flash 
chlomatography. Yield: 81%. 1H-NMR (300 MHz, CDCl3): 7.76-7.85 (m, 3H), 7.52 (b, 
1H), 7.26 (d, J =9.42, 2H), 7.1 (d, J=8.7, 2H), 6.97-6.98 (m, 2H), 3.66-3.70 (m, 12H), 
3.13 (br s, 4H),  1.29-1.33 (t, J=6.6, 12H). MS (ESI): m/z [M+H]+= 511.4.  
 
3',6'-diacetoxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylic acid (19). 
To a solution of resorcinol (5.7 g, 52 mmol) in 50ml CH3SO3H was added trimellitic 
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anhydride (5 g, 26 mmol). The reaction was heated at 80-85 ºC for 12 hours. The highly 
viscous solution was cooled to RT and then poured into ice-cold water. The resulting 
precipitate was collected and dried in vacuo to give compound as a crude yellow solid. 
To assist the purification, the compound was dissolved in 50 ml of acetic anhydride and 
10 ml of pyridine. The solution was heated at 85 ºC for 15 minutes. The resulting solution 
was poured into ice-cold water to give the crude precipitate of 19, which, upon 
recystallization with DCM, afforded pure 19 as white crystals (5.17 g, 53%). 1H-NMR 
(300 MHz, CDCl3) δ 8.45 (s, 1H), 8.33 (d, J = 8.01, 1H), 7.53 (d, J = 8.01, 1H), 7.29 (m, 
2H), 6.96 (m, 4H), 2.51 (s, 6H). MS (ESI): m/z [M+H]+ = 461. 
 
Fluorescein (20). To a solution of 0.5 g 19 in THF/MeOH was added 0.81 ml ammonia 
solution, the reaction was allowed to react 2h at room temperature. After the reaction was 
complete, the solution was added 55 ml cold H2O and acidified with 10% HCl to pH = 2. 
The resulting solution was concentrated under reduced pressure to remove THF and 
MeOH. Subsequently the resulting solution was filtered and the solid was washed with 
cold H2O. Yield: 78%. 1H-NMR (300 MHz, CDCl3) δ 9.00 (s, 1H), 8.90 (d, J = 8.1, 1H), 
7.99 (d, J = 8.01, 1H), 7.29 (m, 2H), 7.13-7.23 (m, 4H). MS (ESI): m/z [M-H]- = 375.1.  
Fluorescein-linker (21). The procedure was similar to synthesis of TMR-linker 16. Yield: 
67 %. 1H-NMR (300 MHz, CDCl3) δ 8.44 (s, 1H), 8.21 (d, J = 8.1, 1H), 7.35 (d, J = 8.01, 
1H), 6.69 (m, 2H), 6.55 (m, 4H), 3.56-3.57 (m, 2H), 3.49-3.54 (m, 2H).MS (ESI): m/z 
[M+H]+ = 418.2.  
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General procedure for the coupling reaction with TMR/RhoB and TFA cleavage of 
Boc protecting group 
Coupling reaction 
To a solution of TMR acid in DMF was added Boc-Gly or Boc-aminooxy acetic 
acid and followed by EDC (1.2eq) and HOBT (1.1eq), the reaction was allowed to react 
at room temperature for overnight and concentrated in vacuo to yield a dark red solid. 
The resulting solid was redissolved in DCM and washed with with 5% NaHCO3, H2O 
and brine respectively. The organic layer was dried with anhydrous Na2SO4 and 
concentrated under reduced pressure to afford a crude mixture, which was further 
purified with flash chromatography with corresponding elution conditions.  
TFA cleavage  
To a solution of Boc protected compound in DCM was added TFA. The reaction 
mixture was stirred for 1h at room temperature. The resulting mixture was concentrated 
at reduced pressure and redissolved in DCM. The organic layer was washed with H2O 
and brine successively. The resulting organic solvent was dried with anhydrous Na2SO4 
and concentrated at reduced pressure. 
 
Aminooxy-TMR (22). Yield: 67%. 1H NMR
 
(300 MHz, CDCl3) δ 8.58 (b, 1H), 8.06-
8.17 (m, 1H), 7.68 -7.22 (m, 1H),  7.37-7.39 (d, J = 8.01, 1H),  7.19-7.24 (m, 2H), 6.92-
7.01 (m, 3H), 4.15-4.21 (m, 2H), 3.41-3.48 (m, 8H), 2.95 (b, 4H), 1.26-1.31 (t, 12H). MS 




Glycine-TMR (23). Yield: 75%. 1H NMR: (300 MHz, CDCl3) δ 8.80 (b, 1H), 8.14-8.23 
(m, 1H), 8.01 (s, 1H), 7.67 (s, 1H),  7.14-7.16 (m, 1H), 6.9 -7.1 (m, 2H), 6.57-6.71 (m, 
2H), 3.64-3.69 (m, 10H), 2.98 (s, 2H), 2.84 (s, 2H), 1.27-1.32 (t, J=6.84, 12H). MS (ESI): 
m/z [M+H]+ = 586.5.  
 
Gly-Gly-TMR (24). Yield: 78%.  1H NMR: (300 MHz, CDCl3) δ 8.4 (m, 1H), 8.15-8.25 
(m, 1H), 8.01 (b, 1H), 7.82 (m, 1H), 7.04-7.16 (m, 2H), 6.94-7.05 (m, 3H), 3.26-3.70 (m, 
12H), 3.03 (s, 2H), 2.90 (s, 2H), 1.30-1.35 (m, 12H). MS (ESI): m/z [M+H]+ = 645.5. 
 
 




 (300 MHz, CDCl3) δ 8.76-8.77 (m, 
1H), 8.22-8.26 (m, 1H), 7.52 (d, J = 8.04, 1H), 6.97-7.12 (m, 6H), 3.6-3.7 (m, 12H), 3.29-
3.30 (m, 4H), 1.27-1.32 (t, 12H). MS (ESI): m/z [M+H]+ = 659.3.  
 
Aminooxy-RhoB (26). Yield: 78%.  1H-NMR (300 MHz, CDCl3): 7.66 (b, 3H), 7.53 (b, 
1H), 7.26-7.40 (m, 4H), 6.69 (b, 2H), 4.47 (b, 1H), 3.54-3.69 (m, 12H), 3.40-3.47 (m, 
6H), 1.28-1.33 (t, J=7.23, 12H). MS (ESI): m/z [M+H]+ = 584.4.  
 
Gly-RhoB (27). Yield: 83%. 1H-NMR (300 MHz, CDCl3): 7.64-7.65 (m, 3H), 7.30-7.32 
(m, 1H), 7.16 (d, J=9.24, 2H), 6.86 (d, J=8.82, 2H), 6.72 (m, 2H), 3.93 (m, 2H), 3.54-




GlyGly-RhoB (28). Yield: 85%. 1H-NMR (300 MHz, CDCl3): 7.60-7.64 (m, 3H), 7.52-
7.53 (m, 1H), 7.17-7.31 (m, 2H), 6.87-6.90 (m, 2H), 6.73 (m, 2H), 4.05-4.07 (m, 2H), 
3.37 -3.71 (m, 18H), 1.28-1.33 (t, 12H). MS (ESI): m/z  [M+H]+ = 625.5. 
 
Aminooxy-Gly-RhoB (29). Yield: 75%. 1H-NMR (300 MHz, CDCl3): 7.68-7.78 (m, 3H), 
7.55-7.58 (m, 1H), 7.15-7.38 (m, 4H), 6.68-6.75 (m, 2H), 4.15-4.28 (m, 3H), 3.42-3.70 
(m, 18H), 1.31-1.43 (t, 12H). MS (ESI): m/z [M+H]+ = 641.4.  
 
Ethyl 2-(2-aminoacetamido) acetate (30). Yield: 93%. 1H-NMR (300 MHz, CDCl3): 
4.04-4.11 (q, J = 7.23, 2H), 3.81 (d, J = 5.61, 2H), 3.57 (d, J = 6.03, 2H), 1.15-1.20 (t, J = 
7.23, 3H). 
 
(Boc)-(Gly)3-OH (31). Yield: 78%. 1H-NMR (300 MHz, CDCl3): 3.82 (d, J = 5.61, 2H), 
3.74 (d, J = 5.64, 2H), 3.58 (d, J = 5.61, 2H), 1.37 (s, 9H). MS (ESI): m/z [M-H]- = 288.1. 
 
GGG-Fluorescein (32). Yield: 85%. 1H-NMR (300 MHz, CDCl3): 8.46 (s, 1H), 8.21 (d, 
J=8.01, 1H), 7.31 (d, J=8.01, 1H), 6.74-6.75 (m, 2H), 6.57-6.60 (m, 4H), 3.87 (s, 2H), 




7.3 Peptide Synthesis 
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The following procedure is used for all peptide synthesis carried out in this thesis 
unless otherwise noted: The peptide synthesis was performed by using standard Fmoc 
Strategy combined with IRORITM directed sorting technology. Rink amide resin was used 
as the solid support. Standard HOBT/HBTU/DIEA coupling method was used throughput 
the whole process unless indicated. Each microreactor contains around 40 mg of rink 
amide resin and a unique Rf tag for sorting application. The resin was swelled in HPLC-
grade DMF for 1 h at room temperature. Subsequently the Fmoc group was deprotected 
by treatment of 20% piperidine for 1 h at room temperature. Following removal of the 
piperidine, the resin was washed extensively with DMF and DCM. The microreactors 
were then dried thoroughly under the high vaccum. Next, the microreactors were sorted 
and distributed into several reaction vessels, and each containing a unique Fmoc amino 
acid (4.0 eq), preactivated with HBTU/HOBt/DIEA (1/1/2 ratio relative to the amino 
acid). The resins were swelled in DMF for half an hour before coupling. The coupling 
reactions were carried out for 8 h at room temperature with shaking. At the end, the 
microreactors were collected and washed thoroughly with DMF and DCM. Any 
unreacted resin residue was capped with a solution of Ac2O (10 eq), DIEA (20 eq) in 
DCM (200 mL), and the reaction mixture was allowed to react for 2 h at room 
temperature, followed by extensive wash with DCM and DMF. Subsequently the resin 
was deprotected with 20% piperidine again and ready for next coupling cycle. Repeat the 
above cycle until the last amino acid has been coupled. After the whole coupling process 
was finished, the microreactors were collected, washed thoroughly and dried under high 
vaccum for 2 h at RT. (Notice: the last wash before vacuum should be done with MeOH). 
The microreactors were then decoded and cleaved under 95% TFA, 2.5% TIS, 2.5% H2O 
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for 4 h at room temperature. For those peptides containing cysteine or methionine residue, 
the peptides were cleaved from the resin by using 94.5%TFA, 2.5% EDT, 2.5% H2O and 
1% TIS. Following prolonged concentration in vacuo until >80% of cleavage cocktail 
was removed. Cold ether (chilled to -20 °C) was added to the liquid residue to precipitate 
the peptides. The peptides were allowed to precipitate at -20 °C for overnight. At the end, 
the ether layer was decanned and the precipitates were dried thoroughly in vacuo. This 
ether precipitation process was repeated for a couple more times. The resulting peptide 
solids were dissolved in 1 ml DMSO and stored at -20 °C for future use. 
 
7.3.1 1000 Member p(Ser/Thr) Peptide Library Synthesis 
The 1000-member phosphopeptide library was synthesized in two different 
sublibraries (N- and C-terminal library) by using the standard Fmoc strategy combined 
with IRORITM technology. The peptide sequences are the followings:   
                 N-terminal sublibrary: (Biotin)-GG-P
-3P-2P-1-p(S/T)-X+1X+2X+3-CONH2 
                 C-terminal sublibrary: (Biotin)-GG-X
-3X-2X-1-p(S/T)-P+1P+2P+3-CONH2  
where the coupling of X was carried out using an isokinetic mixture of 14 different 
Fmoc-protected amino acid residues containing the following molar ratio: Fmoc-Ala-OH, 
0.75, Fmoc-Asp(OtBu)-OH, 1.2, Fmoc-Glu(OtBu)-OH, 1, Fmoc-Phe-OH, 0.6, Fmoc-
Gly-OH, 0.7, Fmoc-His(Trt)-OH, 0.78, Fmoc-Ile-OH, 2.29, Fmoc-Lys(Boc)-OH, 1, 
Fmoc-Leu-OH, 0.77, Fmoc-Asn(Trt)-OH, 1.2, Fmoc-Pro-OH, 0.86, Fmoc-Gln(Trt)-OH, 
1, Fmoc-Arg(Pbf)-OH, 1.1, Fmoc-Val-OH, 1.8. For the coupling of phosphoserine and 
phosphothreonine, p(S/T), an 1:1 molar ratio mixture of Fmoc-Ser[PO(OBzl)-OH]-OH 
and Fmoc-Thr[PO(OBzl)-OH]-OH was used. For the P+/-1 and P+/-2 positions, a total of 10 
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different amino acid building blocks (R, E, F, L, Q, A, G, V, K, P), were individually 
used in a predefined manner. For the P+/-3 positions, a total of 5 different amino acid 
building blocks (R, E, F, L, P) were used. In this way, a total of 500 different peptide 
sequences (10 x 10 x 5) were generated for each sublibrary, giving a total of 1000 
different peptides with both N- and C-terminal libraries. Either (Biotin)-GG or TMR-GG 
was attached at N-terminus of each peptide for microarray immobilization and FP 
experiments, respectively. A total of 1000 microreactors were used throughout the 
synthesis. 
7.3.2 p(CAP) Peptide Library Synthesis 
The unnatural amino acid P(CAP) was incoporated to the growing peptide chain 
using PyBOP and HOAt as coupling agents. The phosphate protecting groups were 
removed by treating the resin with 20 equiv TMSI (0.1113 mL, 0.74 mmol) in anhydrous 
DCM (1 mL). The beads were then washed extensively with DCM, followed by DMF. 
The N-terminal Fmoc group was then removed and the peptides were cleaved off the 
resin as above.  
7.4 Microplate Assay  
7.4.1 FRET Assay against Proteases 
The reaction was carried in a black round-bottom polypropylene 96-well 
microtitre plates (Nunc, USA). The FRET substrate after normalization was diluted in 
1:100 in Tris Buffer (50 mM, pH=8) for general analysis. The 96-well microplates were 
added 98µl Tris buffer (50 mM, pH=8) first, and 1 ul the diluted FRET substrate were 
added and mixed thoroughly. The background of the fluorescence was recorded a 
SpectraMAX™ Gemini XS fluorescence plate reader (Molecular Devices, USA), with 
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λex/em : 355/460 nm. The control of EnzChek Protease Assay Kit (Molecular Probes, USA) 
was included to serve as a comparison by adding 1 µl of the 1mg/ml solution prepared 
according to the Vendor’s protocol instead of the FRET substrates. Subsequently 1 µl of 
each enzyme stock solution was added to give the final concentration of 1µg/ml. The 
fluorescence intensity was continuously monitored at room temperature for one hour by 
the microplate reader.  
7.4.2 p(CAP) Assay against PTPs 
The reaction was carried in a black round-bottom polypropylene 384-well 
microtitre plates (Nunc, USA). The peptide was diluted in 1:100 in Tris Buffer (50mM, 
pH=8) for general analysis. The 384-well microplates were added 48 µl Tris buffer 
(50mM, pH=8) first, and 1 µl the diluted substrate were added and mixed thoroughly. 
The background of the fluorescence was recorded a SpectraMAX™ Gemini XS 
fluorescence plate reader (Molecular Devices, USA), with λex/em: 355/460 nm. 
Subsequently 1 µl of each enzyme stock solution was added. The fluorescence intensity 
was continuously monitored at room temperature for half and hour by the microplate 
reader.  
7.4.3 FRET Assay with SrtA 
The reaction was carried in a black round-bottom polypropylene 384-well 
microtitre plates (Nunc, USA). For performing the hydrolysis reaction of SrtA, different 
concentrations of ACC-GLPETG-Dabcyl ranging from 40 µM, 20 µM, 16 µM, 8 µM, 4 
µM and 2 µM was incubated with 3 µM SrtA in the presence of 5 mM Ca2+. Different 
concentrations of nucleophiles GGG ranging from 40 µM, 20 µM, 5 µM, 1 µM and 0 µM 
were added into the reaction to check whether addition of nucleophiles accelerate the 
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enzyme hydrolysis. The fluorescence intensity was continuously monitored at room 
temperature for one hour by the microplate reader with λex/em : 355/460 nm. For carrying 
out the transpeptidation reaction, different concentrations of fluorescently conjugated 
nucleophiles GGG-FITC ranging from 20 µM, 5 µM, 1 µM and 0 µM were incubated 
with 3 µM SrtA, 20 µM ACC-GLPETG-Dabcyl in the presence of 5 mM Ca2+. The 
fluorescence intensity was continuously monitored at room temperature for one hour by 
the microplate reader with dual wavelength channel: ACC channel (λex/em : 355/460 nm) 
and FRET channel (λex/em : 355/530 nm). 
 
7.5 Microarray-based Enzyme Sreening 
7.5.1 Preparation of Avidin Slide 
 25 mm × 75 mm glass slides (Sigma-Aldrich) were cleaned in piranha solution 
(sulfuric acid/hydrogen peroxide, 7:3). An amine functionality was incorporated onto the 
slides by silanization using a solution of 3% (aminopropyl) triethoxysilane in 2% water 
and 95% ethanol. After 1-2 h incubation, the slides were washed with ethanol and cured 
at 150 ºC for at least 2 h. The resulting amine slides were incubated in a solution of 180 
mM succinic anhydride in DMF for 30 min before being transferred to a boiling water 
bath for 2 min. The slides were rinsed with ethanol and dried under a stream of nitrogen. 
The carboxylic acid derivatized slide surface was activated with a solution of 100 mM of 
HBTU, 200 mM DIEA, and 100 mM N-hydroxysuccinimide in DMF, thus generating the 
NHS-derivatized slides. These surfaces were reacted with a solution of 1 mg/mL avidin 
in 10 mM NaHCO3 (pH 9) for 40 min, washed with water, air dried. The unreacted NHS 
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groups were quenched with a solution of 2 mM aspartic acid in a 0.5 M NaHCO3 buffer, 
pH 9. These slides were washed with water, dried and stored at 4 ºC, ready for printing. 
 
7.5.2 Microarray Preparation 
 All peptide stocks were prepared in an 1:1 DMSO/PBS spotting solution (to either 
~1 mM final concentration or an appropriate concentration), and were distributed in 384-
well plates. All peptides were shown to be completely soluble in this spotting solution. 
Slides were spotted on an ESI SMA arrayer (Ontario, Canada) with the printhead 
installed with 4 Stealth SMP8B Microspotting pins (Telechem, U.S.A.). Spots generated 
were of approximately 350 µm diameter and were printed with a spot-spot spacing of 550 
µm. The pins were rinsed in between samples using two cycles of wash (for 10 s) and 
sonication (for 10 s) in reservoirs containing 70% ethanol followed by drying under 
reduced pressure (for 10 s). The slides were allowed to stand for 1 h on the printer 
platform and stored at 4 ºC until use.  
 
7.5.3 Screening  Peptide Array with pSer/Thr Phosphatases 
7.5.3.1 Pro-Q Assay 
 The phosphorylated peptides together with corresponding nonphosphorylated 
peptides were spotted onto the same avidin slide. The slide was washed with H2O and 
stained with Pro-Q™ Diamond dye for 1 h at room temperature. Subsequently the slide 
was destained with 20% acetonitrile in sodium acetate (pH = 4) for half an hour and 
visualized under the array work station at Cy3 channel: Ex: 548 nm Em: 595 nm.  
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7.5.3.2 Fingerprint Experiment 
 The subgrids were treated with different enzyme on the same slides. Six grids of 
identical 87 phosphorylated peptides were spotted onto the same avidin-functionalized 
slide in DMSO:PBS (1:1) mixture (This concentration was tested to be ideal for substrate 
immobilization). The slide was then washed with H2O for 10 min at RT and incubated 
with 1% BSA in Hepes (pH = 7.4) for half an hour with gentle shaking. The slide was 
then washed with H2O and dried briefly to get rid of the water. Subsequently, 1 U each of 
lambda phosphatase, PP1, alkaline phosphatase and PP2B were applied together with 
their own buffer to the different subgrids on the same slide. The enzyme reaction was 
allowed to incubate in a humid chamber at room temperature for 1 h. The slide was then 
washed with H2O and stained with ProQ Diamond Dye.  The composition of phosphatase 
buffer was as followed: lambda phosphatase buffer: 50 mM Tris-HCl, 100 mM NaCl, 2 
mM DTT, 0.1 mM EGTA, 0.01% Brij 35, pH 7.5. PP1 buffer: 50 mM Hepes, 0.1 mM 
Na2EDTA, 5 mM DTT, 0.025% Tween 20, pH 7.0. Alkaline phosphatase buffer: 50 mM 
Hepes, pH 7.5. PP2B buffer: 50 mM Tris-HCl, 100 mM NaCl, 6 mM MgCl2, 0.5 mM 
CaCl2, 0.5 mM DTT, 0.25% NP-40, pH 7.5.  
 
7.5.3.3 Time-Dependent Experiment 
 The time-dependent experiment was carried out similarly as described above except 
that the different grids were incubated with lambda phosphatae (same concentration) for 
different periods of time (0, 5 min, 15 min, 30 min, 1 h, 2 h, respectively). 
 
7.5.3.4 Solution-Phase HPLC Assay 
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 Three of peptides with different kobs (observed on the array) were further validated 
by solution phase HPLC assay. The reaction was set up as followed: 500 µl of reaction 
buffer, 20 µl of peptide substrate from stock solution, 10 µl of diluted enzyme solution 
(around 1 U of the enzyme). And the enzyme reaction was stopped by adding 1% TFA at 
different time points (5 min, 15 min, 30 min, 45 min and 60 min, respectively). The 
reaction was subsequently analyzed and quantitated by LCMS. 
 
7.5.3.5 Phosphatase Inhibition Experiment 
 
 The enzyme was premixed with different concentrations of the inhibitor (Na3VO4, 0 
mM, 0.35 mM, 0.7 mM and 1.4 mM) and applied to the peptide array. It was found that 
with 1.4 mM of Na3VO4, lambda phosphatase activity was nearly completely abolished. 
 
7.5.3.6 Pin1 Regulation Assay 
 
  Pin1 concentration in the final assay was 2.0 µM. After blocking with 1% BSA in 
Hepes (pH = 9) and rinsing briefly with H2O, the slide was applied with Pin1, PP2A and 
Pin1 + PP2A (1 U of PP2A) at room temperature for 2 h, respectively. Following that the 
slide was washed with H2O, stained with Pro-Q and visualized under the array station 
scanner.  
7.5.4 Highthroughput Sceeening of  14-3-3 Isoforms 
7.5.4.1 Protein Labeling and Screening on the Array 
     Protein samples were minimally labeled with either Cy3 or Cy5 N-
hydroxysuccinimide ester for 1 h on ice, following the manufactor’s protocols and our 
previously published procedures. The unreacted dye was quenched with a 10-fold molar 
excess of hydroxylamine for a further 1 h. The excess dye was further removed with a 
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Sephadex G-25 spin column. After analysis by DED-PAGE gel to ensure successful 
labeling and purity, the labeled protein was reconstituted in a final buffer volume of 80 µl 
TBS (pH 7.4) containing 1% bovine serum albumin (BSA). In a standard microarray 
experiment, the labeled protein (2 µM; 50 µL) was applied under coverslip to the array. 
In a dose-dependent experiment for KD measurements, various concentrations of the 
protein (5000 nM to 50 nM) were applied to different subarrays on the same slide, as 
previously described. For dual-color screening experiments, an equal amount of a Cy3-
labeled protein and another Cy5-labeled protein was mixed and applied together to the 
slide. The samples were incubated with the array in a humidified chamber for 2 h at room 
temperature, before repeated rinses with TBS + 0.05 % Tween 20, typically 2 x 10 min 
washes with gentle shaking. Slides were scanned using an ArrayWoRx microarray 
scanner installed with the relevant filters (Cy3: λex/em = 548/595 nm; Cy5: λex/em = 
633/685 nm).  
 
7.5.4.2 KD analysis with Fluorescence Polarization 
     Fluorescent polarization experiments were performed by incubating a fixed low 
concentration of fluorescently labeled peptides with serial-diluted 14-3-3 proteins in a 
384-well black polypropylene plate, as previously reported. The incubation time of 
peptide and protein was 1 h to ensure it reached the binding equilibrium with the lowest 
protein concentration. The fluorescence readings were taken with a fluorescence plate 
reader (Tecan, USA) installed with 2 pairs of polarizers (λEx: 540 nm; λEm: 590 nm). 
The data obtained was fitted to the following equation:  
 
 145 
7.5.5 Screening Peptide Array with PTP mutants 
PTP mutants were minimally labeled with the protocol described above. The 
excess dye was removed by extensive dialysis against TBS buffer due to the PTP mutants 
were trapped inside the G25 spin column. In a standard microarray experiment, the 
labeled protein was applied on microarray via markpen method. For dual-color screening 
experiments, an equal amount of a Cy3-labeled protein and another Cy5-labeled protein 
was mixed and applied together to the slide. The samples were incubated with the array 
in a humidified chamber for 1 h at room temperature, before repeated rinses with TBS + 
0.05 % Tween 20, typically 3 x 10 min washes with gentle shaking. Slides were scanned 
using an ArrayWorx microarray scanner installed with the relevant filters (Cy3: λex/em = 
548/595 nm; Cy5: λex/em = 633/685 nm).            
                                     
7.6 Gene Cloning and Protein expression 
 
7.6.1 Cloning SrtA Gene into pdest17 Vector 
Primer FW  5’-GGG ACA AGT TTG AAA AAA GCA GGC TTT ACC ATG 
CAA GCT AAA CCT CAA-3’ and 5-GGG GAC CAC TTT GTA CAA GAA AGC TGG 
GTT TCA TTT GAC TTC TGT AGC-3’were used to PCR amplify the SrtA gene from 
the genomic DNA of Staphylococcus aureus. The DNA fragment was cloned into 
pdest17 vector (invitrogen) with N-terminal His tag by using the gateway cloning 
technology. The plasmid was transformed into Bl21-AI strain for protein expression. A 
single colny was picked up from the transfromed E.coli host and grown in Luria Bertani 
LB media with 100 µg/ml Ampicillin at 37 ºC overnight with a shaker.  The overnight 
culture was diluted with fresh LB-ampicillin media in 1:100 and incubated at 37 ºC with 
constant shaking until the OD reached 0.4.  Protein expression was induced with 0.2% 
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arabinose at 37°C for 3 hours. Cells were harvested by centrifugation (4000 rpm, 10 min, 
4 °C) , resuspended in lysis buffer (20 mM Tris-Hcl, 10 mM imidazole, pH 8.0) and 
lysed by sonication (pulse on 5 sec, pulse off 10 sec, 10 cylces)  The cell debris was 
pelleted down by centrifugation (13000 rpm, 30 min, 4 °C) to give white clear lysate. The 
pellets can be stored at -20 °C for one month. 
PCR mixture was prepared as followed: 25 ng/uL genomic DNA, 5 ul 10 times 
buffer, 1 mM each primers, 0.2 mM dNTPs, 1 unit hot star tag polymerase, Amplification 
was carried out in a DNA engine thermal cycle. The PCR amplification conditions are as 
followed: First denaturation at 95 °C for 15 min, Denaturation at 94 °C for 1 min, 
Annealing at 55°C for 1 min and extension at 72 °C for 1 min, the PCR cycle is 28 times. 
The PCR mixture was purified by using gel extraction kit, followed by cloning into 
pDONOR201 with BP reaction, and finally recombinated into pdest17 vector after LR 
reaction. The resulting construct pdest17-srtA was verified by sequencing analysis. The 
following figure illustrates the cloning strategy: 
 
7.6.2 Cloning EGFP Gene into pdest17 Vector 
 
5’-GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC AAT GGT GAG CAA 
GGG CGA G-3’ and 5’-AGG GAT AGG CTT ACC AAG GCC GGT TTC CGG AAG 
GGA CTT GTA CAG-3’ and 5’-GGG GAC CAC TTT GTA CAA GAA AGC TGG 
GTT TCA CGT AGA ATC GAG ACC GAG GAG AGG GTT AGG GAT AGG CTT 
ACC-3’ were used to assembly PCR amplify EGFP gene with an extra C-terminal V5 
tag from pEGFP (Clontech, USA). Similarly the DNA fragment was cloned into pdest17 
vector with N-terminal His tag by using gateway cloning technology. The plasmid was 
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transformed into Bl21-AI strain for protein expression. A single colny was picked up 
from the transfromed E.coli host and grown in Luria Bertani LB media with 100 µg/ml 
Ampicillin at 37 ºC overnight with a shaker.  The overnight culture was diluted with 
fresh LB-ampicillin media in 1:100 and incubated at 37 ºC with constant shaking until 
the OD reaches 0.6. Protein expression was induced with 0.2% arabinose at room 
temperature with constant shaking for overnight. Cells were harvested by centrifugation 
(4000 rpm, 10 min, 4 °C) and suspended in the ice cold lysis buffer containing 10 mM 
imidazole for future protein purification. The cell debris was pelleted down by 
centrifugation (13000 rpm, 30 min, 4 °C) to yield green clear lysate. 
PCR mixture was prepared as followed: 5 µl 10× PCR buffer, 1 mM of each 
primers, 0.2 mM dNTPs, 1 unit hot star tag polymerase, Amplification was carried out in 
a DNA engine thermal cycle. The PCR amplification conditions are as followed: First 
denaturation at 95 °C for 15 min, Denaturation at 94 °C for 1 min, Anealing at 68 °C for 
1 min and extension at 72 °C for 1min. The PCR cycle is 28 times. The PCR mixture was 
purified by using gel extraction kit, cloned into pDONOR201 vector by BP reaction, and 
finally recombinated into pdest17 vector after LR reaction. The resulting construct 
pdest17-EGFP-V5 was also verified by sequencing analysis. The following figure 
illustrates the cloning strategy: 
 
 
7.6.3 Site Directed Mutagenesis of pTYB1-EGFP and PTP mutants 
 
7.6.3.1 SDM with pTYB1-EGFP 
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The last four amino acid residues of EGFP in plasmid pTYB1-EGFP (from Rina) 
were mutated to LPET by using QuickChangeTM XL Site-Directed Mutagenesis 
Kit( Strategene) with upstream primer 5’-CAT GGA CGA GCT GTA CCT GCC AGA 
AAC ATG CTT TGC CAA GG-3’ and downstream primer 5’-CCT TGG CAA AGC 
ATG TTT CTG GCA GGT ACA GCT CGT CCA TG -3’. The four amino acid residues 
LPET were underlined in the primers. Primers were designed to introduce the desired 
mutation site. Appropriate primer sequences were chosen to ensure that the Tm melting 
temperature was above 78 ºC. Codon usage of amino acid was calculated to ensure the 
desired protein would be well expressed in E. coli cells. PCR amplification was first 
carried out to amplify the whole sequence of gene with the primer containing desired 
mutation site. The PCR product was confirmed with the desired PCR band with gel 
analysis. Dpn I enzyme was used to digest the template which contains the methylation 
site. PCR product was then transformed into top 10 competent cells and cultured in 
LB+Amp agar plates at 37ºC. Two of the clonies from the agar plate were picked up and 
cultured in 5 ml LB+ Amp for overnight. Miniprep was used to extract the genes and 
DNA sequencing was carried out to confirm the presence of mutation site and correct 
frame of gene.  
Upon confirmation by automated DNA sequencing (Applied Biosystems), the 
plasmid was transformed into ER2566 and Bl21-AI strain respectively for optimization 
of protein expression. A single colony was picked up from the transfromed E.coli host 
and grown in Luria Bertani LB media with 100 µg/ml Ampicillin at 37 ºC overnight with 
a shaker.  The overnight culture was diluted with fresh LB-ampicillin media in 1:100 and 
incubated at 37 ºC with constant shaking until the OD reaches 0.5. Protein expression 
 149 
was induced at room temperature overnight with 0.3 mM IPTG and 0.2% arabinose 
respectively. Harvest the cells by centrifugation at 4000 rpm at 4 °C for 10 min, the 
pellets were resuspended in the lysis buffer and lysed by sonication in the ice bath. The 
cell debris was pelleted down by centrifugation (13000 rpm, 4°C, 20 min) to give a clear 
lysate. 
7.6.3.2 SDM with PTP Mutants 
      
      The PTP mutants were obtained by using QuickChangeTM XL Site-Directed 
Mutagenesis Kit (Strategene) described as above. The primers for constructing of 
different PTP mutants (C-S) were listed as followed: 
SDM-PTP1B-Fw (C215S)  
5’-CGG GCC CGT TGT GGT GCA CTC CAG TGC AGG CAT CGG CAG GT-3’ 
 
SDM-PTP1B-Rv (C215S)  
5’-ACC TGC CGA TGC CTG CAC TGG AGT GCA CCA CAA CGG GCC CG-3’ 
 
SDM-TCPTP-Fw (C216S) 
5’-ATG GGC CTG CGG TGA TCC ACT CTA GTG CAG GCA TTG GGC GCT C-3’ 
 
SDM-TCPTP-Rv (C216S) 
5’-GAG CGC CCA ATG CCT GCA CTA GAG TGG ATC ACC GCA GGC CCA T-3’ 
 
SDM-SHP1-Fw (C453S) 
5’-CCC ATC ATC GTG CAC TCC AGC GCC GGC ATC GGC-3’ 
 
SDM-SHP1-Rv (C453S) 
5’-GCC GAT GCC GGC GCT GGA GTG CAC GAT GAT GGG-3’ 
 
SDM-SHP2-Fw (C459S) 
5’-CCG GTC GTG GTG CAC TCC AGT GCT GGA ATT GGC-3’ 
 
SDM-SHP2-Rv (C459S) 
5’-GCC AAT TCC AGC ACT GGA GTG CAC CAC GAC CGG-3’ 
 
SDM-LMW-Fw (C13S) 




5’-GAT CGA CAA ATG TTA CCC AGG GAC ACA AAC AGC ACG GAC TTG-3’ 
 
7.6.4 His-Tag Purification 
 
Protein purification was under the standard protocol of His tag purification Kit. Lysis 
Buffer: Phosphate Buffer, 300 mM NaCl, 10 mM imidazole (pH 8). Washing buffer: 
Phosphate Buffer, 20 mM imidazole (pH 8). Elution Buffer: phosphate buffer, 100 mM 
imidazole (pH 8). 200 ml cell culture was centrifuged down, resuspended into 2 ml ice 
cold lysis buffer and lysed by sonication method (Ultra sonic liquid processor model XL 
2020) on ice bath. The columns were prepacked with 200 µl Ni-NTA beads and washed 
with lysis buffer 3 times. The clarified cell lysate was incubated with column at 4 ºC for 
1 h with gentle agitation. Remove the bottom outlet cap and pass the flow through. Wash 
the beads with washing buffer with 0.5 ml each. Finally elute out the protein with 0.5 ml 
elution buffer containing 100 mM imidazole. Each step of purification was analyzed by 
SDS-PAGE and the eluted proteins were confirmed with western blotting with the anti-
His antibody. 
7.6.5 CBD-Tag Purification 
 
     50 ml E.coli culture was resuspended into 500 µl of lysis buffer and lysed by 
sonication method in the ice bath. The columns were prepacked with 100 µl chintin beads 
and washed with column buffer 4 times. The clear lysate was loaded into the microspin 
column. Incubate the protein and beads on the column at 4 °C for 1h by gently agitation 
with 250 rpm shaker. Discard the flow through by centrifugation at 4000 rpm and wash 
the beads with column buffer 4 times. Quick flush the beads with cleavage buffer 
containing different cleavage reagents.  Incubate the resin at 4 °C for another 16 hours to 
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ensure maximum cleavage. Elute out the protein with 50 µl column buffer. Each step of 
purification was analyzed by SDS-PAGE and the eluted proteins were confirmed with 
western blotting with the anti-CBD antibody. 
7.6.6 GST-Tag Purification 
 
     Protein purification was under the standard protocol of GST tag purification Kit. 
Lysis Buffer: 50 mM Tris, 100 mM NaCl (pH 8),  Wash buffer: 50 mM Tris, 300 mM 
NaCl (pH 8), Elution Buffer: 50 mM Tris, 20 mM glutathione (pH 8). 200 ml cell  culture 
was centrifuged down, resuspended into 2 ml ice cold lysis buffer and lysed by sonication 
method (Ultra sonic liquid processor model XL 2020) on ice bath. The columns were 
prepacked with 200 µl glutathione agarose beads and washed with lysis buffer 3 times. 
The clarified cell lysate was incubated with column at 4 ºC for 1 h with gentle agitation. 
Remove the bottom outlet cap and pass the flow through. Wash the beads with washing 
buffer 3 times. Finally elute out the protein with 0.5 ml elution buffer containing 20 mM 
glutathione. Each step of purification was analyzed by SDS-PAGE and the eluted 
proteins were confirmed with western blotting with the anti-GST antibody. 
7.7  In vitro Protein Labeling with SrtA 
 
The purified EGFP protein with LPETG motif at C-terminal or the crude cell 
lysate which expressed the above EGFP protein was incubated with  G-TMR, GG-TMR 
and aminooxy-TMR in a buffer containing 50 mM Tris HCl. In a typical reaction set up, 
the composition is as followed:  3 µM protein substrate, 0.1 µM SrtA, 40 µM probe and 5 
mM Ca2+. Incubate the above mixture with gently agitation at 37 °C. The reaction 
mixture was then denatured with SDS-PAGE loading dye at 95 °C for 10min. Upon 
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separation with a 12% SDS-PAGE gel, the fluorescent labeling was visualized by 
scanning the resulting gel with a Typhoon TM 9200 fluorescence scanner at Cy3 channel.  
 
7.8 Data Processing and Analysis 
 
7.8.1  Dephosphorylation Ratio Analysis 
 Microarray data was extracted using the ArrayWoRx software. Values from 
duplicate points were background subtracted and averaged.  Points that were inconsistent 
across different slides were removed. The dataset showed a good consistency across 
triplicated experiments (Pearson correlation, r > 0.9). The combined dataset was scaled 
from 0% – 60% by setting the contrast as 0.6. The dataset was presented in colored 
heatmaps, using the Treeview software (http://rana.lbl.gov/EisenSoftware.htm). The 
dataset was also subjected to cluster analysis to correlate specificity information from the 
library into hierarchical contributions, providing insights of the similarities across the 
enzyme towards the substrates. Averaged linkage clustering was performed using the 
Systat v11.0 software (San Jose, CA, USA). For comparison, the active site domains of 
the enzymes were retrieved from NCBI and aligned using ClustalW. 
 
The dephosphorylation ratio was calculated as followed: 
                                                         
 Dephosphorylation ratio of x=    
 
 
Pin1 regulation score of x=                                                         
 




 The time course experiment was carried out with the lambda phosphatase as the 
model. The optimum concentration of lambda phosphatase was applied onto array at 
different time points. And the data was extracted using the Array WoRx software and 
fitted with the following relationship. 
RF =RFInit x(1-exp(-kobs x time)) 
The observed intensity change (RF) was plotted over time by fitting the equation 
presented above with the software Graphpad Prism software v.4.03 (GraphPad, San 
Diego, USA). RF (at time x) = Initial Fluorescence reading (at t = 0) – Fluorescence 
reading (at t = x). The dynamics curve reveals the kinetic constant kobs which could 
determine the enzyme substrate specificity. RFinit represents the fitted constant, which in 
theory should correspond to the relative fluorescence intensity of peptide spots prior to 
enzyme desphosphorylation (e.g. t = 0) 
7.8.3 Highthroughput 14-3-3 Fingerprinting Analysis 
Microarray data was extracted using the ArrayWoRx software. Values from 
duplicated points were background subtracted and averaged (Duplicated spots with a 
standard deviation > 0.2 were rejected). The dataset was presented as colored heatmaps, 
using the Treeview software (http://rana.lbl.gov/EisenSoftware.htm). Position specific 
scoring matrix analysis was performed using the software developed by Stephen Shaw 
(sshaw@nih.gov) and obtained and used with permission. Other data analysis was carried 
out with Microsoft Excel. The dataset was subjected to correlation analysis to compare 
the correlation across seven 14-3-3 isoforms (Pearson correlation, r > 0.83, across all 
1000 datapoints). Venn diagrams were generated to identify the potent binders across 
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seven 14-3-3 isoforms, using the Venn Diagram Generator 
(http://www.pangloss.com/seidel/Protocols/venn.cgi).  
7.8.4 Quantiative 14-3-3 KD Analysis  
Selected and/or reconstituted peptides were spotted onto another slide where up to 
8 identical subarrays were generated on the same microarray, so as to allow 
consistent/uniform screening and comparison of different 14-3-3 isoforms, or different 
concentrations of the same 14-3-3 isoform (e.g. Sigma), to be carried out concurrently on 
the same platform. Using dose-dependent experiments, we extracted binding data of 14-
3-3σ against eight potential peptide binders, as well as a 14-3-3 positive control peptide 
and two reconstituted full-length peptides. The corresponding KD was generated by 
fitting the data to the following equation, under the assumption that equilibrium is 
achieved during the incubation period: 
Observed fluorescence of x = [Maximum fluorescence, x] x [Protein concentration]  
                                                                       KD + Protein concentration  
 
Saturation dynamics observed when plotting Observed fluorescence against the applied 
Protein concentration were then fitted to the above equation using the Graph pad Prism 
software v.4.03 (GraphPad, San Diego, USA) revealing the binding dissociation constant, 
KD.  
7.8.5 PTP Substrate Fingerprinting  Analysis 
Microarray data was extracted using the ArrayWoRx software. Values from 
duplicated points were background subtracted and averaged (Duplicated spots with a 
standard deviation > 0.2 were rejected). The dataset was presented as colored heatmaps, 
using the Treeview software (http://rana.lbl.gov/EisenSoftware.htm). Venn diagrams 
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were generated to identify the potent binders across PTP mutants, using the Venn 
Diagram Generator (http://www.pangloss.com/seidel/Protocols/venn.cgi).  
7.8.6 Quantiative PTP Mutant KD Analysis  
Peptides were spotted onto slides where up to 6 identical subarrays were 
generated on the same microarray, so as to allow consistent/uniform screening and 
comparison of different PTP mutants, or different concentrations of the same PTP 
mutants, to be carried out concurrently on the same platform. Using dose-dependent 
experiments, we extracted binding data of against PTP1B, SHP1 and SHP2 mutants, The 
corresponding KD was generated by fitting the data to the following equation, under the 
assumption that equilibrium is achieved during the incubation period: 
 
Observed fluorescence of x = [Maximum fluorescence, x] x [Protein concentration]  
                                                                       KD + Protein concentration  
 
Saturation dynamics observed when plotting Observed fluorescence against the applied 
Protein concentration were then fitted to the above equation using the Graph pad Prism 

















 Herein I have demonstrated several peptide-based approaches capable for 
deciphering the substrate specificities of enzymes in high throughput manner. Spanning 
from microplate to microarray platform, different classes of enzymes ranging from 
proteases to phosphatases were systematically examined.  
The FRET assay allowed the general detection of protease activities and provided 
the substrate fingerprints of proteases from different classes. However this FRET assay 
did not define the exact cleavage site for a given protease. Potentially the problem might 
be solved by synthesizing a complete PS library that scan each position within the 
protease substrate sequence.   
The phosphorylated peptide array presented a powerful approach for qualitative 
and quantitative measurements of enzyme dephosphorylation in high throughput manner. 
With this approach, new phosphatase biology could be discovered. However, since our 
strategy utilized the purified enzymes, it might not work well with phosphatases which 
are only active in their multimeric complexes. 
A novel fragment-based combinatorial peptide array was developed for 
determination of 14-3-3 substrate binding specificity. The platform was able to cover a 
large peptide sequence space without loss of subtle information on protein and peptide 
interactions by using a limited number of peptide libraries. 
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By making use of PTP substrate trapping mutants, a phosphopeptide array 
combining with dual labeling approach was used to identify the strong and selective 
peptide substrates between highly homologous PTP pairs. We were able to identify 
several candidate peptides showing selectivity towards SHP1 and PTP1B over their 
homologous pairs.  
The SrtA-mediated protein labeling approach has been successfully proved in 
vitro. The strategy might eventually allow the studies of enzyme activity in vivo. 
  These assays developed would not only be useful for functional annotation of 
enzymes, but also provide useful information for identifying potential physiological 
substrates and help in the dissection of complex biological pathways. Moreover, the 
substrate fingerprints obtained among closely related enzymes should also aid in the 
design of potent and selective inhibitors. Overall, the methods presented in this thesis 
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10.1 Supplemental Tables 
Table 10.1 List of 87 peptides used in the peptide microarray. The table below shows the 
identity of each peptide, its protein source, the dephosphorylation site in each protein 
source, as well as the peptide quality confirmed by LC-MS. 
 





1 A1 LPNAApSPGAEQ 1474 Daxx-1  Y 
2 B1 VDAAVpSPEERH 1629 APP668  Thr668 Y 
3 B3 APPAPpSPGPFA 1428 Bim-EL  Ser65 Y 
4 B4 QQKKTpSPLNFK 1738 BTK-21  Ser21 Y 
5 B5 LTPPQpSGKKQS 1590 Cy-E  Ser384 Y 
6 B7 PLYVFpSPTEEL 1714 BTK-115  Ser115 Y 
7 B8 EGSGRpSPRYAL 1612 IRF3-339  Ser339 Y 
8 C1 SQRFGpTPLSAS 1570 Y 
9 C2 FFRIEpSPVKSF 1775 Y 
10 C3 QVAPLpSPRSAN 1559 Y 
11 C4 FFRVEpSPVKLF 1788 Y 
12 C5 CHVEDpTPCPGE 1606 Y 
13 C6 QLSCTpSPCYRE 1706 NDb 
14 C7 ANAFLpSPNCDW 1657 Y 
15 C8 PQQTTpSPENAG 1549 








16 D1 SALSSpSPNNLS 1493 Raf-1(human) S296 Y 
17 D2 CTLTTpSPRLPV 1606 Raf-1(human) S642 Y 
18 D3 IYSSSpSPVSMK 1602 Sil(mice) S643 Y 
19 D4 SNGEPpSPVAGP 1428 Sil(mice) S664 Y 
20 D5 SPNNLpSPTGWS 1576 Raf-1(human) S301 Y 
21 D6 ELQVPpTPSLPS 1586 Sil(mice) T574 Y 
22 D7 GMGAYpSPHSNG 1494 Sil(mice) S656 Y 
23 D8 AMCMHpTPNTAP 1592 Sil(mice) T686 Y 
24 E1 AVSLDpSPVSVG 1447 SRC-3(human) S860 Y 
25 E2 PVPPGpTPAPPG 1405 P54nrb(mice) T412 Y 
26 E3 GAIGGpTPPAFN 1418 P54nrb(mice) T452 Y 
27 E4 GSSCIpSPTIVQ 1508 Raf-1(human) S29 Y 
28 E5 VSVGSpSPPVKN 1487 SRC-3(human) S867 Y 
29 E6 GTLGLpTPPTTE 1503 P54nrb(mice) T430 Y 
30 E7 PSGLLpTPPQSG 1473 CyclinE(human) (T380) Y 
31 E8 HSESApSPSALS 1491 Raf-1(human) S289 Y 
32 F1 FELLPpTPPLSP 1629 c-myc(human) T58 Y 
33 F2 LLGRSpSPSKNY 1642 Tis/BTG2/pc3(human) S147 Y 
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34 F3 AIVFRpTPPYAD 1668 NF-kB p65(human) T254 Y 
35 F4 VAGVHpSPMASS 1459 SRC-3(human) S505 Y 
36 F5 PTPPLpSPSRRS 1614 c-myc(human) S62 Y 
37 F6 VPSPPpSPPPLP 1503 RAR-alpha(human) S77 Y 
38 F7 KLPCDpTPGQGL 1548 SRC-3(human) T24 Y 
39 F8 LSTLSpSPGPKL 1516 SRC-3(human) S543 Y 
40 G1 SLSSSpSPFVVL 1542 Y 
41 G2 AEMEMpSPAGQI 1583 Y 
42 G3 GGGLGpTPLRLP 1457 Y 
43 G4 TPCYIpSPELCE 1674 ND 
44 G5 LSHQPpSPFLNM 1690 
plant 




                                plant 
Y 
45 G6 SRIILpSPCVQA 1606  Y 
46 G7 YTVVGpTPCYIS 1622 Y 
47 G8 GGGLSpSPLRLP 1473 
See footnotea Hu Nek8-2 
                             Nek8-4 Y 
48 H1 EQAEGpSPGGPG 1424 P21(human) S120 Y 
49 H2 SYDSGpTPLEDD 1599 ND 
50 H3 DPDVPpSPSNPK 1572 Y 
51 H4 ASHPRpSPKGTV 1556 Y 
52 H5 QQQPVpTPQTAA 1587 Y 
53 H6 SLIIFpSPKGKL 1621 Y 
54 H7 CYENPpSPTAGI 1570 Y 
55 H8 TVTQLpSPMDRE 1696 
plant 





                               plant Y 
56 I1 GMMGLpSPDAYR 1536 Sil(mice) S699 Y 
57 I2 MHRQEpTVDC 1535   Y 
58 I3 RVSNGpSPSLER 1620 Y 
59 I4 GSVEGpTPKKPG 1475 
See footnoteHu P27(human) 
                         P27(human)  Y 
60 I5 MEAQSpSPGLHM 1604 Sil(mice) S760 Y 
61 I6 WFYpSPR 1274   Y 
62 I7 NVSDGpSPNAGS 1423 See footnote  P27(human) Y 
63 I8 RRPGTpSPGLLG 1529 P21(human) S98 Y 
64 J1 SDLLTpSPDVGL 1535 c-Jun S63 Y 
65 J2 PVARTpSPLQTP 1586 Bcl-2(human) S70 Y 
66 J3 LPEVApTPESEE 1619 c-fos(human) T232 Y 
67 J4 PVVTCpTPSCTA 1497 c-fos(human) T331 Y 
68 J5 LLKLApSPELER 1687 c-Jun S73 Y 
69 J6 AGPALpSPVPPV 1423 Bcl-2(human) S87 Y 
70 J7 LEPLCpTPVVTC 1593 c-fos(human) T325 Y 
71 J8 SDSLSpSPTLLA 1510 c-fos(human) S374 Y 
72 K1 VDLACpTPTDVR 1608 CyclinD1 T286 Y 
73 K2 ENNVLpSPLPSQ 1614 P53(human) S33 Y 
74 K3 NNTSSpSPQPKK 1604 P53(human) S315 Y 
75 K4 GSRSRpTPSLPT 1578 Tau (human) T212 Y 
76 K5 DDLMLpSPDDIE 1679 P53(human) S46 Y 
77 K6 APAAPpTPAAPA 1353 P53(human) T81 Y 
78 K7 VKMLGpSPVDSV 1548 Beta-catenin(mice) S246 Y 
79 K8 VAVVRpTPPKSP 1569 Tau (human) T231 Y 
80 L1 YGPVLpSPMNKV 1622 P73 (human) S412 Y 
81 L2 SGSHCpTPPPPY 1561 P73 (human) T482 Y 
82 L3 PEQPLpTPVTDL 1626 Cdc25c (Xenopus) T48 Y 
83 L4 MNILGpSPISAD 1534 Cdc25c (Xenopus) S205 Y 
84 L5 HSSAApTPNLGP 1470 P73 (human) T442 Y 
85 L6 TFSGEpTPKRCL 1658 Cdc25c (Xenopus) T67 Y 
86 L7 RLLCSpTPSFKK 1698 Cdc25c (Xenopus) T138 Y 
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87 L8 SRLYRpSPSMPE 1741 Cdc25c (Xenopus) S285 Y 
aDue to patent issues, the protein source of these peptides cannot be revealed. bND =the 
correct peptide mass was detected by MS, but the peptide was not the major product. 
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Table 10.2  List of 53 peptide kobs values based on time-course experiment of lambda 
phosphatase, against the phospho-peptide library. They are selected based on stringent 
filtering criteria of accuracy curve fits (r > 0.85) and significant desphorylation signals of 
> 40% change from original Pro-Q readings. Absolute fluorescent intensity [Fluorescent 
Intensity – Background Intensity] of each peptide at designated time point is indicated 
in the table below.  
Absolute fluorescence intensity of each peptide at 







0’ 5’ 15’ 30’ 60’ 120’ 
 






1 B1 VDAAVpSPEERH 553 581 468 361 310 248 0.022 0.95 0.008 
2 B3 APPAPpSPGPFA 450 469 396 295 236 158 0.016 0.96 0.006 
3 C1 SQRFGpTPLSAS 962 850 648 603 468 358 0.039 0.97 0.007 
4 C5 CHVEDpTPCPGE 1674 1574 1590 1225 1149 1001 0.033 0.99 0.006 
5 C7 ANAFLpSPNCDW 905 690 678 436 411 443 0.068 0.92 0.022 
6 C8 PQQTTpSPENAG 468 471 477 276 239 192 0.018 0.86 0.013 
7 D1 SALSSpSPNNLS 813 794 823 660 514 434 0.01 0.92 0.009 
8 D2 CTLTTpSPRLPV 1465 1272 1035 1142 844 727 0.032 0.88 0.015 
9 D6 ELQVPpTPSLPS 1022 859 777 748 580 418 0.025 0.93 0.008 
10 D8 AMCMHpTPNTAP 1336 1161 973 696 692 666 0.06 0.98 0.01 
11 E1 AVSLDpSPVSVG 570 496 542 468 411 335 0.013 0.9 0.008 
12 E2 PVPPGpTPAPPG 913 602 338 347 289 202 0.13 0.97 0.03 
13 E3 GAIGGpTPPAFN 712 729 662 447 407 373 0.026 0.9 0.012 
14 E6 GTLGLpTPPTTE 1065 823 823 611 586 541 0.066 0.92 0.021 
15 E7 PSGLLpTPPQSG 1395 963 692 688 550 408 0.12 0.94 0.034 
16 F1 FELLPpTPPLSP 454 396 364 305 308 265 0.056 0.96 0.013 
17 F2 LLGRSpSPSKNY 774 802 640 630 486 390 0.016 0.95 0.005 
18 F3 AIVFRpTPPYAD 714 644 556 388 399 361 0.059 0.93 0.018 
19 F5 PTPPLpSPSRRS 788 664 650 561 457 395 0.031 0.95 0.008 
20 F6 VPSPPpSPPPLP 517 545 501 479 339 288 0.0048 0.93 0.007 
21 F7 KLPCDpTPGQGL 1957 1720 1639 1493 1142 1050 0.028 0.97 0.006 
22 F8 LSTLSpSPGPKL 689 617 532 413 344 364 0.048 0.99 0.006 
23 G2 AEMEMpSPAGQI 957 726 700 568 350 337 0.04 0.94 0.011 
24 G3 GGGLGpTPLRLP 901 743 607 524 389 302 0.042 0.98 0.007 
25 G4 TPCYIpSPELCE 1329 1317 1024 982 710 637 0.026 0.97 0.007 
26 G6 SRIILpSPCVQA 1192 1035 910 778 553 485 0.032 0.99 0.004 
27 G7 YTVVGpTPCYIS 1080 935 919 709 552 419 0.024 0.98 0.005 
28 H1 EQAEGpSPGGPG 570 526 454 413 265 234 0.023 0.98 0.004 
29 H2 SYDSGpTPLEDD 678 596 663 395 337 307 0.026 0.86 0.014 
30 H7 CYENPpSPTAGI 1629 1387 1555 1167 889 901 0.026 0.87 0.013 
31 I1 GMMGLpSPDAYR 1002 900 999 774 585 476 0.012 0.92 0.008 
32 I2 MHRQEpTVDC 1416 1081 921 761 601 483 0.057 0.96 0.012 
33 J1 SDLLTpSPDVGL 1032 985 819 568 477 410 0.033 0.88 0.012 
34 J2 PVARTpSPLQTP 775 708 699 658 502 366 0.008 0.98 0.004 
35 J3 LPEVApTPESEE 1191 1085 987 971 731 605 0.019 0.97 0.005 
36 J4 PVVTCpTPSCTA 1159 1044 756 763 527 519 0.046 0.95 0.012 
37 J6 AGPALpSPVPPV 506 397 368 308 200 171 0.036 0.96 0.009 
38 J7 LEPLCpTPVVTC 1539 1561 1299 1042 802 654 0.022 0.98 0.005 
39 J8 SDSLSpSPTLLA 597 511 570 560 368 295 0.005 0.85 0.01 
40 K1 VDLACpTPTDVR 1219 1234 1113 879 659 558 0.017 0.97 0.06 
41 K2 ENNVLpSPLPSQ 593 482 305 333 247 238 0.09 0.95 0.024 
42 K4 GSRSRpTPSLPT 872 621 567 478 357 307 0.064 0.92 0.02 
43 K5 DDLMLpSPDDIE 1114 929 955 841 691 307 0.0066 0.94 0.006 
44 K6 APAAPpTPAAPA 651 507 362 350 257 191 0.064 0.95 0.016 
45 K7 VKMLGpSPVDSV 781 670 699 690 534 414 0.009 0.89 0.008 
46 K8 VAVVRpTPPKSP 531 402 409 317 212 159 0.031 0.93 0.009 
47 L2 SGSHCpTPPPPY 1308 902 727 583 426 346 0.077 0.96 0.018 
48 L3 PEQPLpTPVTDL 815 680 559 518 411 359 0.051 0.97 0.01 
49 L4 MNILGpSPISAD 843 798 826 781 565 475 0.0045 0.92 0.007 
 177 
50 L5 HSSAApTPNLGP 534 344 372 208 212 180 0.077 0.87 0.033 
51 L6 TFSGEpTPKRCL 1158 1086 967 904 673 591 0.022 0.99 0.004 
52 L7 RLLCSpTPSFKK 950 865 874 665 474 460 0.023 0.95 0.008 







Table 10.3 Dephosphorylation ratio of 87 phosphopeptide with each phosphatase dataset. 
Readings were obtained by treatment the peptide array with 1 U of each enzyme and 
incubated at RT for 1 h.  
Dephosphorylation Ratio of Each Phosphotase   
NO. ID Peptide Sequence Alkaline Lambda PP1 PP2B PP2A 
1 A1 LPNAApSPGAEQ 0.36 0.49 0.11 0.53 0.17 
2 B1 VDAAVpSPEERH 0.41 0.24 0.01 0.32 0.09 
3 B3 APPAPpSPGPFA 0.21 0.34 0.14 0.54 0.00 
4 B4 QQKKTpSPLNFK 0.18 0.08 0.05 0.60 0.00 
5 B5 LTPPQpSGKKQS 0.00 0.08 0.04 0.57 0.00 
6 B7 PLYVFpSPTEEL 0.12 0.09 0.00 0.06 0.07 
7 B8 EGSGRpSPRYAL 0.17 0.09 0.00 0.20 0.00 
8 C1 SQRFGpTPLSAS 0.26 0.40 0.40 0.59 0.00 
9 C2 FFRIEpSPVKSF 0.08 0.08 0.00 0.38 0.08 
10 C3 QVAPLpSPRSAN 0.14 0.29 0.02 0.44 0.00 
11 C4 FFRVEpSPVKLF 0.13 0.00 0.00 0.20 0.27 
12 C5 CHVEDpTPCPGE 0.04 0.46 0.43 0.21 0.00 
13 C6 QLSCTpSPCYRE 0.03 0.32 0.40 0.00 0.01 
14 C7 ANAFLpSPNCDW 0.15 0.49 0.30 0.04 0.30 
15 C8 PQQTTpSPENAG 0.27 0.43 0.01 0.01 0.00 
16 D1 SALSSpSPNNLS 0.29 0.32 0.05 0.41 0.15 
17 D2 CTLTTpSPRLPV 0.10 0.38 0.17 0.45 0.15 
18 D3 IYSSSpSPVSMK 0.14 0.02 0.00 0.29 0.00 
19 D4 SNGEPpSPVAGP 0.24 0.00 0.00 0.00 0.00 
20 D5 SPNNLpSPTGWS 0.05 0.08 0.00 0.08 0.07 
21 D6 ELQVPpTPSLPS 0.06 0.40 0.34 0.46 0.03 
22 D7 GMGAYpSPHSNG 0.14 0.16 0.08 0.19 0.03 
23 D8 AMCMHpTPNTAP 0.12 0.52 0.53 0.27 0.11 
24 E1 AVSLDpSPVSVG 0.39 0.19 0.04 0.18 0.00 
25 E2 PVPPGpTPAPPG 0.21 0.64 0.50 0.53 0.20 
26 E3 GAIGGpTPPAFN 0.16 0.49 0.33 0.24 0.00 
27 E4 GSSCIpSPTIVQ 0.21 0.60 0.43 0.38 0.23 
28 E5 VSVGSpSPPVKN 0.29 0.18 0.05 0.07 0.10 
29 E6 GTLGLpTPPTTE 0.04 0.42 0.21 0.18 0.00 
30 E7 PSGLLpTPPQSG 0.03 0.56 0.11 0.04 0.21 
31 E8 HSESApSPSALS 0.22 0.11 0.09 0.24 0.08 
32 F1 FELLPpTPPLSP 0.14 0.45 0.17 0.29 0.10 
33 F2 LLGRSpSPSKNY 0.25 0.09 0.09 0.44 0.00 
34 F3 AIVFRpTPPYAD 0.20 0.41 0.16 0.29 0.12 
35 F4 VAGVHpSPMASS 0.15 0.32 0.08 0.07 0.00 
36 F5 PTPPLpSPSRRS 0.17 0.20 0.14 0.43 0.01 
37 F6 VPSPPpSPPPLP 0.10 0.34 0.00 0.13 0.19 
38 F7 KLPCDpTPGQGL 0.10 0.40 0.42 0.20 0.00 
39 F8 LSTLSpSPGPKL 0.21 0.42 0.28 0.45 0.00 
40 G1 SLSSSpSPFVVL 0.40 0.17 0.16 0.53 0.32 
41 G2 AEMEMpSPAGQI 0.14 0.37 0.05 0.35 0.06 
42 G3 GGGLGpTPLRLP 0.16 0.39 0.37 0.61 0.18 
43 G4 TPCYIpSPELCE 0.13 0.00 0.00 0.19 0.00 
44 G5 LSHQPpSPFLNM 0.05 0.00 0.01 0.48 0.04 
45 G6 SRIILpSPCVQA 0.11 0.45 0.41 0.25 0.00 
46 G7 YTVVGpTPCYIS 0.07 0.48 0.57 0.28 0.11 
47 G8 GGGLSpSPLRLP 0.02 0.33 0.18 0.31 0.05 
48 H1 EQAEGpSPGGPG 0.29 0.08 0.02 0.25 0.30 
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49 H2 SYDSGpTPLEDD 0.00 0.44 0.29 0.32 0.30 
50 H3 DPDVPpSPSNPK 0.62 0.02 0.00 0.29 0.00 
51 H4 ASHPRpSPKGTV 0.40 0.13 0.01 0.43 0.00 
52 H5 QQQPVpTPQTAA 0.09 0.29 0.09 0.39 0.00 
53 H6 SLIIFpSPKGKL 0.55 0.22 0.21 0.40 0.00 
54 H7 CYENPpSPTAGI 0.26 0.17 0.15 0.18 0.00 
55 H8 TVTQLpSPMDRE 0.31 0.16 0.05 0.07 0.00 
56 I1 GMMGLpSPDAYR 0.14 0.25 0.00 0.30 0.04 
57 I2 MHRQEpTVDC 0.11 0.49 0.36 0.39 0.00 
58 I3 RVSNGpSPSLER 0.20 0.01 0.00 0.31 0.15 
59 I4 GSVEGpTPKKPG 0.18 0.00 0.00 0.46 0.11 
60 I5 MEAQSpSPGLHM 0.26 0.01 0.00 0.36 0.02 
61 I6 WFYpSPR 0.10 0.00 0.04 0.00 0.00 
62 I7 NVSDGpSPNAGS 0.36 0.07 0.00 0.13 0.16 
63 I8 RRPGTpSPGLLG 0.50 0.04 0.07 0.43 0.33 
64 J1 SDLLTpSPDVGL 0.23 0.43 0.03 0.21 0.00 
65 J2 PVARTpSPLQTP 0.12 0.36 0.01 0.26 0.00 
66 J3 LPEVApTPESEE 0.36 0.46 0.08 0.13 0.06 
67 J4 PVVTCpTPSCTA 0.07 0.56 0.59 0.24 0.10 
68 J5 LLKLApSPELER 0.16 0.08 0.00 0.17 0.00 
69 J6 AGPALpSPVPPV 0.17 0.48 0.00 0.49 0.04 
70 J7 LEPLCpTPVVTC 0.00 0.54 0.45 0.21 0.05 
71 J8 SDSLSpSPTLLA 0.33 0.00 0.00 0.19 0.13 
72 K1 VDLACpTPTDVR 0.12 0.53 0.35 0.13 0.00 
73 K2 ENNVLpSPLPSQ 0.22 0.49 0.04 0.36 0.07 
74 K3 NNTSSpSPQPKK 0.16 0.17 0.03 0.40 0.22 
75 K4 GSRSRpTPSLPT 0.09 0.29 0.32 0.56 0.25 
76 K5 DDLMLpSPDDIE 0.31 0.29 0.00 0.00 0.00 
77 K6 APAAPpTPAAPA 0.14 0.29 0.08 0.58 0.30 
78 K7 VKMLGpSPVDSV 0.08 0.00 0.00 0.14 0.08 
79 K8 VAVVRpTPPKSP 0.03 0.14 0.00 0.13 0.12 
80 L1 YGPVLpSPMNKV 0.13 0.44 0.07 0.34 0.00 
81 L2 SGSHCpTPPPPY 0.13 0.64 0.40 0.13 0.25 
82 L3 PEQPLpTPVTDL 0.13 0.53 0.27 0.27 0.08 
83 L4 MNILGpSPISAD 0.21 0.13 0.02 0.17 0.14 
84 L5 HSSAApTPNLGP 0.23 0.45 0.34 0.51 0.20 
85 L6 TFSGEpTPKRCL 0.15 0.28 0.38 0.25 0.07 
86 L7 RLLCSpTPSFKK 0.10 0.41 0.50 0.53 0.10 
87 L8 SRLYRpSPSMPE 0.07 0.26 0.03 0.17 0.15     
Value indicates the dephosphorylation ratio which was calculated according to the following 
relationship. The intensity of each peptide is referred as Absolute fluorescent intensity = [Fluorescent 
Intensity – Background Intensity] 
      
                                                    
Dephosphorylation ratio of x=  
 





Table 10.4 Data from the Pin1-regulation experiments. The regulation scores of 76 










1 A01 YGPVLpSPMNKV P73 (human) S412 0.07 
2 A02 RLLCSpTPSFKK Cdc25c (Xenopus) T138 0.07 
3 A03 ENNVLpSPLPSQ P53(human) S33 0.07 
4 A04 VPSPPpSPPPLP RAR-alpha(human) S77 -0.1 
5 A05 AVSLDpSPVSVG SRC-3(human) S860 0 
6 A06 MEAQSpSPGLHM Sil(mice) S760 0 
7 A07 GSVEGpTPKKPG -0.09 
8 A08 TPCYIpSPELCE 
See footnoteaH P27(human)T187 
Nek8-3 0.06 
9 A09 EGSGRpSPRYAL IRF3-339  0.08 
10 A10 NNTSSpSPQPKK P53(human) S315 -0.22 
11 A11 LLKLApSPELER c-Jun S73 0 
12 A12 PVVTCpTPSCTA c-fos(human) T331 0.08 
13 A13 HSESApSPSALS Raf-1(human) S289 -0.05 
14 A14 IYSSSpSPVSMK Sil(mice) S643 0 
15 A15 SQRFGpTPLSAS 0 
16 A16 ANAFLpSPNCDW 
Hu-1 See footnotea 
Hu-6  -0.15 
17 A17 PVARTpSPLQTP         Bcl-70 0 
18 B01 HSSAApTPNLGP P73 (human) T442 -0.01 
19 B02 MNILGpSPISAD Cdc25c (Xenopus) S205 0.02 
20 B03 APAAPpTPAAPA P53(human) T81 -0.03 
21 B04 AIVFRpTPPYAD NF-kB p65(human) T254 0.06 
22 B05 VSVGSpSPPVKN SRC-3(human) S867 0.01 
23 B06 MHRQEpTVDC See footnoteaHu   0 
24 B07 RRPGTpSPGLLG P21(human) S98 -0.01 
25 B09 LPNAApSPGAEQ Daxx-1   
26 B10 VKMLGpSPVDSV Beta-catenin(mice) S246 0.08 
27 B12 SDSLSpSPTLLA c-fos(human) S374 -0.09 
28 B13 SALSSpSPNNLS Raf-1(human) S296 -0.08 
29 B14 GMGAYpSPHSNG Sil(mice) S656 -0.03 
30 B15 CHVEDpTPCPGE 0 
31 B16 FFRVEpSPVKLF 
       See footnotea Hu-2 
Hu-7 0 
32 C01 SGSHCpTPPPPY P73 (human) T482 0.14 
33 C02 SRLYRpSPSMPE Cdc25c (Xenopus) S285 0 
34 C03 FELLPpTPPLSP c-myc(human) T58 0.02 
35 C04 KLPCDpTPGQGL SRC-3(human) T24 0 
36 C05 PVPPGpTPAPPG P54nrb(mice) T412 -0.02 
37 C06 WFYpSPR See footnoteaHu   0 
38 C07 EQAEGpSPGGPG P21(human) S120 -0.03 
39 C08 APPAPpSPGPFA Bim-EL  0 
40 C10 GSRSRpTPSLPT Tau (human) T212 0.01 
41 C11 AGPALpSPVPPV Bcl-2(human) S87 0.11 
42 C12 GAIGGpTPPAFN P54nrb(mice) T452 0.11 
43 C13 SPNNLpSPTGWS Raf-1(human) S301 -0.03 
44 C14 SNGEPpSPVAGP Sil(mice) S664 0.06 
45 C15 FFRIEpSPVKSF        See footnoteaHu-3 -0.06 
46 C16 PQQTTpSPENAG    See footnoteaHu -8 0 
47 D01 TFSGEpTPKRCL Cdc25c (Xenopus) T67 -0.07 
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48 D02 VDLACpTPTDVR cyclinD1 T286 0.15 
49 D03 PTPPLpSPSRRS c-myc(human) S62 -0.01 
50 D04 VAGVHpSPMASS SRC-3(human) S505 0 
51 D05 GTLGLpTPPTTE P54nrb(mice) T430 0 
52 D06 RVSNGpSPSLER 0.08 
53 D07 GGGLGpTPLRLP 
        See footnoteaHu (human) S10 
Nek8-1 -0.02 
54 D08 PLYVFpSPTEEL BTK-115  0.06 
55 D10 VAVVRpTPPKSP Tau (human) T231 0 
56 D11 LPEVApTPESEE c-fos(human) T232 0 
57 D12 PSGLLpTPPQSG CyclinE(human) T380 0.31 
58 D13 CTLTTpSPRLPV Raf-1(human) S642 -0.09 
59 D14 AMCMHpTPNTAP Sil(mice) T686 0.04 
60 D15 QLSCTpSPCYRE See footnoteaHu -4  -0.01 
61 D16 VDAAVpSPEERH APP668  0.03 
62 E01 PEQPLpTPVTDL Cdc25c (Xenopus) T48 0.21 
63 E02 DDLMLpSPDDIE P53(human) S46 0.07 
64 E03 LLGRSpSPSKNY Tis/BTG2/pc3(human) S147 0 
65 E04 LSTLSpSPGPKL SRC-3(human) S543 0 
66 E05 GMMGLpSPDAYR Sil(mice) S699 0.12 
67 E06 NVSDGpSPNAGS -0.16 
68 E07 YTVVGpTPCYIS 
See footnoteaHu P27(human) S178 
Nek8-2   0.12 
69 E08 QQKKTpSPLNFK BTK-21  0 
70 E10 SDLLTpSPDVGL c-Jun S63 0 
71 E11 LEPLCpTPVVTC c-fos(human) T235 0.02 
72 E12 GSSCIpSPTIVQ Raf-1(human) S29 -0.01 
73 E13 ELQVPpTPSLPS Sil(mice) T574 0.15 
74 E14 GGGLSpSPLRLP -0.05 
75 E15 QVAPLpSPRSAN 
        See footnoteaHu Nek8-4 
Hu-5 0 
76 E16 LTPPQpSGKKQS Cy-E  0 
Value indicates the Pin1 regulation score which was calculated according to the following relationship. The 




Pin1 regulation score of x=   
                                                                 






aDue to patent issues, the protein source of these peptides cannot be revealed.  
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Table 10.5 List of 144 peptides used in this study. The table below shows the identity of 
each peptide, its protein source, the corresponding PTP reported in the literature, as well 
as the peptide quality confirmed with LC-MS. 







1 Plate1_A01 AEKPFYVNVEF 1761.70339 PTP1B BCR 177 
2 Plate1_A02 AEMTGYVVTRW 1731.67106 Mitogen kinase   




4 Plate1_A04 DEELHY ASLNF 1756.63644 SHP1 CD33 340 
5 Plate1_A05 DEGIHYSELIQ 1722.65209 SHP1 SIGLEC2 822 
6 Plate1_A06 DEKVDYVQVDK 1756.69395 SHP1, SHP2 Gab2 643 
7 Plate1_A07 DERVDYVVVDQ 1755.67355 SHP2 Gab1 689 
8 Plate1_A08 DESVD YVPMLD 1701.58638 SHP2, TCPTP PDGF 751 
9 Plate1_A09 DKQVEYLDLDL 1769.71435 SHP2 GAB1 657 
10 Plate1_A10 DSGGFYITSRT 1622.59967 Src-1   
11 Plate1_A11 DTETVYSEVRK 1745.68921 SHP1 CD31 713 
12 Plate1_A12 EANSHYGHNDD 1677.50756 SHP1 CD31 663 
13 Plate1_A13 EDEDYY KASVT 1738.59939 Type 12   
14 Plate1_A14 EDGGVYSSSGL 1489.49928 Photooncogene FER kinase  
15 Plate1_A15 EDGISYTTLRF 1720.67283 SHP1 SIGLEC2 762 
16 Plate1_A16 EDSTYYKASKG 1667.6099 Fak chick kinase   
17 Plate1_A17 EDTLTYADLDM 1705.5813 SHP2 SIRP 470 
18 Plate1_A18 EGVATYAAAVL 1483.59786 SHP1 CATENIN 654 
19 Plate1_A19 EGDNDYIIPLP 1664.63537 TCPTP PDGF 1021 
20 Plate1_A20 ENGLNYIDLDL 1697.65684 SHP2,PTP1B IRS1 1179 
21 Plate1_A21 EPNVSYICSRY 1749.64525 Kinase gsk3   




23 Plate1_A23 ESDGGYMDMSK 1638.4962 SHP2 PDGF 740 




25 Plate1_B01 FEEDDYESPND 1778.52153 SHP1 SLP76 113 
26 Plate1_B02 FGMTRYVLDDE 1764.6449 Tyrosine kinase TXK  
27 Plate1_B03 FLFNMYLTRER 1908.79766 SHP1 HOAX1 343 
28 Plate1_B04 FMMTPYVVTRY 1826.71558 JNK-2 kinase   
29 Plate1_B05 GFLTEYVATRW 1761.71463 PTP1B ERK2 187 
30 Plate1_B06 GNNYVY IDPTQ 1702.62589 SHP1 KIT 570 
31 Plate1_B07 GSAAPYLKTKF 1601.68735 TCPTP STAT3 705 
32 Plate1_B08 GWMEDYDYVHL 1846.62925 P130cas   
33 Plate1_B09 GWMVHYTSKDT 1743.63468 protein kinase c   
34 Plate1_B10 HNSALYSQVQK 1693.68441 p62dok   
35 Plate1_B11 HRQLNYIQVDL 1817.78445 SHP2 FRS2 436 
36 Plate1_B12 IEDNEYTAREG 1715.60587 SHP1 LYN 397 
37 Plate1_B13 IEDEDYYKASV 1750.63577 Type 12   




39 Plate1_B15 IESDIYAEIPD 1683.62995 Type 12   
40 Plate1_B16 IESSNYMAPYD 1708.57108 PTP1B,TCPTP PDGF 771 
41 Plate1_B17 IRYHRYHGRSA 1834.77595 Protooncogene kinase, PIM 1  
 183 
42 Plate1_B18 IYETDYYRKGG 1783.68373 TCPTP INSULIN 1189 
43 Plate1_B19 KAVDGYVKPQI 1636.72446 SHP2, PTP1B STAT5B 699 
44 Plate1_B20 KDRMSYHVRSH 1834.73171 
Myc  Zinc  
protein  
 
45 Plate1_B21 KKRCPYTKHQT 1808.7776 SHP1 HOAX10 326 
46 Plate1_B22 KVVALYDYMPM 1748.69377 BTK kinase   
47 Plate1_B23 LISSDYELLSD  1673.64561 TCPTP JAK3 785 
48 Plate1_B24 LNSDGYTPEPA 1582.55713 LMW ZAP70 292 
49 Plate1_C01 LNSKGYTKSID 1644.67792 Erk kinase   
50 Plate1_C02 LPPEGYVVVVK 1618.73904 SHP2 PTK2B 906 
51 Plate1_C03 MDTSVYESPYS 1697.5551 Tyrosine kinase Zap 70  
52 Plate1_C04 MKDEEYEQMVK 1848.66941 type 13   
53 Plate1_C05 MTGDTYTAHAG 1543.50333 type 12   
54 Plate1_C06 NNHTEYASIQT 1696.61131 SHP1, SHP2 SIRP 453 
55 Plate1_C07 NQSSGYRYGTD 1666.56436 Fyn kinase   
56 Plate1_C08 NSDVQYTEVQV 1700.63137 SHP1, SHP2 CD31 690 
57 Plate1_C09 NSKRDYTGCST 1650.57282 SHP2 MYELIN 200 






59 Plate1_C11 PEGLNYACLTH 1636.59756 SHP1 ROS1 2334 
60 Plate1_C12 PEGHEYYRVRE 1933.71167 PTP1B TYK2 1054 
61 Plate1_C13 PEQDEYDIPRH 1817.66405 P130cas   






63 Plate1_C15 PKGTGYIKTEL 1625.70848 SHP2,TCPTP STAT1 701 
64 Plate1_C16 PLDKDYYVVRE 1895.74632 TCPTP JAK3 981 
65 Plate1_C17 PPDHQYYNDFP 1811.62113 TCPTP SHC 349 




67 Plate1_C19 PSFSEYASVQV 1632.60917 SHP2 SIRP 496 
68 Plate1_C20 PSTRDYEIQRE 1812.70626 Fak kinase   
69 Plate1_C21 PQDKEYYKVKE 1925.75689 JAK kinase   
70 Plate1_C22 QGPVI YAQLDH 1659.66768 SHP2 MYELIN 241 
71 Plate1_C23 QKQPIYIVMEL 1780.78536 FES kinase   




73 Plate1_D01 RNEGVYTAIAV  1611.66768 Type 12   
74 Plate1_D02 REGLNYMVLAT 1685.68671 SHP1 ROS1 2274 
75 Plate1_D03 SAEPQYQPGDQ 1638.5582 PHotooncogene FGR kinase  
76 Plate1_D04 SDDVRYVNAFK 1732.68406 SHP2 VEGF  1213 
77 Plate1_D05 SDGHEYIYVDP 1713.59424 TCPTP PDGF 579 
78 Plate1_D06 SEEPIYIVTEY 1761.67691 SHP1 C-SRC 338 
79 Plate1_D07 SESVVYADIRK 1685.70446 SHP2 MYELIN 263 
80 Plate1_D08 SETDDYAEIID 1689.56775 Type 12   
81 Plate1_D09 SPPALYAEPLD 1591.61899 P62dok   
82 Plate1_D10 SSNPEYLSASD 1588.53132 TCPTP INSULIN 999 
83 Plate1_D11 SSSSEYGSVSP 1505.49421 Mitogen kinase   
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85 Plate1_D13 STEPQYQPGEN 1668.56877 SHP1,PTP1B C-SRC 530 




87 Plate1_D15 TGGSVYTEDND 1576.49493 Type 3   
88 Plate1_D16 TNDITYADLNL 1671.6412 SHP2 SIRP 429 
89 Plate1_D17 TSKLI YDFIED 1762.70854 Type 12   
90 Plate1_D18 TSSVLYTAVQP 1584.64556 SHP2 PDGF 1009 
91 Plate1_D19 VDADEYLIPQQ 1709.65684 SHP2, PTP1B EGFR 1016 
92 Plate1_D20 VDTPHYPRWIT 1803.73643 PKC Kinase   




94 Plate1_D22 VYESPYSDPEE 1733.57284 Tyrosine kinase zap-70  
95 Plate1_D23 YETDYYRKGGK 1798.69463 PTP1B,TCPTP INSULIN 1190 
96 Plate1_D24 YFMTEYVATRW 1885.71293 Mitogen kinase   
97 Plate1_E01 AEGSAYEEVPT 1571.54114 PLC-r   
98 Plate1_E02 AENPEYLSEFS 1704.59391 Erb2 receptor   
99 Plate1_E03 FDNLYYWDQDP 1894.64701 Erb2 receptor   
100 Plate1_E04 AFGTVYKGIWI 1673.72373 Erb2 receptor   
101 Plate1_E05 AFQFSYTAVFG 1656.62442 CAAX Protease   
102 Plate1_E06 AKIQDYHILTR 1776.79428 Jak2   
103 Plate1_E07 APAEMYDIMKT 1688.621 Stem cell growth factor  
104 Plate1_E08 ASEQGYEEMRA 1689.57247 Erb3   
105 Plate1_E09 ATVGHYTAVQN 1579.60509 Cyclin kinase activator  
106 Plate1_E10 AYRQLYLNPKG 1741.75717 
Chromosomal associate 
protein  
107 Plate1_E11 CPEKVYELMRA 1757.69008 Abl 1   
108 Plate1_E12 DINSLYDVSRM 1731.65581 PLC-r   
109 Plate1_E13 DRFIQYANPAF 1760.69423 Camp Phosphodiesterase  
110 Plate1_E14 DVSRMYVDPSE 1716.60852 PLC-r   
111 Plate1_E15 EDIKSYYTVRQ 1820.7365 PTP1B   
112 Plate1_E16 EEIRFYQLGEE 1831.70485 Potassium gate   
113 Plate1_E17 EKIQDYEKMPE 1828.69733 IL-1   
114 Plate1_E18 ELGYEYMDVGS 1681.56017 Erb-3   
115 Plate1_E19 AELEFYMDYEA 1799.60203 Alanine scanning   
116 Plate1_E20 FGAKPYDGIPA 1554.61384 Erb2 receptor   
117 Plate1_E21 GPQDIYDVPPV 1618.62989 P130cas   
118 Plate1_E22 GQESEYGNITY 1679.57352 PTN6   
119 Plate1_E23 GRETIYPNASL 1639.6626 Carcinoembroyonic antigen  
120 Plate1_E24 IGEGTYGTVFK 1590.63498 Cell division kinase 5  
121 Plate1_F01 IYIHRYENVSI 1825.7783 ATP cyclase   
122 Plate1_F02 KAEDEYVNEPL 1725.65175 Erb2 receptor   
123 Plate1_F03 KPKQEYLNPVE 1763.75141 Erb4   
124 Plate1_F04 LARDMYDKEYY 1885.69767 Met growth factor   
125 Plate1_F05 LDSTFYRSLLE 1762.71978 Erb2 receptor   
126 Plate1_F06 LGQRIYQYIQS 1787.76266 
Dual specificity regulated 
kinase  
127 Plate1_F07 LLANAYIYVVQ 1685.74487 Neural cell adhesion   
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128 Plate1_F08 LMGHEYMEMKN 1801.62578 Cell division cycle protein 23  
129 Plate1_F09 LNKQGYKCRQC 1759.69183 Protein kinase C   
130 Plate1_F10 NKPTVYGVSPN 1594.64114 Abl   
131 Plate1_F11 PPDHQYYNDFP 1811.62113 SHC transforming protein  
132 Plate1_F12 PEDTFYFDPEF 1825.6143 ISPK-1 Kinase   
133 Plate1_F13 PEPGPYAQPSV 1560.58803 Adaptor crk   
134 Plate1_F14 RHDSGYEVHHQ 1783.64466 Alzheimer's disease  
135 Plate1_F15 RNPGFYVEANP 1682.64728 PLC-r   
136 Plate1_F16 SADHLYVNVSE 1652.61023 Tumor necrosis factor  
137 Plate1_F17 SSDPTYTSSLG 1533.52551 Tyrosine kinase receptor   
138 Plate1_F18 EEEPVYEAEPE 1727.68267 
Hematopoietic lineage cell 
specific protein  
139 Plate1_F19 STKYFYKQNGR 1810.74226 Erb4   
140 Plate1_F20 TAEPDYGALYE 1647.57244 PLC-r   
141 Plate1_F21 VCAERYSQEVF 1749.64524 Apoptosis Protein cd27  
142 Plate1_F22 VDSSLYNLPRS 1669.67317 Grb2 associated    
143 Plate1_F23 VSSTHYYLLPE 1727.68267 Activated cdc42 kinase  
144 Plate1_F24 VVIALYDYQTN 1717.69832 T cell specific kinase  
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Table 10.6 The absolute fluorescent intensity of each PTP against pTyr peptide library 
 Absolute fluorescence intensity of each PTP NO. ID Sequence 
PTP1B TCPTP SHP1 SHP2 LMW 
1 Plate1_A01 AEKPFYVNVEF 249 193 222 3462 126 
2 Plate1_A02 AEMTGYVVTRW 1171 864 1136 5527 5111 
3 Plate1_A03 AENAEYLRVAP 0 0 445 2352 0 
4 Plate1_A04 DEELHY ASLNF 435 169 4557 10457 1027 
5 Plate1_A05 DEGIHYSELIQ 428 917 1271 9968 219 
6 Plate1_A06 DEKVDYVQVDK 51 0 58 3009 612 
7 Plate1_A07 DERVDYVVVDQ 0 22 472 4016 806 
8 Plate1_A08 DESVD YVPMLD 587 66 29 54 352 
9 Plate1_A09 DKQVEYLDLDL 56 19 1974 8898 437 
10 Plate1_A10 DSGGFYITSRT 1181 112 178 1233 1289 
11 Plate1_A11 DTETVYSEVRK 588 118 9680 9670 2350 
12 Plate1_A12 EANSHYGHNDD 0 0 0 48 834 
13 Plate1_A13 EDEDYY KASVT 321 140 305 1095 604 
14 Plate1_A14 EDGGVYSSSGL 380 282 0 859 1956 
15 Plate1_A15 EDGISYTTLRF 1248 586 6588 12343 1797 
16 Plate1_A16 EDSTYYKASKG 468 68 66 818 1593 
17 Plate1_A17 EDTLTYADLDM 251 355 3399 12782 229 
18 Plate1_A18 EGVATYAAAVL 2705 3936 2849 3002 375 
19 Plate1_A19 EGDNDYIIPLP 683 378 2252 5374 378 
20 Plate1_A20 ENGLNYIDLDL 944 997 1392 12973 403 
21 Plate1_A21 EPNVSYICSRY 6722 6488 2853 10213 5336 
22 Plate1_A22 ESDGSYQKPSY 781 350 105 972 2942 
23 Plate1_A23 ESDGGYMDMSK 585 0 304 1863 2278 
24 Plate1_A24 ETDKEYYTVKD 0 0 0 154 62 
25 Plate1_B01 FEEDDYESPND 0 0 0 0 0 
26 Plate1_B02 FGMTRYVLDDE 43 291 135 814 165 
27 Plate1_B03 FLFNMYLTRER 3025 1875 806 3317 5257 
28 Plate1_B04 FMMTPYVVTRY 3664 2531 4939 7381 9586 
29 Plate1_B05 GFLTEYVATRW 2238 837 4328 3926 3147 
30 Plate1_B06 GNNYVY IDPTQ 1538 524 1758 1433 325 
31 Plate1_B07 GSAAPYLKTKF 3557 950 4957 4457 12409 
32 Plate1_B08 GWMEDYDYVHL 1362 876 1044 719 663 
33 Plate1_B09 GWMVHYTSKDT 90 0 178 1406 1045 
34 Plate1_B10 HNSALYSQVQK 1695 707 1528 3328 4753 
35 Plate1_B11 HRQLNYIQVDL 1565 574 1501 10960 2762 
36 Plate1_B12 IEDNEYTAREG 834 0 0 1339 192 
37 Plate1_B13 IEDEDYYKASV 524 111 1077 1600 1946 
38 Plate1_B14 IEDNEYTARQG 1003 0 119 1186 829 
39 Plate1_B15 IESDIYAEIPD 10095 12914 15308 11860 288 
40 Plate1_B16 IESSNYMAPYD 1051 793 600 2657 0 
41 Plate1_B17 IRYHRYHGRSA 1559 791 1723 3198 10879 
42 Plate1_B18 IYETDYYRKGG 1364 833 1220 1155 3528 
43 Plate1_B19 KAVDGYVKPQI 767 271 1099 5420 4579 
44 Plate1_B20 KDRMSYHVRSH 2355 558 1741 2722 6890 
45 Plate1_B21 KKRCPYTKHQT 1609 683 1105 3174 8123 
46 Plate1_B22 KVVALYDYMPM 1235 852 1738 3630 4748 
47 Plate1_B23 LISSDYELLSD  39 158 285 1196 0 
48 Plate1_B24 LNSDGYTPEPA 0 0 0 268 0 
49 Plate1_C01 LNSKGYTKSID 0 0 128 830 1037 
50 Plate1_C02 LPPEGYVVVVK 1315 243 167 3076 11155 
51 Plate1_C03 MDTSVYESPYS 161 0 51 661 995 
52 Plate1_C04 MKDEEYEQMVK 596 0 37 911 2910 
53 Plate1_C05 MTGDTYTAHAG 491 0 137 916 1165 
54 Plate1_C06 NNHTEYASIQT 2480 2102 5397 8582 1560 
55 Plate1_C07 NQSSGYRYGTD 0 0 28 1286 1148 
56 Plate1_C08 NSDVQYTEVQV 9583 6459 1382 7188 2166 
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57 Plate1_C09 NSKRDYTGCST 602 0 225 730 2425 
58 Plate1_C10 NVVPLYDLLLE 688 200 0 576 445 
59 Plate1_C11 PEGLNYACLTH 2371 2290 9095 17829 2233 
60 Plate1_C12 PEGHEYYRVRE 2158 1810 0 956 623 
61 Plate1_C13 PEQDEYDIPRH 153 0 704 1323 336 
62 Plate1_C14 PGSLEYLCLPA 2047 1697 589 5226 418 
63 Plate1_C15 PKGTGYIKTEL 1006 86 709 3183 3217 
64 Plate1_C16 PLDKDYYVVRE 1013 241 0 932 571 
65 Plate1_C17 PPDHQYYNDFP 125 50 123 751 48 
66 Plate1_C18 PQDKEYYKVKE 484 0 0 444 1081 
67 Plate1_C19 PSFSEYASVQV 3564 3853 5876 5283 2771 
68 Plate1_C20 PSTRDYEIQRE 0 0 0 88 0 
69 Plate1_C21 PQDKEYYKVKE 1229 1909 396 1963 1702 
70 Plate1_C22 QGPVI YAQLDH 1095 676 9279 19158 2309 
71 Plate1_C23 QKQPIYIVMEL 6003 9871 1808 1234 1769 
72 Plate1_C24 QQQEVYGMMPR 1902 538 837 1665 4117 
73 Plate1_D01 RNEGVYTAIAV  1085 2040 1106 1188 1413 
74 Plate1_D02 REGLNYMVLAT 2574 2088 5667 11520 3622 
75 Plate1_D03 SAEPQYQPGDQ 0 48 51 66 164 
76 Plate1_D04 SDDVRYVNAFK 1660 683 3147 6727 3237 
77 Plate1_D05 SDGHEYIYVDP 42 0 531 2295 1144 
78 Plate1_D06 SEEPIYIVTEY 0 0 310 750 0 
79 Plate1_D07 SESVVYADIRK 7119 6577 17579 19127 5101 
80 Plate1_D08 SETDDYAEIID 1748 2140 2122 4859 0 
81 Plate1_D09 SPPALYAEPLD 606 122 0 1028 822 
82 Plate1_D10 SSNPEYLSASD 227 0 0 424 0 
83 Plate1_D11 SSSSEYGSVSP 81 0 382 1574 1000 
84 Plate1_D12 SSTVQYSTVVH 6184 7606 9834 15367 5234 
85 Plate1_D13 STEPQYQPGEN 446 0 0 0 526 
86 Plate1_D14 TDKEYYTVKDD 358 0 0 757 0 
87 Plate1_D15 TGGSVYTEDND 482 0 0 513 482 
88 Plate1_D16 TNDITYADLNL 484 75 4384 10029 704 
89 Plate1_D17 TSKLI YDFIED 0 0 346 1613 397 
90 Plate1_D18 TSSVLYTAVQP 12415 10065 19048 20727 1270 
91 Plate1_D19 VDADEYLIPQQ 250 0 531 1875 0 
92 Plate1_D20 VDTPHYPRWIT 2735 883 2926 4104 4564 
93 Plate1_D21 VNTTLYEKFTY 10414 13706 1884 7611 11381 
94 Plate1_D22 VYESPYSDPEE 0 0 658 0 284 
95 Plate1_D23 YETDYYRKGGK 2208 314 1651 2423 6362 
96 Plate1_D24 YFMTEYVATRW 5359 3723 6285 3795 4279 
97 Plate1_E01 AEGSAYEEVPT 0 0 4 1744 0 
98 Plate1_E02 AENPEYLSEFS 698 458 520 622 2040 
99 Plate1_E03 FDNLYYWDQDP 125 1319 730 29 504 
100 Plate1_E04 AFGTVYKGIWI 3281 1796 2258 7640 13900 
101 Plate1_E05 AFQFSYTAVFG 1286 438 1888 4469 1323 
102 Plate1_E06 AKIQDYHILTR 1535 453 1314 3274 4850 
103 Plate1_E07 APAEMYDIMKT 783 1162 347 896 1545 
104 Plate1_E08 ASEQGYEEMRA 696 0 0 436 75 
105 Plate1_E09 ATVGHYTAVQN 1431 2891 3089 5459 893 
106 Plate1_E10 AYRQLYLNPKG 2329 945 4011 4092 5038 
107 Plate1_E11 CPEKVYELMRA 2408 943 1241 2336 555 
108 Plate1_E12 DINSLYDVSRM 5096 5805 1946 1484 3554 
109 Plate1_E13 DRFIQYANPAF 1090 1100 3926 8788 2062 
110 Plate1_E14 DVSRMYVDPSE 5048 4868 0 1847 1040 
111 Plate1_E15 EDIKSYYTVRQ 1113 1007 2951 4304 4370 
112 Plate1_E16 EEIRFYQLGEE 174 0 0 669 610 
113 Plate1_E17 EKIQDYEKMPE 0 0 0 61 0 
114 Plate1_E18 ELGYEYMDVGS 1285 1034 5289 3714 3386 
115 Plate1_E19 AELEFYMDYEA 19714 17603 7643 7998 2470 
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116 Plate1_E20 FGAKPYDGIPA 1186 18 303 1139 2105 
117 Plate1_E21 GPQDIYDVPPV 10036 8562 2960 3041 1288 
118 Plate1_E22 GQESEYGNITY 440 340 773 1126 2114 
119 Plate1_E23 GRETIYPNASL 1180 623 190 612 1298 
120 Plate1_E24 IGEGTYGTVFK 1820 561 3439 4191 5041 
121 Plate1_F01 IYIHRYENVSI 8592 12658 2995 6891 2449 
122 Plate1_F02 KAEDEYVNEPL 662 0 0 1842 0 
123 Plate1_F03 KPKQEYLNPVE 0 0 231 1089 0 
124 Plate1_F04 LARDMYDKEYY 903 0 438 1546 339 
125 Plate1_F05 LDSTFYRSLLE 1582 1312 882 3838 117 
126 Plate1_F06 LGQRIYQYIQS 3196 3509 2115 5032 3243 
127 Plate1_F07 LLANAYIYVVQ 510 346 1025 1785 988 
128 Plate1_F08 LMGHEYMEMKN 1484 470 3891 3457 2220 
129 Plate1_F09 LNKQGYKCRQC 2677 1274 12417 6322 1387 
130 Plate1_F10 NKPTVYGVSPN 486 0 608 1945 2149 
131 Plate1_F11 PPDHQYYNDFP 599 478 958 1695 0 
132 Plate1_F12 PEDTFYFDPEF 538 503 216 1881 267 
133 Plate1_F13 PEPGPYAQPSV 0 0 605 987 362 
134 Plate1_F14 RHDSGYEVHHQ 738 0 215 689 1260 
135 Plate1_F15 RNPGFYVEANP 611 129 407 2449 0 
136 Plate1_F16 SADHLYVNVSE 3330 1878 5325 1486 337 
137 Plate1_F17 SSDPTYTSSLG 144 0 0 1277 0 
138 Plate1_F18 EEEPVYEAEPE 1424 0 38 241 398 
139 Plate1_F19 STKYFYKQNGR 860 503 3461 1018 33 
140 Plate1_F20 TAEPDYGALYE 1080 361 40 1755 0 
141 Plate1_F21 VCAERYSQEVF 1719 1867 4141 4766 139 
142 Plate1_F22 VDSSLYNLPRS 360 104 547 1770 762 
143 Plate1_F23 VSSTHYYLLPE 0 0 2234 2733 80 
144 Plate1_F24 VVIALYDYQTN 0 0 377 351 0 
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Table 10.7 The summary of KD against three PTP mutants including PTP1B, SHP1 and 
SHP2. 
KD of each PTP mutant Peptide NO. 
384 well PTP1B (µM) SHP1 (µM) SHP2 (µM) 
1 Plate1_A1   1.27 
2 Plate1_A5  4.8 0.73 
3 Plate1_A7   0.56 
4 Plate1_A2  2.7 0.74 
5 Plate1_A4   0.35 
6 Plate1_A6   0.65 
7 Plate1_A9  4.7 0.59 
8 Plate1_A11  1 0.88 
9 Plate1_A13  19  
10 Plate1_A15  1.83 0.37 
11 Plate1_A16   0.9 
12 Plate1_A17  7.9 0.96 
13 Plate1_A19  2.63 0.77 
14 Plate1_A21 1.58 3 0.56 
15 Plate1_A18 0.43 0.96 1.1 
16 Plate1_A20   0.18 
17 Plate1_A22   1 
18 Plate1_C2   1.86 
19 Plate1_C6  1.6 0.47 
20 Plate1_C8 1.6   
21 Plate1_C9   6.9 
22 Plate1_C11 1.9 3.14 0.27 
23 Plate1_C15   1.9 
24 Plate1_C12 5.5   
25 Plate1_C14  5.4 0.69 
26 Plate1_C19 0.29 0.93 0.62 
27 Plate1_C21  14  
28 Plate1_C23 1.48  1.47 
29 Plate1_C22 0.79 1.3 0.18 
30 Plate1_C24 4.7   
31 Plate1_E5  5 1.57 
32 Plate1_E4  2.6 0.33 
33 Plate1_E6  2.7 0.86 
34 Plate1_E9 0.62 3 1.22 
35 Plate1_E11  5.2  
36 Plate1_E13  1.8 0.46 
37 Plate1_E15  2.2 0.18 
38 Plate1_E10   1.8 
39 Plate1_E12 1.12 1.9  
40 Plate1_E14    
41 Plate1_E19 0.54 0.41  
42 Plate1_E21 0.54 1.1  
43 Plate1_E18  0.84 0.49 
44 Plate1_E22   0.94 
45 Plate1_E24  1 0.5 
46 Plate1_B3 1.7 5.2 0.31 
47 Plate1_B5 2.3 4.4  
48 Plate1_B7 1.9 2.8 0.79 
49 Plate1_B4 3.1 1.39 0.91 
50 Plate1_B8 1.3   
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51 Plate1_B11  1.4 0.27 
52 Plate1_B15 0.61   
53 Plate1_B10 1.96 5 1.52 
54 Plate1_B16    
55 Plate1_B17  7.7 0.93 
56 Plate1_B19  1.83 0.41 
57 Plate1_B21 1.6 10.5 0.82 
58 Plate1_B18 2.6 2.1  
59 Plate1_B20 2 2.8 1.6 
60 Plate1_B22   0.46 
61 Plate1_D1  1.92 0.91 
62 Plate1_D5  3.1  
63 Plate1_D7 0.29 0.38 0.15 
64 Plate1_D2  2.2 0.45 
65 Plate1_D4  2.14 0.56 
66 Plate1_D8    
67 Plate1_D11    
68 Plate1_D12  0.69 0.13 
69 Plate1_D16   0.11 
70 Plate1_D19    
71 Plate1_D21 0.55   
72 Plate1_D23  3.1 1 
73 Plate1_D18 0.43  0.03 
74 Plate1_D20 0.97 1.93  
75 Plate1_D24 0.92  0.29 
76 Plate1_F1 0.16  0.17 
77 Plate1_F5   0.55 
78 Plate1_F7  3  
79 Plate1_F6   0.28 
80 Plate1_F8  1.2 0.35 
81 Plate1_F9 0.52   
82 Plate1_F15   1.2 
83 Plate1_F10  12  
84 Plate1_F16   0.76 
85 Plate1_F21   1.28 
86 Plate1_F23   1.2 
87 Plate1_F22  19  
 
 
